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, 2C or not 2C, that is the question, whetheri'tis nobler in the 
mind to suffer the slings and arrows of outrageous fortune or 
... by opposing, end them.' 
Paraphrasing Hamlet in 'Hamlet', Act 3, Scene 1, 
I 
by William Shakespeare. : 
11 
ABSTRACT 
Background: Serotonin neurones have been implicated in the pathophysiology and 
treatment of clinical depression to a greater degree than any other neurotransmitter. 
Additionally, serotonin pathways may playa role in the pathophysiology and treatment of 
eating disorders, anxiety states and schizophrenia. Molecular biological studies have 
confirmed pharmacological evidence suggesting the existence of multiple serotonin 
receptor subtypes and the genes for these receptors, as well as that of the serotonin 
transporter, have common polymorphic variants. 
Aim: To investigate the effect of repeated treatment with selective serotonin fe-uptake 
inhibitors (SSRI's) on the function of central 5-HT2C receptors. To assess the effect of 
polymorphic variation in the 5-HT2c receptor and serotonin transporter on functional 
responses to selective pharmacological challenge. To determine whether polymorphic 
variation in the 5-HT receptor and serotonin transporter influence the clinical response of 
patients with major depression to treatment with serotonergic antidepressants. 
Methods: To assess the effect of repeated treatment with selective serotonin re-uptake 
inhibitors (SSRI's) on the function of central 5-HT2c receptors I used the 5-HT2C receptor 
agonist, m-chlorophenylpiperazine (m-CPP) as a 5-HT2c probe in a neuroendocrine 
challenge paradigm. I used the same approach to assess whether polymorphic variation in 
the 5-HT2c receptor (serine vs cysteine substitution) was associated with differences in 
functional response to 5-HT2C receptor challenge. I then studied whether polymorphic 
variation in the serotonin transporter promotor region (long versus short form) was 
associated with differing functional responses to acute challenge with clomipramine, a 
tricyclic antidepressant with a high affinity for the serotonin transporter. Finally, I studied 
whether either of these polymorphic variants influenced the clinical response of patients 
with major depression to treatment with SSRI's and clomipramine. 
Results: SSRI treatment significantly lowered the sensitivity of 5-HT2c receptors as 
predicted from animal experimental studies. However polymorphic variation in the 
5-HTzc receptor did not significantly influence functional responses to m-CPP challenge. 
In contrast polymorphic variation in the serotonin transporter was associated with 
differing neuroendocrine responses to acute clomipramine challenge with greater 
prolactin release being seen in subjects with the long polymorphic variant. Neither the 5-
HTzc nor the transporter polymorphisms correlated with clinical response to SSRI and 
clomipramine treatment in patients with major depression. 
Conclusions: The ability of SSRI's to produce a functional down-regulation of 5-HTzc 
receptors may be relevant to certain of their therapeutic effects. :Polymorphic variation in 
the 5-HT2c receptor (serine vs cysteine) seems unlikely to explain functional differences 
in responses to 5-HTzc receptor challenge or antidepressant responses to SSRI treatment. 
In contrast variation in the serotonin transporter promotor is associated with differing 
functional responses to acute serotonin re-uptake blockade. However, this did not 
correlate with clinical response to longer-term SSRI treatment. 
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1.1 INTRODUCTION TO THE THESIS 
This thesis investigates the function of two molecules involved in the serotonin neuro-
transmitter system, the 5-HT2c receptor and the serotonin transporter. Interest in these 
receptors derives from the well established link between the serotonin system and 
depression and, more recently, a putative link between the response to the new anti-
psychotic medication in patients with schizophrenia and 5-HT2c (and other serotonin 
receptor) blockade. 
Knowing the effect of serotonergic medication on specific receptor activity is important in 
the attempt to develop a full understanding of the mechanism of action of the anti-
depressants. It is hoped that a fuller understanding of these mechanisms will facilitate the 
development of more effective treatments, both in terms of rates of response and also 
speed of onset of action. The introductory chapter (Chapter 1) and the methods chapter 
(Chapter 2) are therefore followed by the first experimental chapter which deals with the 
effect of three weeks of paroxetine treatment on the level of function of the 5-HT2c 
receptors, using the relatively specific agonist, m-CPP (Chapter 3). 
The introductory chapter presents the background to the clinical condition of depression 
as well as swnmarizing current views on the aetiology and treatment, both biological and 
psychological. The serotonin system is reviewed and the current level of knowledge 
regarding the function of the different receptors is noted. Attention is then focused on the 
receptors of specific interest, initially from a historic and functional perspective and later 
with reference to molecular aspects. 
It was also hoped, in planning these experiments, that the relatively new insights from the 
field of molecular biology might provide a further means of differentiating those patients 
I 
likely to respond to specific drug treatments from those likely t6 be resistant to the effects 
of certain classes of drug. In Chapter 4, therefore, a sample of depressed patients was 
genotyped for polymorphisms of the above two receptors and response rates were 
analysed by using a global clinical improvement scale. The rates of the polymorphisms 
were also compared with those in a large control sample without previous or current 
affective disorder. 
In Chapter 5 m-CPP was again used as a probe to investigate possible differences between 
the function of the two alleles of one 5-HT2c polymorphism (serine substitution for 
cysteine at codon 23), as a correlation of the serine allele with clozapine response in 
schizophrenic patients had suggested that functional differences were likely unless linkage 
disequilibrium was occurring. In a similar manner, in Chapter 6 possible functional 
differences in the alleles of the serotonin transporter promoter polymorphism were 
investigated using clomipramine as the neuro-endocrine probe. 
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The overall findings are further discussed in Chapter 7 and possible lines of further 
research, based on the implications of these projects and other lines of enquiry, are 
considered. 
1.2 DEPRESSION - INTRODUCTION 
Depression is one of the earliest recorded types of mental illness having been mentioned in 
the writings of Hippocrates, approximately 500 years BC (Jackson, 1986). At that time 
all illness was divided into representations of an excess or deficiency of "bile" types. 
Depression was therefore associated with "black bile". 
Literature has recorded depression in both non-medical and medical contexts for as long 
as we have records of writings from history. In 1621, Robert Burton, from Oxford, who 
was not medically trained, wrote about melancholia and is thought to have first 
conceptualised the 'modern medical doctrine of depression' (Shorter, 2001). 
In the early 19th century Pinel, from Paris, predicted modern findings regarding increased 
familial rates of depression with his concept of 'melancholic constitution' (Pinel, 1809). 
The recent clinical history of depression has seen different phases of conceptualisation of 
the illness. 
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Although early papers argued the likely role of psychological aetiological mechanisms, 
such as "Mourning and Melancholia" by Sigmund Freud (Freud, 1917), subsequent 
models of the illness have taken into account both biological and psycho-social factors. 
The psychodynamic formulation of depression proposed an 'unconscious' loss, of a 
symbolic nature, although depressive equivalents, such as bereavement, could also result 
from objective loss in the psychosocial environment. Freud wrote his paper in order to 
compare and contrast the clinical state of melancholia with the symptom profile of those 
recently bereaved. It is generally agreed that there are similarities but that in severe 
depression certain symptoms are more likely to be exaggerated, for example guilt and 
suicidal thinking. Attention has gradually shifted away from this psychodynamic 
formulation for a number of reasons. One central problem concerned the Validity of 
Freud's model of human psychological function which has been increasingly criticised 
from a number of perspectives. One of these is his notion of the primacy of aberrant sexual 
development in the formation of pathological states of mind (Freud, 1905). Although 
subsequent evidence has confirmed his suspicion that child sexual abuse is widespread, 
later recanted to a description of likely fantasy, it is now recognised that the number of 
relevant aetiological factors in the development of depression is usually greater than can 
be explained by a single negative life experience and, in view of current knowledge about 
genetic mechanisms, it is recognised that some individuals will become depressed without 
any evidence of major negative life events. An early major breakthrough in the treatment 
and investigation of the disorder was the discovery in 1958 that iproniazid, a treatment 
being used for tuberculosis, was also able to elevate the mood of depressed patients. 
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This discovery~ and the knowledge that iproniazid had an influence on mono-amine 
systems, generated a search for further compounds which would have a similar or 
improved effect. Therefore, subsequent compounds to be studied included imipramine and 
other monoamine re-uptake inhibitors. 
In view of the success of psychotropic medication in providing sufferers with relief from 
the symptoms of depression and schizophrenia since the late 1950's, it has become a goal 
of psychopharmacological research to optimise the efficacy of compounds available in the 
treatment of severe psychiatric disorders. As fur as the treatment of mood disorders is 
concerned there has been a significant increase in the number of medication types available 
for this purpose which has led to the development of algorithms facilitating the decisions 
regarding the choice of medications to be used. At the same time there has been an 
increase in the numbers of large scale clinical trials to prove the efficacy of the 
compounds and in order to test different augmentation strategies. Much recent research 
has been concerned with establishing a role for the neurotransmitter serotonin (5-
hydroxtryptamine, 5-HT) in the pathophysiology of depression and the therapeutic effects 
of antidepressant medication. This thesis focuses on the role of the serotonin receptors in 
the regulation of mood and the manner in which serotonin receptor sensitivity may be 
influenced by antidepressant and anti-psychotic medication. The work follows from the 
general hypothesis that a better understanding of the psychopharmacology of psychiatric 
illness will lead to knowledge about the relevant aetiological factors an~ once these are 




Along with the differing views of the nature of depression, the classification systems have 
been modelled on the prevailing concept of the illness at any particular time. Depression 
was divided historically into "endogenous" and "reactive". The division was based on the 
underlying concept that these two kinds of depression differed roth in aetiology and in 
characteristic symptom profile. Although this division had some utility in the planning of 
medical or psychosocial interventions, it was not consistently established that the two 
conditions separated well when statistical factor analysis was utilised (Kendell, 1976). 
It has also become evident that this dichotomous classification does not have great 
therapeutic implications as antidepressants have been found to be effective, roth in 
moderate and severe depression as well as in mild or brief recurrent depression (paykel et 
al, 1989). Subsequent attempts at classification have been partially useful but usually in the 
specific context within which they were developed. Paykel proposed a classification 
(Paykel, 1971) and in the same year, Guze proposed a division into primary and 
secondary depression depending on the evolution of the condition and the likelihood that it 
was precipitated by either psychosocial or medical events (Guze et al, 1971), however the 
validity of this model has not been supported from either a clinical or research perspective 
(Weismann et aL 1977). 
A more useful classification was proposed by Leonhard (Leonhard et al, 1962) who 
suggested a division of mood disorders into unipolar and bipolar disorder. 
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This division has been accepted for both its clinical and research utility by the American 
Psychiatric Association in the Diagnostic and Statistical Manual (Classification of Mental 
Illness) IV, used widely in both the United States of America and other countries (DSM 
IV, 1994). 
The division of psychotic illness into dementia praecox (schizophrenia) and the mood 
disorders was described by Kraepelin (1921) and, although the division is not regarded as 
complete, the recognition of psychotic symptoms as part of a mood disorder has 
significant therapeutic implications. The DSM IV classification system describes clinical 
depression as "major depression". The criteria for diagnosis of this disorder are seen in 
Table 1.1. 
The diagnosis requires a minimum two week period of low mood or loss of interest on 
most of the days in addition to a further 4 out of9 other criteria. Bipolar disorder requires 
both the history of depressive episodes as well as manic or hypomanic episodes (Bipolar I 
or II respectively) while the ICD 10 classification permits the diagnosis of "manic 
episode". 
However, the ICD classification system usefully divides the condition into levels of 
severity - mild, moderate and severe. Mild and moderate depression is further divided 
according to the presence or absence of somatic symptoms such as an increase or decrease 
in appetite, weight, sleep, motor activity and energy, and "severe" depression is divided 
into "with or without psychotic symptoms" (WHO, 1992). 
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Features include loss of interest or pleasure and a lack of reactivity to pleasureable stimuli, 
plus three of the following - a variation in the qualitative nature of the mood, early 
morning waking, psychomotor agitation or retardation, significant anorexia or weight loss, 
and excessive guilt. 
Table 1.1: Criteria for major depressive episode in DSM IV. 
i A. One ofthe following two criteria is essential (assuming no other clear cause): 
1 Depressed mood most of the day, nearly every day, as indicated by either . 
subjective report (eg: feels sad or emQty) or observation made by others. 
2 Markedly diminished interest or pleasure in all, or almost all, activities 
most of the day, nearly every day (suQjective account or oQjective view). 
. B. Three of the following criteria if both above criteria or 4 if one above: 
1. Increase or decrease in appetite nearly every day, or weight (more than I 
5% in one month). i 
2. Insomnia or hypersomnia nearly every da~. i 
3. I Ps~chomot()r agitation or retardation nel:U'l~ every da~. i 
4. Fatigue or loss of energy nearly every da~. I 
5. Feelings of worthlessness or guilt (may be delusional) nearly every day, i 
not just about ~ing sick. 
,6. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either sUQjective1y or as observed by others). 
7. Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a plan or a planned intention to commit suicide. 
The division of depression into unipolar and bipolar disorders has been supported in 
further research relating to the genetic aetiology of the condition as well as with regard to 
the gender prevalences of the illness. It is therefore likely that the unipolarlbipolar 
distinction will continue and, from a clinical perspective, the division into mild, moderate 
and severe has practical utility. With regard to the decision to use electro-convulsive 
therapy, the presence of delusions and retardation have been acertained to be important 
factors (Brandon et a~ 1984). 
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1.2.2 Epidemiology 
Depression is a common disorder and lifetime rates are currently reported between 4% 
and 30%, while point prevalences of between 13 to 20 % of the population have been 
reported (Reviewed in Joyce, 2000). Increased rates are seen in women, individuals from 
social classes 4 and 5 and those who are separated or divorced (Boyd and Weismann, 
1982). 
There has been a steady increase in the estimate of the global prevalence of the disorder 
from 100 per million in the late 1950's to over a 100 000 per million in the last years of 
the 20th century (Kessler et al, 1994). In the United Kingdom the National Morbidity 
Survey indicated that, in any week, 7.7 % of the population suffers from 'mixed anxious 
depression' and 2.1 % from 'pure depressive' episodes (HMSO, 1995). 
A significant number of people are not treated by doctors at all, but it is recognised that 
most people (90 %) suffering from depression are treated in primary care by their general 
practitioners, rather than by specialists, (Shepherd et aL 1966) and the precise calculation 
of incidence and prevalence rates is further complicated according to factors dictating help 
seeking behaviour. 
Research done in community studies recognises that there is a greater prevalence of the 
illness in women and this has taken into account the likelihood that they present at a lower 
threshold than men in primary care. 
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The 2: 1 female to male ratio is a consistent finding, with the one exception being an Amish 
study where the ratio was 1:1 and 49 % of the males had suffered from depression 
(Egeland et a~ 1983), however this is a skewed sample in view of the substantial genetic 
risk in the Amish men. 
In the early epidemiological studies the development of a mood disorder was seen to be 
more likely with increasing age up to a mean age of onset of 30 years (Smith and 
Weismann, 1992), however recent studies have suggested an earlier mean of 21 years. 
Following the initial episode further episodes are likely in the majority of sufferers and 
these have been documented as occurring more frequently with increasing age (Roy-Byrne 
et al, 1985). 
1.2.3 Aetiology 
1.2.3.1 Mono-amine hypothesis 
The mono-amine hypothesis (Schildkraut, 1965), that depression relates to a functional 
deficit of mono-amine transmitters, while the reverse is true in mania, derives from a 
number of related findings. It was recognised at an early stage that treatment of 
hypertension with reserpine and guanethidine, while being effectively anti-hypertensive, 
led to depression in a proportion of people taking the medication. It had been previously 
established that these medications function by depleting neurones of their neurotransmitter 
stores (5-HT and NA) in vesicles. 
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In addition it was recognised that the majority of compounds with therapeutic efficacy in 
depression have an effect on monoamine neurotransmitter function. Mono-amines are the 
compounds principally associated with neurotransmission and full into two main groups -
the catechol-amines and the indole-amines. Catechol-amines include noradrenaline and 
dopamine and the indole-amines include serotonin and melatonin (Aghajanian, 1981). 
The tricyclic antidepressant, imipramine, was discovered in 1957 in attempts to treat 
schizophrenia. While it was ascertained that it did not effectively treat symptoms of 
schizophrenia, some positive effects were seen in those patients with depression (Everett 
and Toman, 1959). It was established that imipramine and other tri-cyclic anti-depressants 
enhance monoamine neuro-transmission function by preventing the reuptake of mono-
amines by inlnbition of the transporters in the presynaptic neurone at the synaptic cleft (Ho 
and Estevez, 1982). Further work has established that both electro-convulsive therapy and 
mood stabilisation e.g. with lithium, alter monoamine function, although how far this can 
account for their therapeutic actions is not clear. 
1.2.3.2 Genetic findings 
Twin and family studies have convincingly described a significant familial contribution to 
aetiology. As a whole, in considering the mood disorders, mono-zygotic twins are seen to 
have 68% rates of concordance for illness and dizygotic twins have 20% concordance. 
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When the mood disorders are subdivided, bipolar disorder mono-zygous concordance is 
79% and dizygotic concordance is 19%, while the corresponding rates for unipolar 
disorder are 54% and 20% respectively (Bertelsen et ai, 1977; McGuffin et a1, 1996). 
First degree relatives have an increased likelihood of developing depression, 10-15% in 
unipolar disorder and 15-20% in bipolar disorder, compared with the normal population 
prevalence of 1-3% (Gershon et aI, 1976). In an attempt to tease out psychosocial and 
genetic components, adoption studies have been carried out, however these have reported 
rates of the condition similar to the biological relatives rather than the adoptive families, 
suggesting the increase is not due to adoption itself or the psychological influences of the 
adoptive family (Mendlewiscz and Rainer, 1974). 
With the recognition from the above findings that any model of depression needs to take 
into account biological factors (Kendler and Karkowski-Shuman, 1997), research has 
been directed at establishing whether genetic linkage exists according to Mendelian 
patterns or whether modes of inheritance show gender related differences. 
There is therefore no currently accepted autosomal dominant model which is regarded as 
adequately explaining the genetic findings. As such linkage has been relatively 
unsuccessful, it is now thought that genetic contributions to aetiology most likely occur 
because of genes of small effect in a model of polygenic inheritance. 
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In a similar manner, candidate genes suggested Jargely through studies of the mono-amine 
systems have also not been particuJarly revealing (Cravchik and Goldman, 2000). Findings 
relating to the serotonin transporter will be summarised later in this chapter. 
1.2.3.3 Psychosocial aspects 
Based on a line of investigation deriving from the original psychodynamic perspective 
relating to loss, it has been studied whether major negative life events can precipitate 
depression. This was established experimentally with a series of studies and it was 
therefore subsequently recognised that symptomatic "endogenous" depression can also be 
precipitated by major life events (Brown et aI, 1987). The period within which the studies 
assessed the impact of life events was 6 months prior to relapse although it was also noted 
that a second negative life event could compound the effects of the first (paykel, 1969). 
Further research has recognised that major life events in a social context may not be 
independent of the gradual onset of the condition. Subsequent attempts to separate out 
independent from associated life events (Brown et al, 1987) lead to more recent work 
which has established that there are not only increased familial rates of depressive illness 
but that major life events also follow familial patterns. The above findings have therefore 
led to a complex multi-factorial aetiological framework which includes individual genetic 
aspects as well as a familial tendency to experience negative life events in a combined 





This group of three ringed molecules plus attached side chains is one of the most highly 
researched of the antidepressant compounds. After initial successes in the use of 
imipramine in treating depression a number of other similar compounds have been found 
to be effective antidepressants. From a clinical view point they are most effectively divided 
into those with a sedative effect, the tertiary amine group (with terminal methyl groups on 
the side chain) and those without, the secondary amines. The tertiary amines have a higher 
affinity for 5-HT re-uptake sites and 5-HT receptors and exhibit greater antagonism of 
alpha-l adrenoceptors and muscarinic receptors, the latter effect causing the clinically 
observed anti-cholinergic side-effects. In spite of their well established efficacy the use of 
TCA's has been declining recently because of the advent of compounds with improved 
tolerability and reduced cardiotoxicity (preskom, 1993). The latter property means that 
TCA's must be specifically avoided in patients who are at high risk of impulsive suicide 
attempts, apart from an exception, lofepramine, which is less toxic. Although reported as 
having unacceptable side effects by patients, it has been noted that the percentage drop out 
in controlled treatment studies, when considered by meta-analysis, is only slightly greater 
than that of SSRIs, and it is known that side effects are the principal cause of drop out 
from therapeutic studies (Barbu~ et al, 2000). However, in clinical situations and over 
longer periods of treatment the advantage ofSSRIs is likely to be greater. 
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Serotonin specific re-uptake inhibitors 
This group of drugs was developed subsequent to the tricyclics in an attempt to produce 
effective antidepressant compounds that lacked the side effects and over-dose risk of the 
tri-cyclic anti-depressants. They have a positive efficacy in approximately 60% of patients 
suffering from depression (reviewed in Edwards and Anderson, 1999) and are relatively 
safe in overdose, although fatalities have been rarely reported following over-dose with 
citalopram. They have a specific action at the serotonin transporter preventing reuptake of 
serotonin from the synaptic cleft following a nerve impulse. Although 88RIs are 
therapeutically useful, a minority of patients do experience side effects including nausea 
and GIT effects, dizziness and somnolence. However, these side effects often diminish 
after the first few days and the antidepressants are therefore generally well tolerated. An 
increasingly recognised problem is that withdrawal syndromes are possible when they are 
stopped. This is particularly the case with shorter acting drugs such as paroxetine. 
In addition to their use in depression, 88RIs have been widely used in the treatment of 
OeD, anxiety and panic disorder. There is currently insufficient evidence to delineate 
clearly the role of serotonin in these disorders as there are numerous neuro-tranmitter 
systems involved and serotonergic neurones appear to have complex effects, some 
inhibitory, some anxiogenic. It is also known that the introduction of 88RIs clinically can 
lead to an exacerbation 04 or onset of anxiety symptoms before subsequent benefit ensues. 
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The finding that OCD responds well to SSRIs implies that an underlying abnormality of 
the serotonergic system might exist, however this cannot be assumed in the absence of a 
clear demonstration of a connection as, by ~logy, Parkinson's Disease (involving 
abnormal dopaminergic system function), can respond to anti-cholinergic medication. 
Studies examing the effect of challenges with agents affecting specific receptors have 
mainly implicated the 5-HTm and 5-HT2C receptors (Sasson and Yohar, 1996) (See 
below). 
Mono-amine oxidase inhibitors 
This group was actually discovered shortly before the initial use of imipramine as 
iproniazid is a form of MAO!. They function by inlnbiting the mono-amine oxidase 
enzyme (MAO), which is involved with the intracellular metabolism of noradrenaline, 
serotonin, tyramine and other amines. In the presence of MAOI's therefore, neuronal 
stores of these amines are increased, as is their release into the synaptic cleft. These 
transmitters are then able to positively stimulate post-synaptic receptors for a prolonged 
period. NA and 5-HT are substrates for Monoamine-A while dopamine and tyramine are 
metabolised by both monoamine oxidase A and B. 
In view of the potential for increased noradrenaline activity to promote a 'pressor' effect, 
dietary control is needed in patients taking MAOI's, particularly the avoidance of food 
rich in tyramine as well as sympathomimetic medications. This had led to a reduction in 
their use except in atypical (Quitkin et al, 1989) or resistant depression (Cowen, 1988). 
16 
However, the development of the RIMA, moclobemide, has renewed interest in their 
clinical utility. They have also been used in the management of severe, unremitting anxiety 
states (Nutt and Glue, 1989). 
Mood stabilisers as anti-depressants 
A number of mood stabilisers have been used in the treatment of depression. Their role in 
the treatment and prophylaxis of bipolar disorder is well established but a number of 
studies have also concluded that lithium, in particular, is effective in the treatment of 
depression, both as a primary therapy (Johnson, 1987), as well as in augmentation 
strategies (Katona and Barnes, 1985) which have been tested in eleven double blind 
comparative studies with an overall improvement rate of 52% for ten of the studies 
(reviewed in Fava et al, 2001). Further studies have suggested a similar role for 
carbamazepine but this is less well supported (post et al, 1991; Nurnberg and Finkel, 
1985). Sodium valproate appears to be more effective in the treatment of manic episodes 
and their prophylaxis than in the prevention of depressive episodes. The role of Na 
valproate in the treatment of depression has not been well established. However, for those 
patients with bipolar disorder who have made a partial response to lithium, the addition of 
valproate is a further, relatively safe option. Na valproate has also been added to 
carbamazepine in analogous clinical situations (Post et al, 1991; McElroy et al, 1992). 
While the mode of action of valproate is not clear, there is some evidence that it can slow 
the breakdown of GABA, an inhibitory neuro-transmitter. The anti-convulsant 
lamotrigene has also been used effectively in the treatment of depression in bipolar 
disorder. 
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Both carbamazepine and lithium salts appe~ to facilitate 5-HT function but the precise 
mechanism for this is not well understood. Other hypotheses regarding the mode of 
function of lithium include influences on cAMP and second messenger systems or on 
electrolyte balance, which could have relevance to relapse which may occur in the context 
of decreased fluid intake or heat exhaustion. 
Other anti-depressants 
There has been a recent expansion in the number of products available for the treatment of 
depression with either specific effects or combinations of effects on the mono-amine 
neuro-transmitter systems. The fundamental requirements of an effective antidepressant, in 
addition to efficacy, are that it should have few side-effects that develop within the usual 
dosage range and that it is safe in overdose. Ideally the daily dosage regime should be 
simple and there should not be a significant withdrawal reaction when the drug is 
withdrawn. 
Venlafaxine, a phenyl-ethylamine derivative, is a new SNRI (Serotonin and Noradrenaline 
Re-uptake Inhibitor), with some similarities to clomipramine but without sedative or anti-
cholinergic side-effects. It has been shown to be effective, particularly in in-patients, in one 
specific study, where a more rapid onset of action than the comparator, fluoxetine, was 
reported (Clerc et al, 1994). It is relatively safe in overdose but requires monitoring of 
blood pressure when the dose exceeds 200 mg per day_ Recent studies suggest it is 
modestly more effective than SSRIs in reducing remission (Entsuah et al, 2001). 
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Mirtazapine is a NASSA (Noradrenaline and serotonin specific anti-depressant) which 
blocks 5-HT2 and 5-HT3 receptors in a similar way to mianserin, an older anti-depressant 
that was withdrawn from circuJation due to blood dyscrasias. Further pharmacological 
properties include competitive antagonism at histamine HI, a-I and a-2 adrenoceptors. 
The weaker a-I antagonism than mianserin is thought to contribute to the ability of 
mirtazapine to activate 5-HT as well as NA neurones but the HI effects unfortunately 
cause sonmolence in 10% of patients taking it. However sleep can be mcilitated without 
daytime drowsiness (Radhakishun et al, 2000). Mirtazapine may potentiate centrally acting 
sedatives and could theoretically reverse the effects of a-2 adrenoceptor agonists. 
Trazodone (a triazolopyridine derivative) is another anti-depressant with 5-HT2 antagonist 
properties but the metabolite m-CPP (see below) is a 5-HT agonist. Trazodone also 
blocks post-synaptic a-I adrenoceptors and has a sedating profile, but is safer than the 
TCA's in overdose. 
A further new anti-depressant is reboxetine, a morpho line (structurally related to 
fluoxetine) which is a NARI (Nor-adrenaline re-uptake inhibitor). It is receiving attention 
as an innovative anti-depressant which is relatively safe and specific. Claims that 
reboxetine produces an improvement in socialisation have not been fully studied (Dubini et 
ai, 1997). The suggestion that reboxetine boosts patient's energy specifically has also yet 
to be independantly determined and may just be an effect of the resolution of depression 
itsel£ 
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Bupropion is an anti-depressant which is not licensed for this use in the United Kingdom, 
in view of seizure-related deaths, but it is licensed to assist people withdrawing from 
nicotine and is widely used in America. The mechanism of action has not been fully 
elucidated but may partially involve the blockade of DA re-uptake. 
1.2.4.2 Electro-convulsive treatment 
Five out of six double blind studies that have compared ECT with simulated ECT (sham 
treatment), such as the MRC trial at Northwick Park (Johnstone et aI, 1980) have shown 
a significant effect of the treatment (Gregory et al, 1985; Brandon et al, 1984; Freeman et 
a1, 1978; West, 1981). One study did not support a beneficial effect ofECT however this 
was a patient sample where only low dose unilateral ECT was administered (Lambourn 
and Gill, 1978), a technique now known to be less clinically efficacious. 
Other studies have had methodological difficulties including a lack of blinding or small 
sample size. The use of sham protocols has been necesssary to establish that it is not the 
anaesthetic which is efficacious but that the convulsion is a necessary part of the 
treatment. Psychopharmacological studies involving neuroendocrine challenge have 
shown a difference in the post-ECT activity of 5-HT receptors with an up-regulation of 5-
HT2 receptors rather than the down-regulation seen in psychopharmacological studies 
involving medication, in animals (Gartside et a~ 1992). 
20 
Down regu1ation of a-2 and 13-1 adrenoceptors is reported in rodent studies post ECT 
and post anti-depressant treatment, and ECT shows marked effects on dopamine 
function. Antidepressants can also affect dopamine function but it is difficult to detect 
unless molecular techniques, such as DA gene expression are used, as has been carried out 
in animal studies. Of related interest is the work being done using Transcranial Magnetic 
Stimulation where the convulsion is avoided. These studies have provided some initial 
support for the use of TMS in depression (George et al, 1999; Cowen, 1999 ) but the 
precise indications and long term effects are not well established. It is also not clear 
whether different cerebral regions need to be targeted for maximum efficacy and whether 
specific regional stimulation might be appropriate for different psychiatric conditions. 
1.2.4.3 Psychological Therapies 
In spite of the difficulties researching the efficacy of psychological therapies, 
psychotherapy has now been widely assessed in randomised control trials. Although there 
was little empirical evidence for the efficacy of psychodynamic therapy in the past and 
studies tended to be single case narratives, psychotherapy has now been compared with 
both drug treatment and waiting lists, with interpersonal psychotherapy (Klerman et a~ 
1984), being found to improve depressive symptoms in those patients with mild/moderate 
illness. In one major NIMH study 240 patients were randomly allocated to imipramine, 
interpersonal therapy, cognitive therapy and placebo. 
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Statistically significant improvements were found in both the drug treatment and the 
interpersonal therapy group (E1kin et a4 1989). Although cognitive behaviour therapy did 
not fare well in this study, it is generally regarded as an effective treatment and importantly 
may reduce subsequent relapse rates. These findings are in the process of being replicated 
but a significant body of work has already been summarised in meta-analyses which show 
an overall support for the effectiveness of psychological therapies in depression, including 
both psychodynamic and cognitive behavioural treatments (Leichsenring, 2001). As these 
benefits are not, however always maintained over time (Westen and Morrison, 2001) and 
are generally more appropriate for less severe illness, it is apparent that current 
psychological therapies are not sufficiently effective to obviate the need for 
psychopharmacological intervention. This fact strengthens the rationale for further 
research into techniques to enhance antidepressant efficacy and speed its onset of action. 
1.3 5-HYDROXYTRYPTAMINE 
Since its original discovery in 1933 and subsequent description as a 'serum tonic' serotonin 
(5-HT) has been studied extensively with regard to both the therapeutics and aetiology of 
psychiatric disorders and numerous lines of investigation now place it centre stage in the 
study of the neuropharmacology of mood disorders. While depression and its treatment 
has been an important focus of studies into 5-HT, it has become increasingly clear that the 
5-HT system is a complex, widespread neuronal network, malfunction of which may also 
relate to schizophrenia, anxiety, migraine and the eating disorders. 
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The complexity of the system relates both to its neuroanatomical distribution and to its 
numerous receptor sUb-types. Originally classified as 'M'(morphine) or 'D'(dibenzyline) 
receptors (Gaddum and Picarelli, 1957)~ according to the ability of these substances to 
directly or indirectly antagonize 5-HT functio~ molecular biological studies have now 
characterized seven 5-HT receptor groups, some of which are further subdivided and have 
been reviewed (Boess and Mart~ 1993; Barnes and Sharp, 1999) (See further below). 
1.3.1 Structure 
Serotonin originally referred to material isolated from the blood stream which was able to 
constrict smooth muscle and the analogous material purified from the intestine was known 
as 'enteramine'. Crystallization and later analysis showed both substances to be the same 
and synthetic manumcture followed. The molecule is an indole and structurally related to 
LSD and other psychotrophic molecules (Cooper et al, 1986). 
1.3.2 N euro-anatomical distribution 
The majority of 5-HT neurones arise from the raphe nuclei - the dorsal raphe nucleus 
(DRN), median raphe nucleus (MRN) and B9 which is in the rostral brain stem (See 
Figure 1. 1). 5-HT neurones have widespread connections to other parts of the central 
nervous system, ascending to the fore-brain via the median fore-brain bundle, located in 
the lateral hypothalamus. From there the neurones extend out to the limbic system 
including the amygdala, hippocampus and cingulum as well as to the neocortex and 
ventrolateral cortical regions. 
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Serotonergic projections from the MRN are found mainly in the hippocampus and septum. 
These axons differ morphologically from those arising in the DRN which project to the 
cortex and striatum. 
It has been found in animal studies that 5-HT projections from the dorsal raphe are most 
closely associated with 5-HT2 receptors (Kosofsky and Molliver, 1987). 
Figure 1.1: Diagrammatic representation of the major serotonergic tracts in the human 
brain. A= Median raphe nuclei; B= Dorsal raphe nuclei; C= Deep cerebellar nuclei; 
D=Limbic structures; E= Thalamus; F=Neocortex; G=Cingulum; H= Cingulate gyrus; 
I=To hippocampus. Cells arising from the raphe nuclei project to all of the cortical grey 
matter. Further tracts extend to the basal ganglia and cerebellum. 
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From the above it can be seen that projections from the major collections of serotonergic 
cell bodies are not distributed homogeneously but that differing neuronal types and regions 
of distribution may lead to varying ratio's of receptor sub-types and contribute to 
functional specialisation, by region and morphology. 
It has therefore been noted that this pattern of distribution, according to particular 
subtypes, may underlie development of a modular system with a degree of neuro-
pharmacologically specific activity and it is therefore possible that refining 
pharmacological manipulation will be able to influence behavioural outcomes (Cowen, 
1993). 
1.3.3 Neuro-transrnission 
1.3.3.1 Synthesis and metabolism 
Serotonin is synthesised in the brain from the amino acid trytophan (TRP) via the 5-
hydroxyindole pathway as it cannot cross the blood-brain barrier (Lovenberg et at, 1968). 
TRP is an essential amino acid and is therefore obtained in the diet or, fuiling that, from 
the catabolism of body protein (Wurtman, 1978). TRP enters the brain through the blood 
brain barrier in common with other amino acids such as tyrosine and phenylalanine 
(aromatic amino acids) and isoleucine, leucine and valine (branch chain amino acids) by a 
common transportation carrier. 
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However, TRP competes with these other large neutral amino acids for transport into the 
brain and it is therefore the ratio of TRP to the other amino acids which regulates the 
quantity of tryptophan entering the brain (Wurtman, 1980). In the blood, approximately 
90% of tryptophan is usually protein-bound to serum albumin while the remainder is free 
tryptophan (unbound). 
As can be seen in Figure 1.2 synthesis of serotonin (5-HT) is controlled by hydroxylase 
enzymes. The first step in the formation of 5-HT from the amino acid trytophan is 
hydroxylation to 5-Hydroxytryptophan (5-IITP). The enzyme involved in this 
transformation is tryptophan hydroxylase which is located within serotonergic neurones 
(Knott and Curzon, 1972). This enzyme acts as the rate limiting step in serotonin 
synthesis. Synthesis is finally completed by the conversion of 5-IITP to 5-HT, by a 
decarboxylase enzyme. 
The enzyme activity of this decarboxylase enzyme is greater than the activity of the 
hydroxylase involved in the rate limiting step and it is therefore understandable that little 
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Figure 1.2: Diagrammatic representation of serotonin production and 
metabolisation. Some alternative metabolic pathways have not been demonstrated. 
Following synthesis, 5-HT is stored in granules at the pre-synaptic nerve terminals, 
awaiting the stimulus for release. There is a major cascade on arrival of a nerve impulse 
with thousands of neuro-transmitter molecules being present in every neurotransmitter 
terminal vesicle and there are also multiple vesicles in the pre-synaptic terminal. As can be 
seen in Figure 1.2, metabolism of 5-HT occurs by initial oxidation to 5-Hydroxyindole-
acetaldehyde by monoamine oxidase (MAO) followed by dehydrogenation tQ 5-HIAA by 
aldehyde dehydrogenase. An alternative pathway involves the conversion of 5-
Hydroxyindole-acetaldehyde to 5- Hydroxytryptophol by aldehyde reductase (Cheifetz 
and Warsh, 1980). Other minor metabolic pathways exist including a conjugation pathway 
to a sulphate derivative and action by methyltransferase with the production of methylate 
compounds. 
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1.3.3.2 The 5-HT transporter 
The serotonin transporter is a molecule which has an important function in the regulation 
of serotonergic transmission as it controls the uptake of serotonin into the presynaptic 
neurone and is therefore an early site for the action of both anti-depressant drugs and 
those with a harmful or neuro-toxic action (Amara and Kuhar, 1993). Both tri-cyclic anti-
depressants and SSRIs are considered to function by the occupancy of binding sites 
adjacent to and overlapping with the substrate binding site. In addition to this positive 
effect in drug treatment, certain neuro-toxins, such as substituted amphetamines are 
concentrated in 5-lIT neurones as a result of the transporter action (Lesch et al, 1995). 
The serotonin transporter is also found in the human blood platelet membranes where it 
has been used as a model in numerous investigations of 5-lIT re-uptake. These 
investigations have shown a reduced rate of serotonin transporter in the platelets of 
depressed patients (Coppen et al, 1978; Stahl et al, 1983) and also reduced binding of 
eH)imipramine and eH)paroxetine (paul et a~ 1981; Briley et al,1980). 
1.3.4 Receptor subtypes 
After the original division of the serotonin receptors by Gaddum and Picarelli (1957), into 
M and D receptors, subsequent classifications were based on demonstrable functional 
differences by the use of radio ligands and other pharmacological probes. 
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This was initially useful and the 5-HT 1,2 and 3 receptors were described, with additional 
subtypes of the 'type l' receptor being characterised by radioligands and second 
messenger systems. This allowed inclusion of 5-HT1C with the 5-HT2 group as 5-HT2C• 
After the discovery 'of the 5-HT4 receptor, subsequent divisions resulted from the 
application of molecular techniques to the task. 
Table 1.2: Classification of serotonin receptor subtypes, including information 
regarding chromosomal origin and effects of agents on hormonal responses. 
Serotonin Amino Human Homology Agonist Antagonist Hormonal 
receptor acids chromosome (%) with 5- Ineuro-
BT-tA• transmitter 
responses 
5-HT-1A 422 5q11.2-QI3 100 Buspirone WAY- ACTH, 
8-0H- 100635 Cortisol, PRL, 
D.PAT GH release 
Gepirone 
5-HTIB 390 6q 13 43 RU24969 Pindolol -
5-HTID 377 lq 34.3-36.3 43 Sumatriptan Ketanserin Ac. Ch release. 
PNU 109291 Ritanserin 
5-HT1E 365 6q14-q15 40 - - -
5-HT1F 3qll 42 LY334370 -
CY344864 
5-HT2A 471 13q 14-21 30 DOl MDL Cortisol, 
100907 ACTH, rennin, 
Ketanserin prolactin release 
5-HT2B 481 2q 36.3-37.1 34 5-HT (fuU) SB 200646 -
TFMPP SB 204741 
quipazine 
(partial) 
5-HT2C 458 X 32 m-CPP Mesulergine PRL release 
SB242084 
5-RT3 487 11 14 SR 57227 ondansetron Inhibits cortical 
AC.Ch release 
5-HT4 387 5q 31-33 29 BJMU8 SB 204070 5-HT, CCK and 
RS 67506 RS 100235 AC.Ch release 
5-HTsA 357 7q 36 36 - - 5-RT, DA and 
Ac.Ch. release 
5-HTSB ±370 2q 11-13 39 - - -
5-HT6 440 Ip 35-36 34 - Clozapine -
5-HT1 445-448 lOq 21-24 38 - SB 269970 -
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There are therefore now 7 families of serotonin receptors, some of which have been 
further divided into additional sub-types based on structural, operational and transduction 
information according to the principles of the Nomenclature Committee of the 
International Union of Pharmacology (Hoyer et a4 2002). The chromosomal origin and 
information regarding relevant agonists, antagonists and responses are summarised in 
Table 1.2. 
1.3.4.1 The 5-HTt family. 
The previous nomenclature included three subtypes within this group 5-HT1A' 5-HTIB and 
5-HTtc. Subsequent work has delineated the similarity of the 5-HTtc receptor to the type 
2 fumily and the 5-HT tc receptor was therefore re-named the 5-HT2C receptor. Initial 
typing of the 5-HTt family was based on the affinity of 3H_5_HT for rat cortex binding 
sites (peroutka et a4 1979). Further 5-HTJ receptors which have been recognised include 
the ID, IE and IF receptors. The receptors of the 5-HTt family all couple negatively to 
adenylate cylase via G-proteins and have high amino acid sequence homology. 
( Reviewed in Barnes and Sharp, 1999). 5-HT 1 receptors act through the stimulation of 
cAMP synthesis. 
5-HTIA receptors 
This receptor is the most well characterised of all of the 5-HT receptors. There are 
several reasons for this including the discovery ofthe selective 5-HTIAreceptor agonist, 8-
OH-DPAT (Hjorth et ai, 1982). 
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Another reason has been potential clinical applicability, as 5-HT1A agonists such as 
buspirone have been found to be anxiolytic and have been used in augmentation strategies 
in the treatment of depression (Blier and Bergeron, 1998). 
The rat 5-HTIA receptor has 422 amino acids and has 89% sequence homology with the 
human receptor which is located on chromosome 5 (5Q 11.2 - Q13). Both 
autoradiographic and PET studies have provided us with information regarding the 
distrIbution of receptors in the brain. The density is high in limbic areas especially 
hippocampus, lateral septum and cortical areas including the cingulum and entorrhinal 
cortices as well as the raphe nuclei where the receptor acts an an inhibitory autoreceptor. 
There are areas with a lower frequency of binding sites in other parts of the brain including 
the cerebellum and basal ganglia. The 5-HTIA receptors are located post-synaptically in 
fore-brain regions and on 5-HT neurones in the raphe nuclei. 
Animal studies have shown that administration of 5-HT1A receptor agonists causes a 
range of behavioural and physiological effects including hyperphagia, hypothermia, altered 
sexual behaviour and a tail flick response (Green and Grahame Smith, 1976). One study 
involving chronic administration of m-CPP, which has a greater effect on the 5-HT2C 
receptor (See further below), showed no effect on either the pre- or post-synaptic 5-HT1A 
receptors (Aulakh et al, 1991). 
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Neuroendocrine studies have found that 5-HT1A receptor agotrists cause ACTH and 
corticosteriod increase (Gartside et al, 1990), as well as electrophysiological and neuro-
chemical changes (Clifford et al, 1998). In humans increases in growth honnone are also 
seen (Cowen, 1990). These endocrine responses may be blocked by 5-HT1A receptor 
antagonists (Cowen, 1990; Gartside et al, 1990). 
5-HTIB receptors 
It was established that this receptor was distinguishable from 5-HT1A and 5-HT2 receptors 
due to the low affinity for 8-0H- DPAT (Middlemiss and Fozard, 1983). In the rat brain 
this receptor was characterised as having low affinity for spiperone (Pedigo et al, 1981) 
and a species variant, tenned 5-HTm initially, was found in bovine brain (Heuring and 
Peroutka, 1987), as well as in humans. Cloning studies have established that one of the 2 
human variants of the 5-HTm receptor (5-HTmj!) is a species equivalent of the rat 5-HT1B 
receptor with 96% sequence homology (Jin et al, 1992). Since the phannacology of the 
species variants can differ, prefixes are used to denote species specific receptors e.g. 
human = hS-HTlB• The genes encoding these receptors are located on chromosome 9, 
mouse, and on chromosome 6 (6q, 13), human, respectively. (Saudou and Hen, 1994). 
As regards distribution in the rat brain, a high density of 5-HTlB sites is found in the basal 
ganglia as well as in other regions (pazos et al, 1985). m-RNA has been located in the 
dorsal and median raphe nuclei in the rat as well as in some forebrain sites. 
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It is likely that the 5-HTlB receptors are located both pre- and post- synaptically, as well as 
possibly on some non-5-HT neurons. They are also likely to function as both auto- and 
hetero-ceptors as discussed below. In situ hybridisation has established that m-RNA is 
localised to hippocampal pyramidal and granule cells and, in the caudate, to medium spiny 
neurones. 
Origina1ly, ligands available for use as probes of 5HTlB function were not selective but 
more recently specificity has improved and high affinity has been reported for the 
antagonists SB-224289 and SB-216641 (Roberts et at, 1997). As mentioned previously, 
there are species differences in the pharmacology of equivalent receptors e.g. pindolol, a 
p-adrenoceptor antagonist, has a higher affinity for the rodent 5-HTlB receptor than the 
human receptor. In a similar manner to a number of other 5-HT receptors, it has been 
established that second messenger responses occur by the negative coupling of 5-HT IB 
receptors to adenylate cyclase under forskolin - stimulated conditions (Adbam et al, 1992). 
From a functional perspective it has become clear that the 5-HTIB receptor has auto-
receptor activity at serotonergic nerve terminals (Buhlen et al, 1996). Some data also 
suggest the presence of 5-HTlB auto-receptors in the DRN. 
According to m-RNA presence, 5-HT IB receptors may be found in the DRN but possibly 
also on 5-HT neurones terminating at the DRN, (Starkey and Skingle, 1994). In addition 
to an autoreceptor role 5-HT1B receptors are also thought to have a heteroceptor role and 
regulate the release of other neurotransmitters. 
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This has been suggested for inhibition of acetyl-choline release (Maura and Raiteri, 1986) 
and facilitation of dopamine release by 5-HTm agonists (Lyer and Bradberry, 1996) in the 
frontal cortex. 5-HT 1 B-heteroceptors are also described as underlying the suppression of 
GABAB - mediated IPSP's in rat midbrain dopamine neurones, in vitro (Johnson et a1, 
1992). 
From a behavioural perspective, an involvement of 5-HT m receptors in mouse locomotor 
responses is now better supported by stimulant studies and the absence of this response in 
knock-out mice (Saudou et al, 1994), than previous work suggesting a role in the rat 
locomotor response (Green and Heal, 1985). More precise functional effects on hormonal 
and physiological measures still need to be clarified but studies have reported a negative 
effect of 5-HT1B agonists, such as TFMPP and RU24969, on appetite, with an induced 
hypophagic effect (Kennett et a~ 1987; Kitchener and Dourish, 1994). Although knock-
out mice are more aggressive than wild type mice, 5-HTm antagonists are not generally 
regarded as substances promoting aggression. In a further study involving knock-out mice, 
a 5-HTJB agonist - CP 93129, inlnbited labelled 5-HT release from control hippocampal 
and cortical slices but not from mutants (pifieyro et a1, 1995). 
A further behavioural response which has been observed is contralateral rotation in the 
guinea pig following agonist injection into the substantia nigra, where high levels of 
5-HTJB receptors are found on the terminals of stria to nigra 1 GABA neurones. 
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Other possible responses include agonist induced hypothermia and the potentiation of 5-
HTP induced myelonic jerks (Hagan et a1, 1995). 
5-HTlD receptors 
As discussed earlier, the previously named 5-HT1O receptor is actually a species equivalent 
of the rodent 5-HT1B receptor and was initially characterised from work on bovine and 
human brain tissue (Heuring and Peroutka, 1987). Subsequently, molecular techniques 
have revealed a further receptor with 5-HT1 homology, and this is now the 5-HT1O 
receptor proper (Hartig et a1, 1996). 
The human 5-HT1O receptor gene is located on chromosome Ip34.3 - 36.3. In the rat 
brain 5-HT1O receptors are found in the basal ganglia, hippocampus and the cortex 
(Bruinvels et a1, 1993) while in the human brain, in addition to the basal ganglia, receptors 
are found in the mid-brain and spinal cord (Castro et al, 1997). 
Although found in similar regions with in situ hybridisation studies, m-RNA was not 
detected in globus pallidus, ventral pallidum and substantia nigra, suggesting, with other 
evidence, that the 5-HT 10 receptor is largely based presynaptically - on axon terminals. 
The pharmacology of the 5-HTIB and 5-HT1O receptors is similar in humans and in other 
species, apart from the rat 5-HTIB receptor. In humans, ketanserin and ritanserin have 
some selectivity for the 5-HT1O receptor, (Pauwels et al, 1996) and exhibit antagonist 
properties. 
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It is not yet clear which second messenger response can be linked with the 5-HTlD 
receptor in native tissue but in transfected cells cloned receptors couple negatively to 
adenylate cyclase, as is seen with other 5-HT receptors. In a similar manner to the 5-HTm 
receptor an additional auto receptor role has been proposed for the 5-HTlD receptor, 
however agonist-induced 5-HT inhibition in 5-HTlD knock-out mice has been both 
confirmed and refuted (piiieyro et a~ 1995). Further research with more specific drugs is 
needed to confirm both an auto-receptor role and various heteroceptor possibilities. The 
latter include the inlubition of glutamate release in both rats and humans (Maura et a~ 
1998) and an inhibitory effect on GABA in humans (Feuerstein et al, 1996). Other 
findings have included influences on acetyl-choline release. Low levels of 5-HTlD 
compared to 5-HTlB receptors and poor brain penetration have complicated attempts to 
assign functional responses to the 5-HTlD receptor but it is of interest that one recent 
paper has described a reduction in sensitivity of these receptors in patients with 
melancholic depression (Whale et al, 2001). Further work involves the testing of agonists 
with putative anti-migraine effects, such as PNU-142633 (McCall RB et ~ 2002). 
5-HTIE receptors 
The finding of a biphasic response curve when 5-CT application followed the introduction 
of tritiated 5-HT, suggested that more receptors than the 5-HTlD receptor (high affinity) 
existed. It was the 5-HT1E receptor which was shown to have a low affinity in these ligand 
binding studies. Although other receptors could have demonstrated similar findings the 5-
HT IE gene was then subsequently isolated by molecular techniques. 
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The gene encodes a 365 amino acid protein and is intronless. It is located on human 
chromosome 6q 14~q 15 (Levy et al, 1992). 
It can be inferred from data from a number of sources that the 5-HTlE receptor is located 
post-synaptically. This is suggested by auto~radiographic studies showing that lesions of 
5~HT neurons lead to no variation in 5-HTIE binding sites in the rat forebrain. (Barone et 
al, 1993). Additional support for the above is that 5-HT1E m-RNA is present in the 
monkey and human brain in cortical areas, the putamen and the caudate. Somewhat lower 
levels are detected in the amygdala and hypothalamic regions, a pattern similar to that seen 
with 5-HTIB and 5-HTm m-RNA (Bruinvels et al, 1994a and b). There is as yet, however, 
no evidence that the raphe nuclei contain 5-HTlE m-RNA. The absence of a 5-HTlE 
selective ligand has complicated attempts to work out its distribution and function. In 
addition to the m-RNA studies described above, distribution is inferred from areas of non-
5-HTIA/IB/n/2c [3H] - 5-HT binding in human and other species. These include cortical 
areas, especially entorrhinal but also caudate, putamen and claustrum, hippocampus and 
amygdala. (Miller and Teitler, 1992). 
From a pharmacological perspective the 5-HTlE receptor is characterised by low affinity 
for 5-CT and higher affinity for 5-HT. In this respect it is similar to the 5-HTIF receptor 
but they are differentiated by the lower affinity of the 5-HTIE receptor for sumatriptan. 
The physiological role of the 5-HT1E receptor has not been clarified however one 
functional capacity which has been established is the mediation of a moderate inhibition of 
forskolin stimulated adenylate cyclase (Adham et al, 1994b). 
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In studies of radioligand binding 5-CT has a very low potency as an agonist while 
methiopin behaves as a weak agonist (Adham et al, 1994a). 
5-HT1F receptors 
The 5-HT1F receptor was initially termed the 5-HTlEp receptor as it showed low affinity 
for 5-CT (Similar to the 5-HTlE receptor) but differed in distribution from the 5-HTIE m-
RNA, (Amlaiky et al, 1992). Following characterisation of the mouse 5-HT1F receptor as 
having high sequence homology with other type I receptors - the 5-HTlB and 5-HTm 
receptor, the human receptor was itself sequenced (Adham et aI, 1993b) and located on 
chromosome 3q11. Following in-situ hybridisation studies, m-RNA was located at 
significant rates in the mouse and guinea-pig brains in the hippocampus (CAl - CA3 
layers), cortex and DRN. Human studies have been carried out where correlation was seen 
with m-RNA distribution in the guinea-pig i.e. binding at the highest levels was found in 
cortical and hippocampal areas, claustrum and the caudate nucleus. 5-HT1F receptor 
binding sites are low in the substantia nigra (Waeber et ai, 1995). 
Unlike the 5-HTlE receptor, the 5-HTIF receptor has a high affinity for sumatriptan. 
However, they both have high affinity for 5-HT and low affinity for 5-CT (Amlaiky et aI, 
1992). As with other 5-HTl receptors, the human and mouse receptors couple to the 
inhibition of forskolin - stimulated adenylate cyclase. 2 novel agonists have been reported -
LY334370 and L Y344864, (Johnson et aI, 1997). Studies with these two novel agonists 
have not, however, supported clear behavioural profiles in rats. 
38 
The function ofthe 5-HT IF receptor is not known but it may be involved in both visual and 
cognitive roles and as an auto-receptor (Waeber et ai, 1995). 
1.3.4.2 The 5-HT 2 family 
Activation of both 5-HT2A and 5-HT2C receptors stimulates phosphoinositide hydrolysis. 
This fact, and the low divergence of amino acid sequence homology between the type 2 
receptors (60% homology between the three subtypes) lead to their current classification 
grouping. This family therefore includes the 5-HT2A' 5-HT2B and 5-HT2creceptors. 
They display numerous similar features including structure - a high level of amino-acid 
sequence homology is seen in the 7 transmembrane domains (Baxter et ai, 1995); function 
- all couple positively to phospholipase C and stimulation leads to the mobilisation of 
intra-cellular caIcium; genetic structure - all have either 2 or 3 introns in the coding 
sequence ( Chen et a~ 1992); and pharmacology- a relatively low affinity for 5-HT, a high 
affinity for the 5-HT2 receptor agonist DOl and a high affinity for other 5-HT2 receptor 
antagonists including Ritanserin. The 5-HT 2A receptor was previously known as the 5-HT 2 
receptor and the 5-HT2C receptor was previously the 5-HTlC receptor. 
The 5-HT2B receptor was termed the 5-HT2F or SRL receptor in previous studies and had 
been originally related to the 5-HT2 receptor as a 5-HT2-like receptor in the fundus of the 
rat stomach. 
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5-HT2 receptors have all been shown to desensitise after being exposed to 5-HT and other 
agonists for prolonged periods although the precise modes of this loss of function may 
differ (Sanders-Bush, 1990). 
5-HT2A recf!ptors 
Originally termed the 5-HT2 receptor, the 5-HT2A receptor was subsequently grouped with 
the 5-HT2C and 5-HT2B receptors in the 5-HT2 family on the basis of having a similar 
pharmacological profile and second messenger system. It was later confirmed that the 
three receptors were also closely structurally related with high amino-acid sequence 
homology, although greater between 5-HT2A and 5-HT2C than between 5-HT2A and 2B. 
5-HT2A receptors were initially characterised as 5-HT receptors with a high affinity for 
[3RJ-spiperone and low affinity for serotonin itself (Leysen et al, 1978). 
The human 5-HT2A receptor is located on chromosome 13 q14- q21. Specific amino-acids 
have been studied within the receptor which are available for glycosylation and 
phosphorylation and others have been shown to affect ligand binding and effector coupling 
(reviewed in Boess and Martin, 1994). 
A number of different study methods have ascertained the distribution of the 5-HT2A 
receptor in the human brain, including auto-radiography with eRJ-spiperone and [1251]_ 
ketanserin, in-situ hybridisation and immunocytochemistry. In addition it is well 
established that 5-HT2A receptors are present in the same location as the cells expressing 
them by m-RNA distribution (Mengod et al, 1990; Burnet et al, 1994). 
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High levels are found in numerous forebrain and cortical regions as well as in the caudate 
nucleus, nucleus accumbens and some limbic areas. (pazos et al, 1985). 
This distribution also corresponds to that ofaxons arising from the DRN (Blue et al, 
1988), and the predominant neuronal location of the receptor is supported by other m-
RNA studies (Burnet et al, 1995). Evidence has also shown receptor activity on GABA-
ergic interneurones (Morilak et al, 1993) and glutamatergic pyramidal neurones (Burnet et 
al, 1995). 
Original attempts to delineate functional attributes of the individual 5-HT2 receptors were 
hampered by the lack of selective agents, a situation which is now improving with the 
development of highly selective antagonists such as MDL 100907 (Sorensen et aL 1993) 
and SB 200646A (and others) which distinguish between the 5-HT2A' 5-HT 28 and 5-HT 2C 
receptors (Baxter, 1996). Work on agonists is relatively less advanced. 
As regards second -messenger responses, 5-HT2A receptors have been shown to activate 
phospholipase-C through G-protein coupling (Sanders-Bush et aL 1995), as mentioned 
above. In different studies agonists such as DOl have exhibited partial agonist properties, 
m-CPP displays 5-HT2A antagonist activity and other ligands act as inverse agonists. 
A further interesting finding is the evidence that altered gene expression can follow 5-
HT2A receptor stimulation, as exemplified by brain-derived neurotrophic factor (BDNF) 
(Vaidya et al, 1997). 
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Other evidence for a downstream regulatory role of other systems comes from electro-
physiological studies suggesting a 5-HT2A role in the regulation of NA neurones. 
There is also evidence from micro-dialysis studies (Done and Sharp, 1994) that 5-HT 2 
antagonists increase NA release. Whether this is a 5-HT2A or 5-HT2C receptor-mediated 
event activity is not currently clear. Behavioural responses to 5-HT2A receptor activation 
are now more reliably known to include rat 'wet dog shakes' and mouse 'head twitches' 
(Green and Heal, 1985). A close link between hallucinogenic potency and 5-HT2 binding 
has lead to a search to discriminate whether 5-HT2A or 5-HT2C receptors are more 
involved. Although both correlate, the predominantly 5-HT2C agonist m-CPP is not 
hallucinogenic. 
The 5-HT2A binding site has a high affinity for anti-psychotic drugs and interest in the link 
with psychosis has been increased following the correlation of 5-HT 2A polymorphic 
variants with treatment response (Busatto and Kerwin, 1997). Other functional responses 
include hyperthermia, and increased secretion of cortiso~ ACTH, renin and prolactin 
(Bagdy, 1996). 
5-HT2B receptors 
In 1959, Vane established that serotonin induced contraction of the rat stomach fundus. 
Subsequent work linking this action to a specific receptor suggested that the effect was 
mediated by a 5-HT1-like receptor (Baez et a~ 1990). 
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Although the receptor behaved in a similar pharmacological way to the subsequently 
named 5-HT2C receptor, 5-HT2C receptor m-RNA was not detected in the same location. 
Molecular genetic studies subsequently established the identity of a similar receptor, 
initially termed the 5-HT2F receptor but renamed later as the 5-HT2B receptor (Humphrey 
et al, 1993), and located the gene on chromosome 2 from q36.3-37.L The receptor is 481 
amino acids in length and shows significant sequence homology with both the 5-HT2A and 
5HT2C receptors. As discussed above, the 5-HT2B receptor is similar to the other members 
of the 5-HT2 family from a genetic perspective: the gene has two introns which 
correspond to those in the 5-HT2A and 5-HT2C genes (Foguet et al, 1992b). The 
distnbution of the receptor in the brain is more limited than other members of the family, 
being found in the cerebellum, lateral septum, dorsal hypothalamus and medial amygdala. 
The receptor binding of the 5-HT2B receptor is similar to the 5-HT2C and 5-HT2A 
receptors, although it has lower affinity for ritanserin and higher affinity for yohimbine 
(Kennett et at, 1994b). 
Some species differences in pharmacology seem to exist but less so between the rat and 
human (Bonhaus et a~ 1995). From a functional perspective, the cloned rat and human 5-
HT2B receptors stimulate phosphatidylinositol hydrolysis. In functional models 5-HT itself 
and analogues behave as full agonists while TFMPP and quipazine are partial agonists. 
5-HT2B receptors may regulate mitogenic effects during neural development (Choi et a~ 
1997). Apart from a possible anxiolytic effect there is limited information on behavioural 
effects. (Duxon et at, 1997). 
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5-HT2C receptors 
The 5-HT 2C receptors are distributed extensive1y throughout the brain but the greatest 
density is found in the choroid plexus (Pazos et al, 1987). Lower densities are found in 
the hippocampus, amygdala, cingulate, corpus striatum, subthalamic nucleus, supra .. 
chiasmatic nucleus and the grey matter ofthe spinal cord. The relevance of this receptor to 
psychiatric illness and its treatment will be discussed further in subsection 1.5 and further 
aspects of the receptor itself will be detailed in subsection 1.7.2.1. 
1.3.4.3 The 5 -HT 3 Receptor 
Unlike the other 5-HT receptors, the 5-HT3 receptor is a ligand -gated ion channel. From 
a molecular perspective , only one gene, encoding the 5-HT 3A subunit, has been 
characterised (Maricq et aI, 1991). This sub-unit is formed from 487 amino-acids and 
displays greater similarity to members of other receptor super-families such as the 
nicotinic and glycine receptors. Two forms of the sub-unit have been characterised- the 
short form, 5-HT3S being reported in a number of species ( Reviewed in Barnes and 
Sharp, 1999) but the m-RNA of the long form is not expressed in humans (Werner et aI, 
1994). The short form results from a deletion of 18 nucleotides in exon 9 ofthe gene and 
in humans the gene is found on chromosome 11 (Uetz et aI, 1994). The ion channel is 
formed by a lining of 5 sub-units, with gating by an inward bend at a hydrophobic leucine 
residue, in common with other similar receptors (Unwin et aI, 1993).The N- and C-
terminals of the subunit are extracellular and the channel itself is 3 nm in diameter (Boess 
et aI, 1995) and selective for cations. 
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The 5-HT3 receptor is mainly found in the brainstem. By comparison,. forebrain 
expression is generally low, but there is both species and regional variation, with higher 
levels in some limbic areas and in humans - high levels are seen in the caudate and 
putamen (Abi-Dargham et ai, 1993). In rodents, relatively higher cortical expression is 
seen than in humans. A relatively high level is seen in the hippocampus in most species 
(Parker et ai, 1996), and m-RNA is mainly found in the inter-neurones. Data from 
different sources supports the role of the receptor in the activation of GABA inter-
neurones, leading to downstream inhibition of pyramidal neurones (Tecott et ai, 1993). 
These GABA neurones , in the human basaI ganglia, are also those that are seen to 
degenerate in Huntington's disease (Steward, 1993). 
The pharmacological aspects of the receptor have been noted for their inter-species 
variation as well as for the receptor's capacity for allostearic modulation by numerous 
compounds which also affect other superfiunily members. Clinically relevant compounds 
include alcohols, steroids and anaesthetic barbiturates (Miller et al, 1996). 
There has been some evidence for the further delineation of 5-HT3 receptor subunits since 
the cloning of 5-HT3A by current/voltage relationships rather than pharmacological means 
in one case (Hussy et ai, 1994) and further conductance studies by another group (Yang 
et al, 1992). These additional subunits were suspected by the fimctional diversity of the 
receptor and may interact with other receptor subunits. 
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From a functional perspective, 5-HT3 receptors in the dorsal vagal nuclei in the brainstem 
are considered important in the anti-emetic action of the 5-HT3 antagonists. Initial hopes 
of a use for antagonists in a number of different kinds of psychiatric disorder, have not 
been supported well, although animal models have often suggested an anxiolytic action of 
\ 
these compounds. 
The relationship of 5-HT3 to CCK and the capacity of CCK to induce panic further 
supports this link. Unfortunately, other than a possible elevation of pain threshold, 
knockout mice have not thrown light on this and other questions (Guyet aI, 1997). 
Some early work has supported a positive effect of antagonists such as ondansetron on 
cognitive performance and this has also been seen with other antagonists, although not 
uniformly between groups (Bentley and Barnes, 1995). One possible mechanism for this 
effect is that 5-HT 3 stimulation decreases cortical acetyl choline release, thereby 
supporting the reverse i.e: enhancement of cognition by 5-HT3 antagonism (Consolo et al, 
1994). This is further supported by the fact that acetyl choline activity has been correlated 
with cognitive performance and Ac-Ch deficits, such as are seen in Alzheimer's Disease, 
reduce performance (Bartus et al, 1982). 
A further role of the receptor relates to its capacity to influence dopamine activity in 
central brain regions, by facilitatory mechanisms. This is shown in rat studies following 
receptor activation in the nucleus accumbens and striatum (Blandina et a~ 1988). 
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Other studies have used electrochemical techniques to investigate effects on the dopamine 
system; however it would seem, ovemll, that 5-HT3 antagonists do not alter basal 
metabolism or release of dopamine (Koulu et al,1989). 
1.3.4.4 The 5-HT 4 Receptor 
It has been known for some time that serotonin is able to stimulate adenylate cyclase in the 
brain (Fillion et al, 1975). This and other functional responses due to the activity ofthe 5-
HT 4 receptor have been demonstrated in animal studies, centrally in mouse colliculi 
neurones and guinea pig brain and also in peripheral tissues (reviewed in Ford and Clarke, 
1993). Two species of the receptor have been sequenced, short or 5-HT4(a) and long or 5-
HT4(b) , which arise by alternative splicing of the m-RNA from position 360 (Hoyer and 
Martin, 1997). There are two further splice variants and these have been confirmed in 
animal and human genomes - 5-HT4(C) and 5-HT4(D) with common sequences up to amino 
acid 358. The receptor gene has been located on chromosome 5 between 5q31 and 5q33 
(Cichon et al, 1998). The 5-HT4A' B and c isoforms are found in both the brain and the 
GIT while 5-HT4D receptors have only been located in gut tissue (Blondel et aI, 1998). 
Both receptors and m-RNA in the bmin are found chiefly in nigrostriatal and mesolimbic 
areas. All 4 receptors couple positively to adenylate cyclase but differences in efficiency 
are likely following phosphorylation and this process is probably also related to 
desensitisation of the 5-HT 4 receptor (Ansanay et al, 1992). One of the functional 
attributes of the 5-HT4 receptor is through the modulation of other neurotmnsmitters 
including acetyl - choline. 
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This capacity has been supported with both agonist and selective antagonist studies, 
(Consolo et al, 1994). Post mortem brain samples have also shown reduced hippocampal 
5-HT4 receptor density in Alzheimer's patients (Reynolds et al, 1995). In addition to the 
modulatory effect on the cholinergic system, evidence exists for a role in dopamine 
modulation, with both in vitro and in vivo studies showing increased striatal dopamine 
release, by indirect means, as 5-HT4 receptors seem to be found, not on dopamine neurone 
terminals, but on GABA-ergic terminals of neurones with striatal cell bodies (Gerfen, 
1992). 
In addition to the modulation of other neuro-transmitters, 5-HT release itself is modulated 
by the 5-HT4 receptor. Microdialysis techniques have revealed that activation of 5-HT4 
receptors leads to serotonin release from the hippocampus. This release was further 
modified by 5-HT4 antagonists by inhibition, an effect also seen in the substantia nigra 
(Thorre et al, 1998). 
In spite oflaboratory evidence for the above modulatory effects, no behavioural effects are 
seen either with administration of drugs affecting 5-HT4 function or behaviours related to 
variations in Dopamine function (Reavill et al, 1998). This finding is also supported in 
primate studies (Terry et al, 1998). While the modulatory e:ffect of 5-HT4 activity on 
Acetyl Choline may provide the link with enhanced memory, it is also known that 5-HT4 
receptors are found in hippocampal pyramidal neurones and thus might implicate long 
term potentiation as a mechanism (Ullmer et al, 1996). 
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Evidence is currently lacking in humans for a cognitive enhancing effect of 5-HT 4 
stimulation. From a psychiatric perspective, 5-HT 4 may playa role in anxiety however the 
findings have been contradictory, with animal models showing both evidence for anxiolysis 
(Kennett et al, 1997) and inhibition of benzodiazepine anxiolysis (Costall and Naylor, 
1992) by 5-HT4 antagonists. Interesting parallels are evident concerning the role of the 5-
HT 3 receptor in anxiety and a possible interactional model has been investigated in some 
studies (Andrews et al, 1994). 
1.3.4.5 The 5-HT 5 Receptor 
5-HTs receptors have been isolated from mice (Hen et ai, 1992) and rat brain c-DNA 
libraries (Wisden et ai, 1993) in A and B forms. A human 5-HTsA receptor has aIso been 
cloned (Rees et al, 1994) but no evidence is currently available for these receptors in the 
natural state. It is likely that 5-HTsA comprises 357 amino acids while 5-HTsB may have 
approximately 370 amino acids. 
The 5-HTSA human receptor gene has been located on chromosome 7 at position 7q 36 
and the 5-HTsB human receptor gene on chromosome 2 at 2qll-13, however it is not 
clear if this receptor is expressed (Rees et al, 1994). The receptor would appear to have a 
widespread brain distribution, according to in-situ hybridisation studies (Waeber et ai, 
1998). 
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In mice, the regions linked with 5-HTsA m-RNA are neurones within the cerebral cortex, 
dentate gyrus and the hippocampal CAI-3 pyramidal layers, cerebellum granule layer and 
the olfactory bulb (plassat et at, 1992). Similar studies have shown the B receptor m-
RNA in the hypothalamus, hippocampus, medial and lateral habenula, DRN, olfactory 
bulb, and the entorrhinal and pyriform cortices (Erlander et at, 1993). These are at low 
intensity and post-natal timing studies also show different rate of expression, between the 
two m-RNA species. Human brain tissue also exhibits increased translation in adults, and 
astrocytes are a major expression site early in post-natal life. 5-HTsB is late in expression 
but appears shortly after birth in the rat (Wisden et at, 1993). 
In its pharmacology 5-lITs is similar to 5-lIT4• As with many other 5-HT receptors, 5-lIT 
receptors are G-protein coupled receptors with 7 transmembrane domains. The receptor 
appears to reduce production of forskolin stimulated adenylate cyclase, (Francken et at, 
1998a and b). In knock-out mice increased locomotion has been seen and exploratory 
behaviour, but this did not seem to be related to anxiety features on animal testing (Grailhe 
et at, 1997). 
1.3.4.6 The 5 -HT 6 Receptor 
In common with the other 5-HT receptors, the 5-lIT6 receptor is a member of the G-
protein-coupled, seven putative transmembrane domain, receptor superfiunily. It was 
detected by the technique of nucleotide sequence homology screening, by two groups 
(Ruat et at, 1993; Monsma et at, 1993). 
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Agonist induced desensitisation has been described, probably caused by c-AMP-dependant 
protein kinase, leading to receptor phosphorylation The receptor gene is located on 
chromosome 1 at Ip35-36. In the rat, high levels of receptor m-RNA are only found in 
the central nervous system, especially in the caudate nucleus (Monsma et al, 1993). 
High levels of 5-HT6 receptors have been located in the hippocampus, olfactory tubercles 
and nucleus accumbens, and immunocytohistochemistry has concurred with these regions 
as well as labelling the cerebral cortex and striatum (Gerard et al, 1997). In spite of the 
difficulty localising the receptors, due to low levels of expression and the high rate of non-
specific binding of ligands, studies have supported a post synaptic position of the 
receptors. This has been confirmed by the absence of loss of raphe 5-HT6 receptor m-
RNA after neuronal lesions. It has also been proposed that localisation occurs on 
dendrites of hippocampal and striatal neurones as well as on GABA-ergic neurones 
terminating in the substantia nigra and globus pallidus (Gerard et al, 1997). 
From a psychiatric perspective, interest in the psychopharmacology of the receptor 
has centred around the capacity of antipsychotics, including clozapine, to antagonise 
the receptor and a further study has used the radio ligand eH) Clozapine, in an 
additional attempt to characterise the receptor, (Glatt et al, 1995). Other drugs are 
also now being evaluated, with known effect on the receptor as a target (Branchek et 
al, 2000; Bromidge et al, 2001). Both native and recombinant 5-HT6 receptors have 
been shown to positively enhance adenylate cyclase (Boess et al, 1997). 
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Behavioural effects of the antagonism of the 5-HT6 receptor have included rat 
'yawning and stretching' following I.e.v. antisense rryection in [3H] LSD sites (not 
D2 or 5-HT2), (Bourson et al, 1995). This finding has been further supported by a 
different group and prefronta15-HT release was attenuated (Yoshioka et al, 1998). 
Knock -out mice have shown increased anxiety in animal models. In studies where 
levels of corticosterone are artificially adjusted, 5-HT6 receptor m-RNA is elevated 
with corsticosteroid absence. This may be relevant to the vulnerability of some 
people to depression (Boess et aI, 1997). 
1.3.4.7 The 5-HT 7 Receptor 
This most recently identified serotonin receptor seems to be an equivalent of the fruitfly 
(Drosophila Melanogaster) 5-HTdro\ receptor (Witz et a4 1990) and is between 445 and 
448 amino-acids in length. Its gene, containing 2 introns, is located on chromosome 10 
(q21-24) in humans (Gelemter, 1995). The receptor exhibits features common to the G 
protein-coupled receptor superfamily. 
While 4 receptor splice variants exist (q-d), 5-HT7(d) is absent in rat tissues and 5-HT7(c) 
has not been detected in human tissue, (Heidmann et a4 1997). The 5-HT7 receptor is 
found in higher concentrations in the hippocampus, thalamus and hypothalamus than in the 
cortex and amygdala (Gustafson et a4 1996). 
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The 5-HT7 receptor is also affected by anti-psychotic and anti-depressant drugs but the 
gene has not been implicated in vulnerability to either schizophrenia or bipolar disorder 
(Erdmann et a~ 1996). The receptor transduction system involves stimulation of 
adenylate cyclase. 
From a functional perspective, it would seem that suprachiasmatic nucleus activity and 
phase shifting potential support a role for the receptor in circadian rhythms. 5-HT7 m-
RNA has been located in the SCN and cAMP also induces a phase shift , as is seen with 5-
HT (prosser and Gillette, 1989). 
One possible neuropsychiatric role for the receptor would be in the reduction of fits in 
epilepsy for which hypothesis animal models exist (Bourson et a~ 1997). In anti-sense 
experiments with rats, an anxiety paradigm was not supported (Clemett et a~ 1998). 
Fluoxetine has been shown to cause down regulation in 5-HT7 receptors over time 
(Sleight et ai, 1995) but other SSRIs were not found to affect 5-HT7 receptor mediated 
stimulation of cAMP levels. However, desensitisation was seen after direct receptor 
stimulation (Shlmuzu, 1998). Some tricyclic drugs have been shown to enhance 5-HT 
stimulated cAMP production. 
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1.4 DEPRESSION AND S-HT 
1.4.1 Measures of brain S-HT function 
1.4.1.1 CSF 5-HlAA 
Following on from knowledge of the metabolic cycle of serotonin production and 
degradation, it is apparent that measuring the quantity of breakdown products of 5-HT 
may give an estimation of the total activity of serotonin at earlier stages in the cycle. In 
order to closely assess serotonin activity within the central nervous system studies have 
looked at the level of 5-HIAA in the cerebro-spinal fluid withdrawn from the subarachnoid 
space by the clinical procedure oflumbar puncture. 
Studies have generally not shown reduced levels in depressed patients (Koslow et al, 
1983) , but some studies have shown decreased levels in patients with a history of suicide 
attempts (Brown and Linnoila, 1990). It has also been reported that this correlation is 
greater where the attempts to self harm have been particularly violent (Mann and Malone, 
1996). It is of note that similar low CSF 5-HIAA levels have been found in patients 
diagnosed with personality disorders, chiefly dissocial personality disorder, where violent 
and aggressive behaviours have been evidenced (Linnoila and Virkunen, 1992) leading to 
the theory that the low levels may be markers for personality traits associated with 
violence and anti-social expression and these traits mod.ifY behavioural presentations in 
variable mood states (Roy et a~ 1990). 
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It has also been clarified in the latter reference that the finding oflow 5-HIAA levels is not 
diagnosis specific and some studies have shown similar low levels in schizophrenia. 
1.4.1.2 Post-mortem binding studies 
A further prediction of the above discussion is that levels of 5-HT receptor binding should 
be reduced in the brains of those dying by means of suicide. Studies have not provided an 
unequivocal answer~ but it would presently seem that the evidence is not consistent for 
reduced levels (Horto~ 1992). However~ as discussed above, there is more consistent 
evidence that those depressed patients attempting to commit suicide have lower levels of 
CSF 5-HIAA. As this finding is not only seen in depressives following suicide attempts 
but also in some samples of schizophrenic patients and those with personality disorder 
where there is a history of aggressio~ it has been suggested that the finding in suicides 
may also correlate less with mood and more with a tendency to react impulsively in certain 
situations (Brown and Linnoila~ 1990). 
Attempts have also been made to establish whether variations in brain 5-HT or 5-HIAA 
are abnormal post suicide as a more direct test of the mono-amine hypothesis. 
Interpretation of results of these studies is potentially complicated by factors including 
brain changes which may have occurred following deat~ and changes which may have 
occurred before death but due to factors other than depression eg: anoxia or due to drugs 
taken therapeutically or by over-dose. An early series of studies evaluated Tritiated 
imipramine binding in suicide victims~ as a measure of serotonin transporter number. 
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Although the initial studies showed a reduction in cortical binding (Stanley et al, 1982; 
Perry et a~ 1983), a later study was unable to replicate the finding (Horton, 1992). More 
recently, Lawrence was also unable to replicate the original finding ( Lawrence et 
~1998), and agreed with the Horton study, with a general current perspective that levels 
of 5-Hf and 5-ffiAA are not consistently reduced. 
Receptor subtypes examined in post-mortem tissue other than the serotonin transporter 
include 5-HfJ and 5-Hf2 subtypes. The 5-HT1A receptor numbers seen in brains of suicide 
victims do not show changes in a specific direction (Horton, 1992; Arranz et al, 1994). 
Lowther has looked at both this receptor (Lowther et ~ 1997a) and other 5-HfJ 
receptors (Lowther et al,1997b). An increase in pallidal5-Hfm receptors was found in the 
drug-naive depressive group but the 5-HTlE and 5-HTIF receptor numbers were 
unchanged. 
Some receptor studies revealed an increase in the number of 5-HT2 binding sites in the 
frontal cortices of suicide victims (Mann et ~ 1986) however, although initially reported 
as correlating especially well in those dying by violent means (Arora et a~ 1989), a more 
recent extensive study did not show this (Lowther et al, 1994). Most recently, the brain 
scanning method SPET has been used to assess receptor function in serotonergic drug 
naiVe suicide attempters. In one study involving a 5-Hf 2A antagonist, deliberate self 
harmers had significantly reduced measures of frontal binding than controls. This effect 
was also more pronounced in self injury than self-poisoning (Audenaert et al, 2001). 
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It is also not clear that severe depression would be the only mediating factor towards 
upregulation of 5-Hf2 receptors as a similar finding was reported in the brains of those 
dying of other causes than suicide (Yates et al, 1990), and dieting has lead to an increase 
in the sensitivity of one receptor subtype, the 5-HT2C receptor (Cowen et ai, 1996). 
Drug therapy is also known to affect 5-HT2A numbers. A reduction of 5-Hf2A receptors 
has been seen with chronic treatment using tri-cyclic anti-depressants (Cowen, 1990) but 
this is not the effect seen, after similar treatment periods, on platelet 5-Hf2A receptor 
numbers, which are increased. 
1.4.1.3 N euro-endocrine studies 
The tests described in this section relate to attempts to use hormonal measures to index 
the activity of 5-HT receptors. Probes that increase 5-HT function increase the secretion 
of anterior pituitary hormones by facilitating the release of peptide releasing hormones in 
the hypothalamus. 
As can be predicted by an understanding of the cellular systems for the production and 
metabolism of 5-Hf and related aspects of neuro-transmission, probes exist which relate 
to both pre-synaptic neuronal function and to direct effects on post-synaptic receptors. 
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Responses to Tryptophan: 
In normal subjects plasma hormonal responses to intra-venous tryptophan (TRP), the 5-
HT precursor, include elevations of prolactin and growth hormone. As discussed 
previously, these responses can be attenuated by the administration of pin dolo I but not by 
5-HT2 or 5-HT3 receptor antagonists, implying that 5-HT1A antagonism is causing the 
attenuation of the response (Cowen, 1993). Endocrine responses to TRP in depressed 
patients are blunted in most of the relevant studies. In some of these studies changes in 
body weight or TRP availability have to be considered in interpretation ofthe findings. 
Thus in two studies (Cowen et aI, 1987; Deakin et al, 1990), significant blunting of the 
hormonal responses was only seen when those patients with significant recent weight loss 
were excluded, and this has been recognised as a confounding variable in diet studies 
where weight loss has lead to an increased PRL response to TRP. In another study the 
plasma levels of TRP were low, implying that this might be the reason for a reduced 
response, however five studies have reported blunted PRL and GH responses of 
depressives to TRP in the absence of changes in TRP availability (Reviewed in Power, 
1992 ). 
In order to establish whether these attenuated responses might reflect a trait abnormality, 
one study examined neuro-endocrine responses to TRP once patients had recovered from 
the depressive episode and been withdrawn from treatment. The results suggested that 
abnormal endocrine responses to TRP normalised with clinical recovery (Upadhyaya et al, 
1991). 
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Responses to 5-HTP 
An increase in plasma cortisol is seen following the administration of 5-HTP (Gartside 
and Cowen, 1990). As this response is not attenuated by pindolol, it is unlikely that the 5-
HTIA receptors are involved in the response, however the response is blunted by ritanserin, 
suggesting mediation via indirect activation of 5-HT2 receptors is the underlying 
mechanism (Meltzer and Maes, 1994). Results from studies in depressed patients are 
contradictory but an increased response may be present in depressed women. Whether this 
could be due to concomitant weight loss is unclear. 
Responses to d-Fenjluramine 
d-Fenfluramine is an amphetamine analogue which promotes the release of 5-HT from 
terminal vesicles and also functions as a serotonin re-uptake inhibitor. The prolactin 
responses to d-Fenfluramine are probably mediated via indirect activation of 5-HT 2 
receptors as the PRL response is blocked by ritanserin but not pindolol (park et a~ 1995). 
The origin of the cortisol response is less clear. 
Some studies have reported blunted responses to d-Fenfluramine in depression but this has 
not been seen consistently. Four studies have reported attenuated responses but these have 
included specific subtypes by either severity of mood (Mitchell et ~ 1990; Lichtenberg et 
~ 1992) or personality disorder (Coccaro et al, 1989; Malone et al, 1996) where blunted 
responses have also been reported, in the absence oflow mood (Stein et al, 1996). 
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This latter effect has been further investigated by deriving separate measures of the 
personality traits psychoticism and aggression. d-Fenfluramine induced cortisol non-
response occurred to a greater extent in those with higher psychoticism scores while PRL 
blunting was more evident in those with aggressive traits (Netter et al, 1999). In a study 
involving offenders, psychopathy correlated with reduced initial cortisol responses while 
non-psychopathy and schizoid personality were associated with enhanced PRL response. 
Reduced 5-HT function was reported in those with borderline disorder, recurrent se1f-
harm or alcoholism (Dolan et at, 2001). There is some evidence that the PRL response to 
d-Fenfluramine is a trait marker of depression (Reviewed in Lerer et al, 1996). 
d-FEN has also been used to test the Cloninger model oftri-dimensional personality types. 
In the severely depressed patient group mentioned above, the blunted responses have been 
investigated in a similar way to those following TRP, once the person has recovered. 
Likewise, in two studies including intra- and post-illness testing, normalisation was seen 
following clinical recovery, however in one study with a more extended follow-up period 
of one year, patients had stopped their medication by the time of the second test and 
blunting again returned, suggesting a possible return to a vulnerable state, but without 
clinical relapse (Gerra et aI, 2000). In a further investigation of the relationship between 5-
HT release, hormonal responses and mood, d-fenfluramine was administered to patients 
with unipolar major depression. Baseline cortisol measures correlated inversely with 
severity but higher initial cortisol responses predicted better therapeutic response (Cleare 
et aI, 1998). It has also been shown that pindolol can block prolactin but not cortisol 
release after d-fenfluramine administration (Palazidou et al, 1995). 
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Unfortunately, risks are now recognised to be associated with fenfluramine use and indices 
of neurotoxicity, pulmonary hypertension and cardiac valve pathology have been reported. 
Direct toxic effects on the serotonin transporter have been described using a human 
placental cell model involving DNA fragmentation and apoptosis but this effect was 
blocked by the use of the SSRI, Fluoxetine, suggesting that intact 5-HTT function is 
necessary for apoptosis to occur (Bengel et ai, 1998). However, other data suggests that 
d-FEN induced valvular heart disease only occurs with the involvement of 5-HT2B 
agonists, implying a complex toxicity model (Rothman, 2000). 
Responses to clomipramine: 
All tricyclic anti-depressants exhibit a combination of serotonergic and noradrenergic 
activity but Clomipramine has been widely used as a probe of 5-HT function as it is the 
tricyclic antidepressant with the most significant level of serotonergic activity by re-uptake 
inhibition and relatively low levels of noradrenergic activity. By using this drug as a probe 
it is possible to use prolactin and cortisol as proxy markers of central 5-HT function, as 
described above (Cowen, 1993). Chronic treatment with clomipramine has been shown to 
lead to down-regulation of 5-HT 2 receptors and a possible serotonin! dopamine interaction 
using PET (Attar-levy et al, 1999). The major metabolite of clomipramine is 
desmethylclomipramine, which is a potent inhibitor of noradrenaline re-uptake but is not 
detectable within the testing period following administration of intra-venous clomipramine 
and is therefore not thought to intefere with interpretation of the outcomes of the 
clomipramine challenge as a measure of 5-HT activity. 
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It has been reported that the prolactin response to i1v clomipramine is abolished by the 
non-selective 5-HT receptor antagonist, methysergide, suggesting that post synaptic 
receptors are involved in the response. Unfortunately doses high enough to cause 
significant hormonal responses are often associated with nausea and vomiting, limiting the 
use of the challenge. Three studies in depressed patients have found blunted PRL 
responses to clomipramine, in comparison with healthy controls (Reviewed in Cowen, 
1998). 
5-HT receptor agonists 
There are a number of drugs which have been studied in view their high affinity for the 5-
HTIA receptor, including buspirone, gepirone, ipsapirone and tandospirone. Although 
administration of buspirone, the most widely studied, increases plasma ACTH, PRL, GH 
and cortisol as well as eliciting a hypothermic response in most studies, elucidation of the 
specific mechanism has been complicated by additional effects on the dopamine system. As 
the effects common to the listed 5-HT1A agonists include GH and ACTH release and 
hypothermia it has been possible to use pindolol to attenuate these responses (Reviewed in 
Cowen, 1993). PRL responses to the probes are inconsistent. 
A further 5-HT1A agonist, 8-0H-DPAT has been used in animal studies where 
reproduction of the above effects by direct injection into the hypothalamus has supported 
previous evidence that the endocrine responses are due to post-synaptic 5-HTIA receptors 
(van der Kar, 1991). 
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However, direct irliection of 8-0H-DPAT into the DRN causes hypothermia, suggesting 
that this response is mediated by autoreceptors on the cell bodies of 5-HT1A neurones, as 
ligand binding studies have shown that these receptors are located on both cell bodies and 
post-synaptically in the hypothalamus. 
The relatively selective 5-HT2C receptor agonist m-CPP will be discussed in detail below. 
A further receptor agonist acting on this receptor is MK212, which also affects 5-HT2A 
receptors but has a similar hormonal response profile to m-CPP. Both 5-HT1A agonists 
and 5-HT2C agonists therefore increase ACTH and cortisol but increases in OH are seen to 
a greater extent in 5-HTIA activation. PRL elevation is more reliably caused by 5-HT2C 
activation which also causes hyperthermic responses while 5-HT lA activation leads to a 
hypothermic reaction (Reviewed in Cowen, 1998). The above agonists are the most 
widely investigated probes of function however newer, more highly selective agonists and 
antagonists are also being studied, as discussed in the sections above, describing the 
individual receptors. 
1.4.1.4 Tryptophan studies 
Plasma studies 
In view of the competition between TRP and other amino acids for entry to the brain, it 
was previously hypothesised that a correlation should exist between brain TRP and both 
plasma TRP and the relative ratio of TRP to the other large neutral amino acids. One 
animal study showed that 5-HT synthesis increased following an increase in available 
peripheral TRP (Gibbons et al, 1979). 
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A corollary of the hypothesis that optimal serotonin activity is necessary to protect 
individuals against depression is that plasma levels of TRP, if reflecting brain tryptophan 
activity, should be lower in depressed patients. A number of studies have investigated this 
corollary with variable results. One study looking at serum 5-HT itself only showed a 
reduction in the plasma of the melancholic subgroup of depressed patients (Perez et al, 
1998). The most consistent reductions are seen in total plasma tryptophan both in the 
latter study and others (De Myer et al, 1981; Karege et al, 1994; Anderson et al, 1990; 
Malatino et al, 1982) and the TRP: amino acid ratio (Anderson et al, 1990; De Myer et al, 
1981; Cowen et at, 1989). However, no change was seen in total TRP levels in some 
studies (Niskanen et ai, 1976; Moller et aI, 1979; Perez et al, 1998; Perret et al, 2000). 
Total TRP was actually increased in daytime measures in depressives in the circadian 
study (Malatino et al, 1982), a finding also seen for serum 5-HT in the summer (Sarrias et 
at, 1989). Results have been equivocal for free plasma tryptophan with a reduction in 
depressives (Cowen et al , 1989), an increase in depressives (Niskanen et al, 1976) or no 
difference in comparison with normals reported (Moller et at, 1979). 
Tryptophan depletion studies 
As TRP is a precursor for serotonin it has been hypothesised, as a corollary to the 
evidence linking 5-HT and depression, that experimental manipulation ofTRP levels in the 
body might contnbute to a lowering of mood. Previous animal studies have shown that 
peripheral TRP depletion leads to a reduction in available TRP for central synthesis 
(Biggio et at, 1974). 
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This has been investigated in healthy individuals with both positive (Smith et al, 1997a and 
b; Young et aI, 1985; Ellenbogen et al, 1996) and negative results (Oldman et al, 1994; 
Abbott et al, 1992). In one study a deterioration in mood only occurred in those patients 
with a positive family history of affective disorder (Benkelfat et al, 1994) while in another 
study the effect was confined to females (Smith et al, 1997a). In depressive patients 
tryptophan depletion has also been shown to lower mood, during periods of remission 
(Smith, 1997b). 
The technique - 'Tryptophan depletion', is achieved by subjects drinking an amino-acid 
rich drink which lacks 1RP. There is evidence that this technique lowers the concentration 
of tryptophan in plasma (Delgado et al, 1990), and inhibits transport across the blood-
brain barrier (Biggio et al, 1974; Young et al, 1985). Two physiological means by which 
the technique might achieve this are through the production of protein in the liver, which 
could be stimulated by the amino-acid drink, and subsequent uptake of existing stores of 
1RP in the plasma or through competition of the other amino acids for transport across 
the blood-brain barrier. It is likely that both mechanisms playa part in reducing TRP 
availability to the brain. 
1.4.1.5 Platelet studies 
Platelet 5-HT has been shown to have either consistent levels between normals and 
depressives (perez et aI, 1998; Karege et al, 1994) or a reduction in depressives (Quintana 
et al, 1992). 
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As human platelets were found to express a functional 5-HT receptor (Geaney et al, 
1984), which resembled pharmacologically the 5-HT2A receptor in the brain, it was 
hoped that peripheral measures of 5-HT 5-HT2A receptor binding might relate in a direct 
manner to brain 5-HT2A receptor function. 
In addition to the 5-HTr like receptor, thought to promote platelet aggregation, there is 
also a binding site, to which tritiated forms of imipramine and paroxetine bind, which may 
be part of the 5-HT transporter (Nemeroff et at, 1994). However, it is not clear that 
peripheral measures of 5-HT binding can be used to estimate brain activity as one study 
comparing the effects of central 5-HT lesions in rats on levels of 5-HT and receptor 
binding showed significant brain changes but peripheral changes were not observed in the 
paroxetine binding (Moret et aI, 1991). 
In the following section attention is focused more specifically on the 5-HT2C receptor and 
the most widely used agonist used in the investigation of its action. As has been seen 
above, the 5-HT 2C receptor is influenced significantly by some anti-depressants and in 
view of further studies (See below) linking one of the polymorphic variants of its gene 
with response to clozapine, it is important that due consideration is given to a possible key 
role in drug treatments for both depression and the psychoses. 
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1.5 5-HT 2C RECEPTOR FUNCTION 
In this section relevant studies relating to the function of the 5-HT 2C receptor are 
reviewed, including investigations reported from animal studies, healthy human controls 
and psychiatric patients including a broader range of diagnoses than depression and the 
psychoses. 
1.5.1 Animal studies 
The majority of studies investigating the role of 5-HT2c receptors have utilized meta-
chlorophenylpiperazine(m-CPP) as a neuroendocrine probe (See Figure 1.3). m-CPP is a 
5-HT agonist whose pharmacological effects have been extensively studied in both humans 
and animals. According to ligand-binding studies m-CPP binds to a variety of 5-HT 





Figure 1.3: Diagrammatic representation of the 5-HT2C selective agonist, 
meta-Chlorophenyl-piperazine. 
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1.5.1.1 Locomotor effects: 
Decreases in locomotor activity in rats is a characteristic behavioural effect of m-CPP. 
Studies with selective antagonists suggest that the hypo locomotor effects are produced by 
activation of 5-HT 2C receptors because they are antagonised by a variety of drugs that 
have in common the ability to block 5-HT2C receptors. (Kennedy et al, 1993; Kennet and 
Curzon, 1988; Klodzinska, 1989). The locomotor effect is also blocked by less selective 
compounds such as metergoline, methysergide, and mianserin pre-treatment (Lucki et al, 
1989). The locomotor suppressant effects of m-CPP have been enhanced following long 
term, but not short term, treatment with imipramine (Aulakh et al, 1987). In animal studies 
the hypolocomotor response was enhanced by intraventricular injection compared to intra-
peritoneal injection, suggesting a central site of action (Kennet and Curzon, 1988). 
1.5.1.2 Appetite and weight 
In animal studies m-CPP has consistently lowered food intake (Sarnanin et aI, 1979; 
Kennett and Curzon, 1988 and 1991), probably by activation of the 5-HT2C receptors in 
the paraventricular nucleus (Aulakh et al , 1995). m-CPP induced hypophagia has also 
been reversed by the 5-HT antagonists - metergoline, mianserin and mesulergine but not 
ritanserin, in one study (Aulakh et al, 1992). The negative finding with ritanserin was 
replicated, along with ketanserin, in a further study (Kennet and Curzon, 1988). 
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However, the hypophagic effects were inhibited by ketanserin and ritanserin in a 
subsequent study by the same authors (Kennet and Curzon, 1991). Hypophagic effects 
were enhanced in an earlier study following long tenn treatment with imipramine (Aulakh 
et a~ 1987). Further work has suggested that gender differences in the hypophagic 
response to m-CPP may occur (Clifton et al, 1993). 
As a test of the above model one study (Teeott et at, 1995) has reported the behavioural 
and morphological changes resulting from the genetically engineered, 'knock-out' mice 
lacking 5-HT2C receptors. In keeping with the above studies establishing the relevance of 
the 5-HT2C receptor to appetite and weight, these mice were significant1y overweight and 
displayed other differences such as a lower seizure threshold. Further studies involving 
these knock-out mice established that their obesity was behavioural rather than metabolic 
and that hypophagic effeets of m-CPP were abolished in neuro-endocrine testing. 
1.5.1.3 N euro-endocrine effects: 
Intra-venous administration of m-CPP to rats has increased plasma prolactin and 
corticosterone levels in some studies (Aulakh et al, 1988; Fuller et al, 1981; Quattrone et 
at, 1981; Bagdy et aI, 1989), however antagonist studies have shown attenuation of 
prolactin release by metergoline but not ritanserin in rats and only partial blockade by 
ritanserin in Rhesus monkeys (Kahn and Wetzler, 1991). 
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ACTH/corticosterone is increased by m-CPP in rats and Rhesus monkeys (Fuller et aI, 
1981; Bagdy et al 1989; Aulakh et al, 1988; Calogero, 1990). Metergoline and ritanserin, 
but not ketanserin, attenuated ACTH release but corticosterone was not blocked by 
metergoline in one study ( Aloi et al, 1984) which may be explained by the intrinsic ability 
of the antagonists to increase corticosterone themselves (Aulakh et al, 1992). m-CPP has 
also been shown to increase growth hormone levels in Rhesus Monkeys but to decrease 
levels in rats (Aulakh et al, 1993). Long term administration of m-CPP has been shown 
not to affect prolactin and corticosterone release (Ulrichsen et al, 1992). In one study 
involving rats, high doses of intra-venous m-CPP caused increases in adrenaline and 
noradrenaline in plasma (Bagdy et al, 1988). 
1.5.1.4 Sleep 
Early animal work established a central role for serotonin, and other amines, in the 
regulation of sleep and wakefulness (Sallonon, 1983). In hamsters 5-HIP increased total 
sleep time and methysergide facilitated REM sleep but inhibited non-REM sleep (Guha et 
aI, 1988). In rats, decreases in REM sleep caused by destruction of 5-HT neurons is 
reversed by the transplant offoetal raphe suspensions (McRae et al '88). 
Anti-depressants have variable effects on sleep and SSRI induced increases and decreases 
in slow wave sleep have both been reported (Hilakivi, 1987), but most reduce REM sleep 
volume. 
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An early study involving mice showed the prolongation of thiopentone induced sleep by 
both Trazodone and m-CPP, an effect which was not prevented by cyproheptadine 
(Adamus et aI, 1985). However, studies in rats have shown a reduction in slow wave sleep 
due to m-CPP (Dugovic and Van den Broek, 1991). 
Another drug with 5-HT2 agonist properties, 001, aIso decreases slow wave sleep 
(Stutzmann et ai, 1992). In addition, increases in slow wave sleep are seen with selective 
5-HT2 antagonists (Dugovic and Waquier, 1987; Stutzmann, 1992). 
1.5.1.5 Temperature 
Intraperitoneal administration of m-CPP has been shown to cause a hyperthermic response 
with a peak effect at thirty minutes (Mazzola et aI, 1996). This effect is thought to be 
mediated by 5-HT2c receptors as it is attenuated by pre-treatment with low-dose 
metergoline, mesulergine and mianserin but not propanolol, yohimbine or ondansetron. 
High doses of ketanserin, ritanserin and spiperone have also attenuated the hyperthermic 
responses to m-CPP and both acute and chronic treatment with MAOI's and tri-cyclic anti-
depressants has also been shown to attenuate this response (Wozniak et aI, 1989). 
Interestingly, in mice temperature is decreased by m-CPP. 
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1.5.1.6 Anxiogenic effects 
The anxiogenic effect of m-CPP has been recorded by a munber of investigators, in 
humans (Charney et ~1987; Mueller et al, 1985). This effect has been subsequently 
substantiated in male rats by a model involving decreased social interaction and activity, 
using m-CPP and TFMPP (Kennett et aI, 1989) and is thought to be mediated by 
hippocampa15-Iff2c receptors. This finding was further corroborated by studies involving 
5-Iff2C antagonists (Kennett et al, 1989). Support for this paradigm representing a model 
of anxiogenesis has also been found with the prevention of the effect by a benzodiazepine 
(Tyers et al, 1989) . 
1.5.2 Humau studies - m-CPP use in healthy subjects 
m-CPP, a metabolite of the anti-depressants trazodone and nefazodone, has also been 
extensively studied in healthy humans. It has been found to be one of the more reliable 
probes with which to measure aspects of brain 5-Iff function although debate continues 
regarding its specificity. It is a 5-Iff 2C and possibly 5-Iff 18 agonist but is a 5-HT 2A 
antagonist (Kahn and Wetzler, 1991; Fiorella et al, 1995). It also binds weakly to 5-HTIA' 
5-Iff1D, and 5-HT3 receptors and also has 0'.2 adrenergic activity. It has a weak effect on 
0'.1 and ~ adrenergic receptors and binds very weakly to dopamine and muscarinic 
receptors (Hamik and Peroutka, 1989). It is a partial agonist at 5-HT2c and 5-Iff18 
receptors and may release 5-HT from the pre-synaptic terminal (Baumann et al, 1993). 
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The studies involving animals have established the basic effects of m-CPP and subsequent 
work has examined whether the findings can be extrapolated to humans. The effect of m-
CPP on temperature, appetite, sleep and neuroendocrine measures has therefore been 
studied in healthy humans for more than a decade (Mueller et al, 1985). 
1.5.2.1 The effect of m-CPP on temperature 
As in animal studies, m-CPP has been found to increase temperature after oral (0.5 mglkg) 
and intravenous (O.lmglkg) administration (Mueller et ai, 1985; Murphy et al, 1989) in 
most studies, however Kahn and colleagues failed to find a hyperthermic effect (1990). 
1.5.2.2 The effect of m-CPP on sleep 
The possibility that 5-HT2 receptors may inhibit slow wave sleep (Stages 3 and 4, < 5Hz) 
in humans was suggested by an increase in slow wave sleep following acute and chronic 
ritanserin treatment (Idzikowski et al, 198617; Sharpleyet ai, 1990). 
In an initial report on six normal subjects m-CPP reduced total sleep time and sleep 
efficiency and decreases in slow wave sleep and REM sleep were found (Lawlor et al, 
1991). Furthermore, stage 1 sleep was prolonged. This finding was replicated at two doses 
against placebo (7,5 mg and 15mg) with a significant reduction in slow wave sleep and 
the number of REM periods (Katsuda et at, 1993). 
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Further studies with the 5-HT2 receptor antagonists ritanserin and ketanser.in have 
established that this effect is almost entirely a 5-HT 2C response as both have equivalent 
affinities for the 5-HT2A receptor but ritanserin has a higher affinity for the 5-HT2c 
receptor than ketanserin and produced a substantially larger .increase of slow wave sleep, 
51,4 % versus 17,2 and 24,4% (Sharpley et al, 1994). In an effort to establish whether this 
effect would diminish followmg SSRI treatment, 8 depressed patients were compared with 
8 controls with no difference seen between the groups, suggest.ing that no reduction .in 5-
HT2C sensitivity had occurred (Wtlliams et a~ 1994), at least as far as this measure was 
concerned. 
1.5.2.3 The effect of m-CPP on appetite and weight 
The .involvement of the 5-HT system.in appetite has been well established.in animals such 
as the rat (above) and the leech, where serotonergic neurons regulate the cycle ofarousa~ 
food seeking, ingestion and satiation (Lent and Dickenson, 1988). In humans, food .intake 
was not reduced following m-CPP given in a standard oral dose regimen (7.5 or 15 
mg)(Smith et ai, 1994). 
Subsequently, using a dose calculated according to weight (OAmg/kg), food .intake .in a 
test meal has been shown to be reduced .in both males and females following the 
administration of m-CPP to 12 healthy volunteers (Walsh et al, 1994). This was further 
replicated .in 24 subjects (Cowen et al, 1995). 
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Furthermore, the fact that drugs such as olanzapine and mianserin which block 5-HT2c 
receptors, cause troublesome weight gain in clinical use supports the notion that 5-HT2c 
receptors play a role in food intake in humans. The effect on weight is supported by 
weight gain in patients on drugs such as mianserin which also block these receptors. 
1.5.2.4 Neuroendocrine findings 
m-CPP has been used extensively as a neuro-endocrine probe in humans and reliably 
elevates plasma levels of prolactin, cortisol and ACTH (Kahn and Wetzler, 1991). Peak 
ACTH levels were shown to precede elevation of cortisol levels in one study, suggesting 
causation (Kahn et al, 1990). Intravenous m-CPP, but not an oral dose, has been noted to 
increase growth hormone levels (Cowen, 1993) as well as causing physiological effects 
such as light-headedness, increased blood pressure in some subjects or headache (in 
approx.50% of people), as well as panic in 10-30% ofpeople (Silverstone et al, 1994). 
The exact control mechanism of prolactin has been extensively studied and it is clear that 
both stimulatory and inhibitory transmitters playa role. However there is evidence that m-
CPP induced prolactin release is a reliable measure of 5-HT2 function as the increase is 
attenuated by pre-treatment with the 5-HT2 antagonists metergoline and ritanserin This 
attenuation is not found with the growth hormone response. Because mCPP is a 5-HT2A 
receptor antagonist its effects on prolactin and cortisol are likely to be mediated via 
activation of 5-HT2c receptors (Hamik and Peroutka, 1989). Gender differences in 
responses are seen with a greater female prolactin but not cortisol response (Charneyet al, 
1987; Kahn et al, 1990). 
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1.5.3 Human studies - m-CPP use in psychiatric patients 
1.5.3.1 Depression 
As previously reviewed (Kahn and Wetzler, 1991), when given to patients with major 
depression, m-CPP was found to cause more physical symptoms than in the healthy 
controls, but without other behavioural differences. Hormonal responses such as cortisol 
and prolactin did not differ from controls and the blood levels of m-CPP in the two groups 
were not significant1y different either. 
A seasonal variation in behavioural responses to m-CPP has been found in patients 
suffering from seasonal affective disorder when compared to controls (Joseph-Vanderpool 
et ai, 1993). m-CPP has also been studied as a therapeutic agent and was found to be 
mild1y anti-depressant when 80mglday was given for two weeks (Mellow et al, 1990). 
1.5.3.2 Schizophrenia 
While the original studies evaluating the effect of m-CPP on the symptoms of 
schizophrenic patients produced equivocal results, some suggesting a blunting of 
behavioural and hormonal responses and others an enhancement, a later study has shown 
an exacerbation of positive symptoms, particular1y the BPRS thought disorder factor, in 
the patient group but not in controls (Krystal et at, 1993). 
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This finding, supporting a role for 5-HT2C receptors in schizophrenia, is further 
strengthened by the correlation of positive responses to m-CPP challenge prior to 
treatment with likelihood of treatment response to Clozapine (Kahn et al, 1993). In 
addition Clozapine has been found to block responses to m-CPP while fluphenazine had 
no effect (Owen et al, 1993). 
1.5.3.3 Obsessive Compulsive Disorder 
Studies reviewed previously (Kahn and Wetzler, 1991) suggested that an oral dose ofm-
CPP (0.5 mglkg) increased obsessions and caused more anxiety in obsessive compulsive 
disorder (OCD) patients than in normal controls. This symptomatic worsening was 
abolished by treatment with clomipramine. In one replication (pigott et al, 1992), 
intravenous m-CPP (O.lmglkg) increased OCD symptoms and anxiety ratings, an effect 
blocked by metergoline. The m-CPP was given as a 90 second bolus compared to a 
previous study where intravenous administration occurred as an infusion over 20 minutes 
and no increase in OCD symptoms was seen (Charney et al, 1988). 
In a further study peak m-CPP aggravated symptoms in 55% of the OCD patients but the 
increased behavioural measures correlated with less effect on prolactin release, suggesting 
a complex system involving numerous neuro-transmitter and neuro-modulatory effects. 
(Hollander et al, 1992). In another attempted replication, (Goodman et al, 1995) no 
exacerbation ofOCD symptoms was seen but both i.v. and oral m-CPP caused anxiety. 
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1.5.3.4 Anxiety and panic 
The anxiogenic effect of m-CPP seen in rats has been noted in human studies. 
Although an original study reported no behavioural differences between panic disorder 
patients and controls to an m-CPP challenge (Charneyet al, 1987), a subsequent study 
showed increased anxiety and cortisol responses in a group of panic subjects compared 
with normal subjects and depressives (Kahn et ai, 1988). This was further corroborated by 
the finding of a subject with sub-clinical panic attacks who displayed exaggerated 
responses to m-CPP (Kalus et a4 1990). 
In a sample of 10 patients with generalised anxiety disorder a greater behavioural response 
to m-CPP was seen than in healthy subjects, as well as an anger response (Germine et a4 
1992). More recently repeated administration of m-CPP has been found to attenuate 
behavioural responses, such as anxiety, to an m-CPP challenge (Benjamin et ai, 1996). 
The role of the serotonergic system in anxiety has been further supported by the 
association of a serotonin transporter gene polymorphism with anxiety related personality 
traits in individuals as well as in sibships (Lesch et a4 1996; Goldman, 1995). 
1.5.3.5 Eating Disorders 
In one study of the effect ofm-CPP on bulimic patients (Brewerton et al, 1992), 
a number of the patients developed migraine headaches. There would thus appear to be a 
correlation between the eating disorder and a tendency to develop migraines. 
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This was not only the case where the bulimic patients had a personal history of migraine 
but was also seen in those with a fumily history of migraine. Although it could be 
predicted that patients with either bulimia nervosa or binge eating disorder would have a 
higher rate of the less common serine substituted 5-HT2C polymorphism than the general 
female population, this was not shown in one Oxford study (Burnet et aI, 1999). 
The work of Tecott and colleagues (1998) also has relevance as the 5-HT2C receptors 
would appear to be needed to evoke the satiety response in feeding, as 5-HT2C knock-out 
mice become obese. 
The neuro-endocrine results ofthe studies involving bulimic patients have shown a blunted 
prolactin response. In a further study anorectic patients were seen to exhibit a greater 
behavioural response to m-CPP prior to weight gain and diminished neuroendocrine 
responses. After weight gain the prolactin· response remained reduced (Hadigan et at, 
1995) suggesting a trait subsensitivity of hypothalamic 5-HT2C receptors. Conceivably this 
could be related to a tendency to binge-eat. 
1.6 5-HT TRANSPORTER IN DEPRESSION 
The serotonin transporter (5-HTT) is the pre-synaptic membrane receptor responsible for 
the re-uptake of serotonin from the synaptic cleft following neuro-transmission, in 
serotonergic neurones. 
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The transporter is therefore the target of the serotonergic anti-depressants including 
selective serotonin re-uptake inhibitors and the tri-cyclic anti-depressant, clomipramine 
(Anderson et al, 1992). It is also found in blood cells and the transporter proteins 
expressed in both brain and platelets have been shown to be identical (Lesch et at, 1993b). 
1.7 GENETIC STUDIES IN PSYCHIATRY 
1.7.1 Introduction 
As discussed in the general introduction above, the family, adoption and twin studies have 
established a significant genetic contribution to the aetiology of the affective disorders 
although the specific chromosomes and genes involved are yet to be elucidated. It is now 
more apparent, however, that aetiology is multi-factorial and that both genetic and 
environmental factors are relevant (Kendler and Karkowski-Schuman, 1997). It is also 
evident that the genetic contribution is likely to be complex as single gene defects have not 
been consistently correlated in patient groups, in comparison with controls. It is therefore 
more likely that the genetic contribution relates to more than one system in a polygenetic 
modeL Single genes and the polymorphic variation of genes with a recognized role in 
neuro-transmitter and other systems related to mood have been studied, both by rates 
within groups and by comparison between groups with either demographic (eg: gender or 
ethnicity effects) or treatment (eg:response versus non-response) differences. 
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1.7.2 Polymorphic variation 
Polymorphic variation refers to the existence of 2 or more alleles of genes occurring at 
significant levels in the population, (Strachan and Read~ 1996). Interest in allelic variation 
exists in view of the potential for not only structural but also functional differences to 
occur. In the case of psychiatric disorders it is hoped that the understanding of either 
influences on the development of the condition or variations in response to treatment 
might be improved by the elucidation of any functional aspects of allelic variation. 
Should the polymorphism in question not seem to relate directly to any known aspect of 
function it is then hoped that the variation might represent a marker with a possible 
linkage to a gene of actual effect and this would then be established by methods of linkage 
analysis (Owe~ 1997). 
In the following section and in three of the project chapters attention is focussed on the 5-
HT 2C receptor and serotonin transporter from a genetic perspective, in view of the above 
mentioned links of the 5-HT2C receptor with satiety and the reported correlation of one 5-
HT2C receptor polymorphism with response of schizophrenic patients to c10zapine (See 
below). The 5-HTT has also been a focus in view of its pivotal role in the re-uptake of 5-
HT from the synaptic cleft and the effect of anti-depressants on its function. 
81 
1.7.2.1 5-HT2c RECEPTOR 
Polymorphic variation 
The human 5-HT 2C receptor has been localised to the long arm (q) of the X chromosome 
(Xq24). Complementary DNA (c-DNA) sequencing, achieved using reverse transcriptase, 
has revealed a C - G polymorphism (the cytosine base exchanged for guanine) at 
nucleotide 68 such that the amino acid serine is substituted for cysteine in the receptor 
protein at codon 23. The position of this polymorphism can be seen diagrammatically in 
Figure 1.4. (See below). 
The proportion of the normal population who have the substitution is approximately 13 
per cent in one study (Lappalainen et at, 1995), while the number of homozygous females 
is approximately one per cent. However, although this polymorphism has been studied 
extensively, there are now other described polymorphic variations including 2831 T/G and 
promoter variants. 
Further work is now also continuing with the study of RNA-editing which occurs 
following transcription but prior to translation of m-RNA into proteins, leading to further 
modification of the final receptor protein structure (Fitzgerald, 1999). 
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edited amino acids 
Figure 1.4: Diagrammatic representation of the 5-HT2C receptor illustrating the 
seven transmembrane domain structure and the position of the cys23ser 
polymorphism. Editing of m-RNA ( additional points shown) is discussed in the 
final chapter. Used, with permission, from Dr.M.Sodhi, PhD thesis (University of 
London). 
Polymorphic variation has also been demonstrated for the 5.,.HT2A receptor gene which is 
found on chromosome 13 (13q 14-21), with six reported polymorphisms including one 
causing a T - C substitution at codon 102. This substitution is silent, with conservation of 
the final receptor amino-acid sequence and is present in 40 per cent of the general 
population. Other 5-HT2A polymorphisms include 452 HisITyr as well as 1438 G/A. 
Function 
It is of clinical relevance to know whether two receptor variants are functionally different. 
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Although initial in vitro work on receptors expressed on xenopus oocytes showed equal 
concentration/response curves to 5-HT applicatio~ later work has shown a difference in 
binding affinity (Goldman et ai, 1995). In the treatment of refractory schizophrenia by 
clozapine (which includes among its many pharmacological properties that of 5-HT2c 
receptor blockade), as mentioned above, one study has shown significantly increased 
clinical response rates in patients possessing at least one serine substituted allele (Sodhi et 
al, 1995) but this was not supported in more recent studies (Masellis et al, 1995; Segman 
et al, 1997; Malhotra et al, 1998). However, one further weakly positive study has been 
reported by Arranz and colleagues and a recent meta-analysis has supported serine 
substitution correlating with response at a statistical significance of p=O.02 (Sodhi, 
personal communication) in a serine dominant model 
This finding refers only to those of caucasian ethnic origin and other explanations than 
simple changes in the function of 5-HT2C receptor function need to be considered. These 
include the possibility of the allelic variant being in linkage disequilibrium with another 
gene coding for a functionally relevant protein or the serine substituted group being a 
marker for longer hospitalisation which the group on clozapine treatment would represent. 
Further association studies have been carried out with psychiatric patients, with a slightly 
greater but non-significant frequency of serine alleles being found in patients with Bipolar 
disorder and with later onset depressives (Gutierrez et al, 1996) as well as correlating 
with the presence of hallucinations in patients suffering from Alzheimers Disease (Holmes, 
1998). A further explanation is that the polymorphism may alter the way in which 
c10zapine binds to the 5-HT2C receptor. 
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1.7.2.2 5-HT transporter 
Polymorphic variation 
The identity of the human platelet and brain serotonin transporter gene was established 
following sequence analysis of a c-DNA and the location was revealed to be on 
chromosome 17 (17ql1.1-q12) (Lesch et ai, 1993a and b) (See Figure 1.5 below). 
Subsequent molecular studies have revealed that the transporter gene has a number of 
polymorphic variants. 
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Figure 1.5: Diagrammatic representation of the human serotonin transporter gene 
(h-5HTT) illustrating the 44 base pair (bp) insertion! deletion in the promoter 
region. Reproduced with permission from Dr.K.P.Lesch. 
One of these, in the promoter region for the transcriptional control of SLC6A4 (5-
HTTLPR), consists of varying lengths ofa repeat sequence of20-23 bp long elements. 
It is a polymorphism with a 44-base-pair insertion!deletion, giving rise to a bi-allelic 
variant, with 16 repeats- 'long', and 14 repeats-'short' (1 and s, respectively). 
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It causes a variation in the extent of tissue expression of the transporter (Heils et ai, 1995) 
with the '1' form being associated with increased rates of transporter site expression 
(Lesch et al 1996; Little et a1, 1998) and the short, 's' version with lower rates of 
expression and activity, whether homozygous or heterozygous, implying that the short 
version is dominant. 
The situation is more complicated than originally thought as it has been recently 
established that even the known 5-HTILPR alleles have other subdivisions and further 
variants have been discovered, most recently ten novel alleles (Nakamura et a1, 2000), 
leading to a recommendation that each of these alleles should also be considered in studies 
for a potential contribution to functional differences. Comparison of different mammalian 
groups has confirmed that the 5-HTTLPR is unique to humans and simian primates and it 
is estimated that a progenitor sequence may have been introduced into the genome 
approximately 40m years ago. Great apes such as the orangutan, gorilla and chimpanzee 
have an over-representation of 18 and 20 repeat elements (Lesch et ai, 1998). In contrast, 
the majority of alleles seen in humans are either 14 or 16 repeat elements, while the above 
two are rare. 
Further variability occurs in the comparison of different ethnic groups. Caucasians in one 
study were seen to have 32% '1/1',49% '1/s' and 19% 'sis' (Lesch et a1, 1996). In addition 
to the above polymorphism, a second polymorphism is found in intron 2 of the 5-HTT 
gene, a VNTR with 9, 10 or 12 repeats (Lesch et a1, 1994). 
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Function 
In establishffig whether 5-HTTLPR alleles differ in their functional capacity, the finding 
referred to above involved the fusion of the 5-HTT gene promoter with a luciferase 
reporter gene and transfection into human lymphoblastoid cell lines (Lesch et al, 1996). In 
addition to the main finding - increased tissue transporter expression of the long ('1') 
allele, it was also established that '1' homozygosity leads to higher concentrations of 5-
HTT m-RNA and antagonist binding density. 
In an analogous study in platelets, the '1' variant was associated with more rapid initial 
platelet 5-HT uptake. However, the genotype did not affect platelet eH)-paroxetine 
binding, affinity for eH)5-HT or eH)-paroxetine, or 5-HT content (Greenberg et al, 
1999). In a post mortem study a genotype effect was also seen in dorsal raphe C25I)CIT 
binding, with higher levels of presumed 5-HTT bound in ethanol abusers either 
homozygous for the short's' allele or heterozygotes (Little et al, 1998). 
A alternative means of investigating possible genotype effects has been through the 
measurement of metabolic break-down products of the major neuro-transmitters in the 
CSF. This method, widely used in the early investigation of the mono-amine hypotheses 
in psychopharmacology, has also been applied in the evall,Jation of possible transporter 
variations. Both of the two serotonin transporter polymorphisms discussed above were 
investigated by CSF analysis following the lumbar puncture of healthy volunteers. 
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For both the intronic and promoter po1ymorphisms significant relationships were found 
with MHPG levels but not with HV A and HIAA concentrations. As multiple comparisons 
were made, however, following a Bonferroni correction only the intronic difference 
remained significant (Jonsson et ai, 1997). Problems exist with this finding, as 5-HT is 
usually metabolised to 5-HIAA and the proportion converted to MHPG is minimal, by 
comparison. Furthermore the intronic polymorphism is not yet known to have a functional 
significance. 
Studies in psychiatric conditions 
Affective Disorders 
In one population based case-control study there was an association of the 5-HTTLPR 
short allele with affective (predominantly bipolar) illness (Collier et al, 1996a), but this 
was not replicated in three subsequent studies ( Ohara et al, 1998; Bellivier et ai, 1997; 
Rees et al, 1997). If depressive spectrum disorders are included, one family-based study of 
alcohol dependance showed preferential transmission ofthe short allele (Lichtermann et al, 
2000). In a post-mortem sample there was a positive association of the long allele in 
depressed suicide victims ( Du et al, 1999). In a symptom rating based study no genotype 
interaction with depressive symptomatology was found (Serretti et al, 1999) however, in 
another study, '1' homo zygotes showed an enhanced mood improvement after sleep 
deprivation (Benedetti et al, 1999). As regards the VNTR in intron 2, an initial study in 
Scotland reported an association between the 9-repeat allele and unipolar depression 
(Ogilvie et al, 1996) in the patient group compared with controls. 
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Other studies have failed to replicate this finding (Collier et aI, 1996b; Stober et ai, 1996; 
Bellivier et ai, 1997). Two further studies were negative for the nine repeat allele (Rees et 
ai, 1997; Kunugi et aL 1997) but found a positive association between the 12 repeat 
version and bipolar disorder, as first reported by Collier (1996b). This association was not 
reported by Ogilvie et aI (1996), or in the three studies negative for the nine repeat allele 
cited above. Following from the above it can be seen that three studies have been positive 
for the 12 repeat allele association with affective disorder and four have been negative. In 
a chi-squared analysis of the combined replication findings, but excluding the one 
Japanese study for reasons relating to ethnic variability of population allele rates, a 
positive association was reported, but only when the Collier findings were included 
(Greenberg, 1998). X2 =13.15; P<O.Ol. In one study ofpuerperaI affective psychosis, an 
excess of the Stin2.12 variant was associated with a four-fold increased risk of psychosis 
(Coyle, 2000). 
Further studies have focussed on a possible association with clinicaI response to anti-
depressant medication, as has been done in chapter four of this thesis. Work has focussed 
on two polymorphisms which occur in the serotonin transporter (5-HTT) gene - one in 
the promoter region (5-HTTLPR) and the other in intron 2 (Stin2). Some studies have 
detected allelic association between this gene and clinical response to SSRls. In one 
study patients with the long polymorphic variant - 'l/l' and heterozygotes with the short 
and long - 's/l' - versions of the promoter region polymorphism were more likely to show 
an improved response to fiuvoxamme, an effect abolished in the group also treated with 
pindolol (Smeraldi et aL 1998). 
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In two similar studi((s utilising paroxetine, an increased response rate was seen in subjects 
with at least one copy of the long variant of the 5-HTILPR polymorphism in a study 
involving young adults (Zanardi et a~ 2000) and in a further study involving an older 
group of patients. In the latter study a more rapid response was seen for those patients 
homozygous for 'VI' promoter alleles compared to those with an's' allele (heterozygotes 
or homozygotes) (Pollock et al , 2000). However, in a further study an enhanced clinical 
response has been reported in patients homozygous for the short version - 's/s' - of the 
5-HITLPR polymorphism, and in homozygotes with the Stin2.12 version of the intron 2 
polymorphism (Kim et al, 2000). 
Neuroticism/anxiety disorders 
Another approach to elucidating the relevance of polymorphic variation to psychiatric 
syndromes involves the use of large populations to carry out association studies between 
polymorphic variation and personality traits such as harm avoidance or neuroticism. An 
increase in neuroticism scores was seen to a greater extent in individuals with the short 
arm of the 5-HTILPR polymorphism in one large study (Lesch et ai, 1996), however in 
two smaller studies no association was seen with the short allele in either neuroticism or 
harm avoidance (Ball et a~ 1997; Ebstein et ai, 1997). 
In other psychiatric populations studies of association have aIso been negative. Two 
studies involving patients with panic disorder showed no association with this 5-HTILPR 
genotype (Deckert et a~ 1997; Matsushita et aI, 1997). 
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Other studies of anxiety related factors include a Japanese sample with a trend towards an 
association (Nakamura et al, 1997), and a Finnish study with equivocal findings (Mazzanti 
et al, 1998), however a study from Israel showed an interaction with the D4DR Dopamine 
polymorphism (Ebstein et al, 1998). Two further studies showed positive associations 
(Ricketts et al, 1998; Osher et a1, 2000). 
Obsessive Compulsive Disorder 
Although both the central importance of serotonergic drugs in the treatment of OCD and a 
significant genetic contribution as inferred from the twin and family studies would suggest 
that polymorphic variation ofthe serotonin transporter gene might be relevant, two studies 
have not supported this (Altemus et al, 1996; Di Bella, 1996). In one 5-HTTLPR study a 
trend was seen towards patients being homozygous more frequently than controls and if 
controls without formal diagnostic interviews were excluded the finding was significant 
(Billett et al, 1997). This was replicated in two further studies where population-based 
analysis showed an excess of III alleles in the OCD group (Bengel et al, 1999; McDougle 
et al; 1998). 
Autistic syndromes 
Preliminary evidence of linkage and association between the 5-HTT gene and autism was 
reported from a study including 86 trios (parents and probands) where preferential 
transmission of the short variant was found and, in spite of the lack of any linkage between 
the condition and the intron 2 polymorphism, a multi-alleleic TDT confirmed the 
significance of the region (Cook et al, 1997). 
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Unfortunately, an attempted replication by a different group showed the preferential 
transmission of the long 5-HTTLPR variant (Klauck et al, 1997), thereby failing to claifY 
the issue. One study analysed rates in schizophrenic patients (Stober et al, 1998), but 
neither the 5-HTTLPR polymorphism or the intron 2 polymorphism genotypes or allele 
frequencies varied between the schizophrenia group and control group. 
While the above chapter has covered the background knowledge relating to the field of 
inquiry and has argued the case for a likely involvement of serotonin receptors in the drug 
treatment of depression and psychosis, the following chapter summarises the methodology 
used to test the hypotheses derived from the theoretical model. 
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CHAPTER 2 
EXPERIMENTAL APPROACH AND 
GENERAL METHODS 
2.1 NEURO-ENDOCRINE CHALLENGE TESTS 
2.1.1 Subject selection 
In the three projects involving subjects rather than psychiatric patients (paroxetine study, 
5-HT2C function study, and clomipramine study) volunteers were included following an 
interview regarding clinical details. Specific inclusion criteria included: age between 18 
and 50 and absence of personal history of psychiatric illness according to diagnostic 
criteria. Exclusions were: current use of illicit substances or excessive alcohol intake; 
particular sensitivities to the nature of the endocrine challenge procedure e.g. needle 
insertion or nausea immediately following cannulation and any significant organic 
condition. In the m-CPP challenge tests subjects with a history of migraine were 
excluded. In the patient study (Ch.4) individuals were questioned regarding different 
aspects of possible psychiatric symptoms as delineated in the schedule for clinical 
interviews (SCID) in order to derive a diagnosis according to the Diagnostic and 
Statistical Manual- 3rd edition, revised or 4th edition (DSM3R or IV). 
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2.1.2 Randomisation 
In all three studies involving healthy subjects the sequence of neuro-endocrine test 
challenges was dictated by randomisation and included a balanced order design. In the 5-
HT2c function study both the subjects and investigators were blind to the day of active 
drug administration vs placebo day however in the paroxetine and clomipramine studies, in 
view of the intravenous administration, blinding only occurred from the subjects' point of 
view (single-blinded) as the investigators were aware of the content of the intravenous 
syringe. The randomisation procedure involved a colleague in the Psychopharmacology 
Unit drawing up a code using randomisation tables as provided by a member of the Oxford 
University Department of Mathematics. The codes were kept under lock and key and only 
subsequently consulted when the subjects had been tested. Code breaking and analysis of 
results occurred jointly between at least two members of the department involved with 
each specific study. 
2.1.3 Timing of tests 
It was thought that a minimum gap of one day between the tests would obviate any 
possible lasting drug effects as all of the half-lives of the drugs involved are less than 16 
hours. It has not previously been established in related experiments that there are any 
residual effects on the hormonal and behavioural responses the following day, leading to 
an order effect. 
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2.1.3.1 Gender issues 
As m-CPP challenges have been found to have differing behavioural and hormonal effects 
according to the menstrual cycle (Cowen et al, 1995), female subjects were only tested 
during the follicular phase (days 1-14) of the menstrual cycle where 'day one' is the first 
day of menses. Days were, however, calculated to ensure that both test days (placebo and 
drug) could be completed in the early part ofthe follicular phase. 
2.1.3.2 Effect on receptors 
It is unlikely that any receptor effects could occur following the administration of an active 
substance on the first test day that would have significantly altered responses on the 
second test day if the order determined by randomisation stipulated that the placebo day 
should follow the active substance day. Serotonin receptor changes have been described 
following the administration of anti-depressants and with chronic m-CPP use but these 
effects characteristically occur after weeks, rather than days taking the drugs. Further 
studies of relevance to this question include receptor studies where drug effects appear to 
occur via a greater number of mechanisms than post-synaptic neuro-transmitter effects 
alone. Intra-cellular responses also occur, leading to changes in gene expression and 
subsequent influences on trophic and neuro-adaptive changes. In one study four days of 
imipramine treatment of rats lead to a significant increase of 5-HT2C m-RNA levels but a 
single dose only caused a slight increase (Tohda and Watanabe, 1996), 
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Although it is assumed that periods of time longer than the lag between the test days in 
these studies will be needed to see significant and lasting effects on receptors, the specific 
nature of the changes and time periods involved are still under investigation (Barnes and 
Sharp, 1999). 
2.1.3.3 Separation of test days 
The 5-HT2C function tests occurred with a minimum gap between each pair of test days of 
two days, as did the clomipramine study. In the paroxetine study a separation of 1 day 
was permitted and the paroxetine was stopped following the second test day, after the 
three week period of paroxetine treatment. 
2.1.4 Setting of tests 
2.1.4.1 Cannulation procedure 
Subjects attended the Psychopharmacology Research Unit at Littlemore Hospital or the 
Warneford Hospital, Oxford, after an overnight fast and were cannulated half an hour 
before the first samples were withdrawn (yenflon cannulae, 16 - 18 gauge). After this rest 
period samples were withdrawn to analyse baseline hormonal levels. Following this 
heparinised saline was used to maintain patency of the venflon in conjunction with a 
butterfly set in order to facilitate multiple sampling over time. 
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Heparin was used in a mixture with normal saline (lOmls normal saline to 0.02mg of 
heparin). The heparin was stored in a refrigerator prior to testing and the mixed 
heparinised saline was discarded following the completion of each test. During sampling, 
an initial blood specimen of 10ml was withdrawn to be discarded, following which the 
sample for analysis was withdrawn. 
2.1.4.2 Pre-test protocol 
Patients and subjects were transported to the Psychopharmacology Unit, by taxi-cab as 
some subjects experience anxiety or somnolence following the test and this might impair 
concentration for driving. It was also hoped that being brought to the Research Unit might 
be less stressful than driving and therefore contribute to a more rapid stabilisation of the 
hormonal stress response. 
As elevations in the PRL level have been found following the stress of cannulation it was 
necessary to leave a minimum half hour period of adjustment following cannulation and 
samples were therefore withdrawn at both '-30' minutes as well as at time '0' (base-line), 
in order to assess possible outliers exhibiting major stress effects on the hormonal levels. 
97 
2.1.5 Sample and specimen storage 
2.1.5.1 Centrifugation 
Lithiwn heparin tubes were used for blood sample storage following extraction from the 
intravenous cannula. 20m1s of blood was extracted at each time point and the samples 
were stored in ice at the bedside until the study was completed. Plasma was separated by 
centrifugation at 2000RPM for 10 minutes. 
2.1.5.2 Refrigeration 
Following centrifugation the super-natant was removed by pipette and placed in further 
sample tubes without lithiwn. These plastic tubes were then frozen and stored at -22QC 
until assay. The samples were stored in wire mesh containers in the freezers until required 
for analysis of the contents. Plastic containers do not perish or break which ensures the 
maximwn nwnber of samples are available for study. The sample containers are labelled 
according to test and the tubes by code to ensure confidentiality for the subjects and 
blindness in relation to laboratory staff involved in multiple projects. 
98 
2.2 SUBJECT ASSESSMENTS 
2.2.1 Rating scales in depression 
In the treatment response study involving depressed patients two scales were utilised. The 
Beck Depression Inventory (BDI) is a self -rated scale composed of 21 categories of 
attitudes and statements, each category consisting of 4-5 self-evaluative statements (See 
Appendix 1). Numerical values between 0 and 3 are assigned to each category statement 
in order to denote the measure of severity, 3 being the most severe. Scores of 11 or less 
suggest no depression is present; scores between 11 and 18 suggest mild depression; 19 to 
29 suggests moderate depression and 30 and over is severe depression. The Hamilton 
Depression Scale (HAM-D) provides a method of scoring the severity of symptoms and is 
completed by a clinical interviewer who has been trained in the eliciting of 
psychopathological features but is not necessarily a psychiatrist. Symptoms are rated 
according to a series of scores ranging from 2 to 4 as a maximum for each of 17 items 










Mild to moderate 
Moderate depression 
Moderate to severe depression 
Investigators testing response to anti-depressant treatments usually take a level of 8 on the 
BDI (Beck et a~ 1961) and 7 on the HAM-D (Hamilton, 1960) as a measure of 
resolution. A further scale used by collaborators in the SSRI response study (See Chapter 
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4) is the Montgomery and Asberg Depression Rating Scale (MADRS) (Montgomery, 
1979) which has been shown to have greater sensitivity to change over time. As with the 
other scales, response can be measured according to a reduction by a specified percentage 
of the original score or a set number of points. 
2.2.2 Visual Analogue Scales 
Scales of this type have been used extensively in neuro·endocrine testing paradigms and 
are used to record physiological and behavioural responses to the particular probe in 
question (Silverstone et al, 1994; Cowen et a~ 1995). Physiological measures include 
sweatiness, light·headedness and nausea whereas psychological measures include mood 
states such as "happy" or "sad". For the purposes of the 5·HT2C function test appetite 
was also rated on both days. The rating scales consisted of 10cm lines divided into 10 
equal sections by a scale from 0·100 where 0 represents "not at all" and 100 represents 
"very much". (See Appendix 3) 
The visual analogue scales are administered by first showing the subject the card. The 
subject then notes the point on the card which corresponds to the physiological or 
psychological measure. This point is recorded on a separate sheet and not directly on the 
visual analogue scale. In addition to the visual analogue scales mentioned, observation 
was made of any untoward physiological response to the challenge e.g. subjects feeling 
faint or vomiting, although in practice this did not occur. 
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2.2.3 Routine observations 
Throughout the neuro-endocrine challenge tests measurements were taken of pulse and 
blood pressure by automatic recording (Dynamap, model 3341A, Sage instruments) on an 
hourly basis. These measurements were also routinely taken before the first sample of 
blood was extracted, as a baseline measure. Temperature readings were taken as part of 
the experiments but were not an essential part of the monitoring of physical signs from a 
health perspective. Subjects had all been nil per mouth from midnight on the preceding 
night however sips of water were permitted. 
2.3 ENDOCRINE ASSAYS 
2.3.1 Prolactin assay 
Determination of prolactin levels in human plasma was carried out by solid phase, two 
site, immunoradiometric assay. 
2.3.1.1 Materials 
Prolactin reference material available in horse serum was purchased from SkyBio 
(Wyboston, Berkshire UK). The monoclonal radio labelled prolactin antibody 1125 (raised 
from the mouse) and the anti-prolactin solid-phase (raised in the sheep) were also 
purchased from SkyBio. 'Solid-phase' refers to the second anti-body or anti-prolactin 
which binds to the antigen epitope (sub-component of an antigen), 
101 
All solvents and chemical reagents used were of the highest grade available. The stock 
phosphate buffer consisted of O.1M (lS.3g) sodium dihydrogen orthophosphate 
monohydrate, O.3M (S7.1g) of disodium hydrogen orthophosphate dihydrate and 2mls of 
1 % thiomersol (a reagent which acts as an antibacterial agent, prolonging the stability of 
the stock solution), dissolved in 1 litre of high purity water. The pH of the solution was 
7.4. 
The wash buffer consisted of 100mls of stock phosphate buffer and Smls of Tween 20 
(Merk Eurolab Ltd. UK), which is a surfactant added to the wash buffer to prevent other 
constituents from plasma and solution matrices from non-specifically binding to the solid-
phase and labelled antibody binding sites. 
The assay buffer consisted of 1% bovine serum albumin (BSA) (Sigma-Aldrich, UK) in 
100mls of wash buffer. This solution prevents endogenous plasma matrix and other 
solution constituents, including fractions of radiolabelled antibody, from binding to the 
plastic surfaces of test tubes. This was to ensure the removal of erroneous radioactivity 
counts in the precipitate (see below) and the precise identification of the bound tracer-
antibody complex, thus keeping the NSB to a minimum. 
2.3.1.2 Methods 
All samples, standards and quality controls were analysed in duplicate over a two day 
period. 
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The standard curve range used for this assay included the concentrations ofO, 40,80, 160, 
400, 800, 1600 and 4000 milli-international units per litre (mIU/L). The prolactin serum 
standards were diluted in hnl of high purity water before use according to the supplier's 
specifications. 
Day 1 
L 50111 of plasma sample, standards, totals (see below) and quality controls were added 
to clearly labelled 75 x 10unn polypropylene test tubes (Sarstedt Ltd. UK). 
2. 50111 of the solid-phase (anti-prolactin) and 400ul of assay buffer was added to all 
tubes except the totals. 
3. Vortexing then incubation was carried out at room temperature on rotary mixers for 3-
5hrs. 
4. 2m1s of wash buffer was added to all tubes and centrifuged for 5mins at 2100 RPM. 
5. The supernatant was decanted to waste, leaving the prolactin bound solid-phase 
precipitate remaining at the bottom of the test tubes. 
6. SOIlI of the radio labelled antibody (I 125 -antibody) and 4001-11 of assay buffer was added. 
7. Vortexing and incubation was again carried out, overnight on rotary mixers. 
Day 2 
L 2m1s of wash buffer was added and centrifuged for 5minutes at 2100 RPM. 
2. The supernatant was decanted to waste and the washing step repeated. 
3. Finally, the prolactin bound radiolabelled-antibody complex was counted for 5mins on 
a RiaStar Packard gannna ray counter (Packard Bioscience. Berkshire UK). 
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i 
The totals are those tubes that only contain radiolabelled antibody 1125 solution prepared in 
assay buffer. This was used as a measure of the total amount of radioactivity to be added 
to each test tube. The optimal level of radioactivity from the labelled antibody for this 






Table 2.1: Inter-assay coefficients of variation (% CV) for the determination of 
prolactin in human plasma (n 20). 
Mean Standard deviation CV(%) 
114.1 9.9 8.7 
361.9 15.8 4.4 
Table 2.2: Intra-assay coefficients of variation (CV) for the determination of 
prolactin in human plasma (n = 10). 
Mean Standard deviation CV(%) 
71.3 6.4 9.0 
825.1 43.5 5.3 
The statistics for both the inter-assay variation data were calculated from 20 sets of 
replicate samples for each low and high QC's. For the intra-assay data 10 sets were used 




2.3.2 Cortisol assay 
Determination of hydrocortisone (cortisol) in these studies was performed using 
radioimmuno-assay according to the following protocol. 
2.3.2.1 Materials 
Hydrocortisone reference material was purchased from Sigma (Sigma-Aldric~ UK) and 
the radio labelled cortisol (I125 cortisol) stock solution was obtained from Arnersharn 
Biosciences (Bucks, UK Ltd.). 
The assay buffer consisted of 8Ag of citric acid monohydrate, 8.5g of disodiurn hydrogen 
orthophosphate dihydrate and Ig of gelatin dissolved in 1 litre of high purity water. The 
pH of the solution was 4.0. 
The cortisol antibody raised in the rabbit was purchased from BioClin (Bioclinical 
Services, Cardiff, UK). A second antibody, "SAC-CEL", is another antibody which 
attaches itself to the bound radio labelled cortisol antibody complex raised in the rabbit. 
This was used to separate and immobilize by precipitation, the bound antibody complex 
from the free "non-bound" radiolabelled cortisol and was purchased from IDS (Boldon 
Ltd., Tyne &Wear, UK). 
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2.3.2.2 Methods 
The cortisol antibody was diluted in 1ml of high purity water, then divided into 200fll 
aliquots and stored at -20°C. When required for assay, a 200fli solution of the diluted 
antibody was retrieved and further diluted with 19.5mls ofthe assay buffer prior to use. 
All samples, standards and quality controls were analysed in duplicate over a two day 
period. The standard curve range used for this assay includes the concentrations of 0, 0.1, 
0.5, 1,5,25 and 75 micrograms per 100 millilitres (flg/cl). 
Day 1 
1. 25fll of plasma sample, standards and quality controls. 
2. 75fll and 25ul of assay buffer in tubes were labelled NSB and "zero "respectively. 
3. 50fll of cortisol antibody was added to all tubes except those labelled NSB and totals 
(see below). 
4. All tubes were incubated at room temperature for 90mins. 
5. 200fli of the of the diluted 1125 cortisol solution was added to all tubes. 
Day 2 
1. 1001-"1 of the solid-phase (SAC-CEL) was added to all tubes except the 'totals' and 
incubated for 30 mins at room temperature. 
2. 1m! of high purity water was added to all tubes except the 'totals' and centrifuged at 
2500RPM for 15mins at 4°C. 
106 
3. Supernatant containing all of the "non-bound" 1125 cortisol was decanted to waste, 
leaving the bound 1125 cortisol antibody complex to be counted for 5 minutes on the 
gamma counter. 
The 'totals' are those tubes that only contain radio labelled 1125 solution prepared in assay 
buffer. This was used as a measure of the total amount of radioactivity to be added to each 
test tube. The 1125 cortisol solution was diluted in assay buffer to achieve the optimal level 





Table 2.3: Inter-assay coefficients of variation (CV) for the determination of 
cortisol in human plasma (n = 20). 
Mean Standard deviation CV(%) 
9.9 1.0 7.7 
31.8 4.6 11.3 
Table 2.4: Intra-assay coefficients of variation (CV) for the determination of 
cortisol in human plasma (n 10). 
Mean }tandard deviation CV(%) 
3.35 0.19 5.6 
21.5 1.9 8.7 
The statistics for the inter-assay variation data were calculated from 20 sets of replicate 
samples for both low and high QC's. The intra-assay data set was calculated from 10 sets 





2.4 PHARMACOLOGICAL ASSAYS 
2.4.1 m-CPP and paroxetine measurement 
The m-CPP and paroxetine levels were determined by reverse phase High Performance 
Liquid Chromatography (HPLC) (Franklin, 1992). The end-point detection was achieved 
by utilising coulometric electrochemical detection (ESA, Bedford, MA, USA). The 
operating potentials selected for detectors 1 & 2 were 750 and 930 millivolts respectively. 
Detector 1 was used to preoxidise any extractable compounds that are of no interest and 
might interfere with the analytes at detector 2, the analytical electrode. The analytical 
column used was a "mixed mode" (ODS CN) (a combination of a C18 and cyanonitrile 
material) (Capital HPLC, Edinburgh, UK). The mobile phase consisted of a 74 % 
methanol in phosphate buffer (v/v) with the flow rate set at 1.00ml/min. 
The isolation of both compounds from the plasma matrix procedure involved utilising 
solid-phase extraction (SPE) technologies. To both samples and standards an internal 
standard drug was added to monitor both the extraction recovery and the detector 
response variation. Plasma samples were then loaded onto carboxymethyl (CBA) solid 
phase SPE cartridges after conditioning with a phosphate buffer and the analytes were 
eluted with an ammonia / methanol solvent into glass collection vials. The solvent was 
evaporated to dryness and reconstituted in the mobile phase. 
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An aliquot of this solution was injected onto the HPLC analytical column for 
chromatographic separation and quantitation. 
Standard curves were freshly prepared daily and consisted of concentration points over the 
range of 0 - 5 Ong/mI. The linearity of ooth the extraction procedure and the detector 
response was verified over the range of the standard curves. This was determined by 
measuring pooled drug-free plasma spiked with known amounts of m-CPP, paroxetine and 
the internal standard drug. The calibration curves for both compounds were calculated by 
peak-height ratio's relative to the internal standard drug. 
The concentrations of both compounds were assessed by interpolation of the standard 
curves using the general linear equation y = ax + b. The mean linear equations for the 
calibration curves for m-CPP were y = 0.035x + 0.090 (r = 0.994; n = 5) and for 
paroxetine were y 0.024x +0.078 (r = 0.995; n = 4). 
The mean intra-assay CV was 4.7% for m-CPP (n = 15) and 5.6% for paroxetine (n = 15) 
for a spiked plasma quality control containing lOnglmI for ooth compounds.The mean 
inter-assay CV was 7% (n = 10). The lowest level of quantitation (LLQ) for both 
compounds was lng/mI. 
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2.4.2 Clomipramine Assay 
The clomipramine and its major metabolite nor-clomipramine levels were determined by 
reverse phase HPLC utilising ultraviolet-visible (UV NIS) (Jasco, UK) end point detection 
(Odontiadis, 1996). The detector wavelength was set at 215 nanometres (nm). The 
analytical column used was a cyano-nitrile (CN) (Capital HPLC, Edinburgh, UK) and the 
mobile phase used consisted of 40% acetonitrile in a phosphate buffer (v/v) with the flow 
rate set at 1.5mls lmin. 
The isolation of both compounds from the plasma matrix procedure involved utilising SPE 
technologies. To both samples and standards an internal standard drug was added to 
monitor both the extraction recovery and the detector response variation. Plasma samples 
were then loaded onto carboxymethyl (CBA) solid phase SPE cartridges after 
conditioning with a phosphate buffer and the analytes were eluted with an ammonia I 
methanol solvent into glass collection vials. The solvent was evaporated to dryness and 
reconstituted in an acetonitrile I distilled water solution. An aliquot of this solution was 
injected onto the HPLC analytical column for chromatographic separation and 
quantitation. 
Standard curves were freshly prepared on a daily basis and consisted of concentration 
points over the range of 0 - 200Ong/ml. The linearity of both the extraction procedure and 
the detector response was verified over the range of the standard curves. 
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This was determined by measuring pooled drug-free plasma spiked with known amounts 
of clomipramine, nor-clomipramine and the internal standard drug. The calibration curves 
for both compounds were calculated by peak-height ratio relative to the internal standard 
drug. The concentrations of both compounds were assessed by interpolation of the 
standard curves using the general linear equation y = ax + b. The mean linear equations for 
the calibration curves for clomipramine were y = 0.00245x + 0.031 (r = 0.998; n 3) and 
for nor-clomipramine y = O.OOl64x + 0.020 (r = 0.999; n 3). The lowest level of 
quantitation (LLQ) for both compounds was 10ngiml. 
2.5 GENETIC ANALYSIS 
Analysis of samples to establish details of their genetic polymorphic variation was 
necessary in the SSRI response study, the 5-HT2c function study and the clomipramine 
study but not the paroxetine study. 
2.5.1 DNA extraction 
Blood samples or buccal smears from patients and subjects were refrigerated initially in 
plastic tubes at -70°C in order to avoid deterioration of DNA. Genomic DNA was 
subsequently isolated from lymphocytes or from buccal epidermal cells using commercial 
kits (Nucleon) in batches, and stored at -20°C prior to use. 
111 
2.5.2 5-HTzc polymorphism determination 
Polymerase chain reaction (PCR) is a rapid, in vitro technique by which selective 
amplification of a target DNA sequence within a more heterogenous group of DNA 
sequences can be achieved. In order for this to occur, known sequence information from 
the DNA target is used to generate two primer sequences, called amplimers, which bind to 
the c-DNA regions immediately adjacent to the target region. A heat stable DNA 
polymerase is required and for these experiments the Taq polymerase, obtained from the 
hot-spring micro-organism Thermus aquaticus is used (Strachan and Read, 1996). 
Extracts were subjected to PCR with oligodeoxynucleotide primers corresponding to 
nucleotide positions 101 to 121 (5'-CACCTAATTGGCCTATTGGTT-3') and 406 to 386 
(5'-AAGGATTGCCAGGAGAGACAG-3') of the human 5-HT2c receptor gene (Stan et 
aI, 1994). Reactions were performed in amplification buffer (perkin Elmer) containing 20-
100 ng DNA, 250llM dNTPs, 400nM of each primer and 1 unit of Amplitaq (Perkin 
Elmer), in a :final volume of 20111. Amplification consisted of 35 cycles of 94°C for 45 
seconds, 55°C for 1 min and 72 °c for 1.5 min. The genotype of the 305bp PCR 
products was initially determined by a 'dot-blot' method. Amplimers were denatured at 
94°C for 5min and quenched on ice for a further 5 min. Samples were pipetted onto nylon 
membrane filters, dried at room temperature and cross-linked by baking the membranes at 
80°C for 90 min. The filters were then hybridized over-night with [32P]-dATP labelled 
oligonucleotide probes specific for the cysteine or serine variant. 
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They were then washed in stringent conditions according to standard protocols. Blots 
were apposed against X-ray film for 24-48 hours so that allele specific signals could be 
visualized. The genotypes of each subject were confinned using standard restriction 
fragment length polymorphism (RFLP) methods (Segman et al, 1997; Lappalainan et al, 
1995). 
2.5.3 Serotonin Transporter polymorphism analysis 
The amplification of the genomic DNA isolated as described above (see section 2.5.2) was 
performed with oligonucleotides corresponding to nucleotide positions -1416 to -1397 
(5'-GGCGTTGCCGCTCTGAATGC-3') and -910 to -888 (5'-
GAGGGACTGAGCTGGACAACCAC-3') of the gene encoding the serotonin transporter 
transcriptional control region (5-HTTLPR) (Lesch et al, 1996; Klauck et al, 1997). 
Samples were added to 20 J.lI amplification buffer (Perkin Elmer) containing 20-100 ng 
DNA, 200J.lM dNTPs (dGTPI7-deaza-2-dGTP=I:1), 0.5J.LM primers, 1.5mM MgCh, 0.5 
U Taq andl2% DMSO. Using the method previously described by Klauck and colleagues 
(1997), initial denaturation was at 95°C for 3 minutes followed by 2 cycles at 95°C (30s), 
63°C (30s), and 72°C (lmin), two cycles with annealing at 62°C (30s) and 35 cycles with 
annealing at 61°C (30s), with a final extension of 10 ruins at 72°C. 10 J.lI of the reaction 
mix was electrophoresed through 3% agarose gels containing ethidium bromide. Markers 
of DNA molecular weights (Sigma) were electrophoresed adjacent to samples. 
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The long form ('1') of the 5~HTTPLR was identified as a 16 repeat product, and the short 
form ('s') as a 14 repeat product. 
2.6 TEST MEAL PROCEDURE 
2.6.1 Selection of food options 
At the initial screening interview, once the subject had agreed to take part in the 5-HT2C 
study, a food selection sheet was completed (See Appendix 4). This enabled the 
individual to choose sandwiches which they would normally find palatable i.e. a choice 
between brown and white bread, a choice between mayonnaise or no mayonnaise, 
cucumber or no cucumber, but margarine was standard. Optional fillings were tuna 
chunks, cheese, fine sliced chicken and ham. 
The subjects were asked to choose a first and second choice of the filling. The second 
choice was used for a preliminary test meal at the time ofthe physical examination as part 
of the health screening procedure~ during which time questionnaires were also completed. 
The subjects were alone in an interview room with a table and the sandwiches were 
prepared according to a standard protocol, in order to be iso-calorific (See next section). 
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2.6.2 Standardisation of preparation 
The bread was weighed previously and specific amounts of margarine were used with a 
previously known mass. A set number of slices ofham and chicken were used as well as a 
set proportion of tuna, if chosen. Cheese was bought in grated form and weighed in order 
to be iso-calorific. Mayonnaise was measured in cooking scoops to ensure consistency of 
amount. The sandwiches were prepared immediately before consumption and presented 
to excess Le. 5 rounds divided into 4 quarters. The sandwiches were provided with no 
garnishing and only a glass of water accompanied them. The sandwiches were provided 
with the instruction that there was no time limit and the individual must consume the 
quantity dictated by their appetite rather than by any personal notion of study aims or by 
reference to previous occasions. 
2.6.3 Results of food consumed 
Once the individual had completed the meal they notified members of staff. At this stage 
the remaining quarters were counted and the number of quarters consumed was 
determined. Quarters which had been started but not finished were counted as full 
quarters. At the time of the two neuro-endocrine challenge days the first choice of food 
was given to the subject unless practical considerations prevented this in which case the 
second choice was again administered. This was then repeated on the second day of 
testing. 
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Measurement of the quantity eaten was evaluated both by number of quarters consumed 
as well as by calorie content based on calculations concerning the specific food stuffs 
chosen. Although sandwiches were iso-calorific on both test days, for each person, the 
amount varied between individuals, depending on their specific choice of food. 
2.7 PATIENT SELECTION 
2.7.1 Inclusion and exclusion criteria 
The Psychopharmacology Research Unit, previously based at Littlemore Hospital, Oxford 
has been recruiting patients suffering from mood disorders and obsessive compulsive 
disorder for a number of years. In order to facilitate recruitment for the studies clinical 
research workers have been linked with general practices in and around Oxford. These 
clinical researchers are all psychiatrists in higher training. They hold clinics in the surgeries 
and patients are referred by the general practitioners if it is thought that a psychiatric 
assessment and further management may be beneficial As these studies have been carried 
out over a number of years there is a large database of patients suffering from major 
depression (DSM3R and DSMIV) who have been treated by psychiatrists attached to the 
unit and who have agreed to take part in research projects. As clinical information is 
available regarding the treatment of these individuals, the procurement of samples for 
genetic analysis allowed a correlation of clinical response with genetic variations. 
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Following approval of the study through the local Ethics Committee (OPREC) patients 
were contacted to see whether they would be prepared to take part in the SSRI response 
study (Chapter 4). Patients were contacted by telephone where possible and, fulling this, 
by letter. Patients were then asked if they were prepared to attend the unit where a blood 
sample or buccal swab would be taken. Alternatively a research nurse or one of the 
psychiatrists involved in the project would ask the patients to attend the general practice 
surgery at the time of a subsequent research clinic. 
Those patients who were prepared to participate but were unwilling to attend for a blood 
sample were sent a buccal swab pack by post and asked to return this in a prepaid first 
class envelope, following which the swab material was frozen. The above procedure 
enabled a retrospective collection of a number of patient samples for genetic analysis, 
following which the genotypes were linked with clinical information from the case notes as 
well as by interview for those able to attend. 
A similar process was carried out by the research team at the Neuroscience Centre, 
Elizabeth II Hospital, Welwyn Garden City. They also had information regarding patients 
who had been treated on SSRIs with response determined by the MADRS rating scale 
(Montgomery, 1979). This team was able to recruit patients to participate and provide a 
number of samples for genetic analysis as well as clinical information regarding treatment 
response/non-response according to the CGI used in Oxford. 
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A prospective ann of the study involved the further recruitment of patients suffering from 
major depression, who provided blood samples at first assessment or following a period of 
treatment on antidepressant medication. This was carried out in the general practice 
surgeries by clinical researchers from the unit and the response was rated according to the 
CGI criteria. 
Patients were also recruited during their attendance at the Warneford Hospital Mood 
Disorders Clinic as well as from outpatient clinics at the Warneford Hospital where 
psychiatrists with previous involvement with studies in the research unit were involved in 
the follow up of patients. 
2.7.2 Screening interview 
At the initial clinical interview routine information regarding demographic details, clinical 
history and current presentation were recorded. Patients were diagnosed according to the 
diagnostic criteria ofDSM IV for major depressive episode, single episode or recurrent. 
Patients were not asked to provide a blood sample if there was evidence of an organic 
condition or if alcohol or illicit substances appeared to playa major role in the patient's 
presentation and it was thought that comorbidity for other psychiatric or medical 
diagnoses might be present. If it was not possible to detennine this at the initial interview 
a subsequent decision was made at further follow-up appointments. 
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2.7.3 Diagnostic procedures 
Where patients were interviewed it was confirmed that they fulfilled diagnostic criteria for 
major depression. Where patients were not prepared to attend for a further interview the 
case notes were examined and a case note diagnosis of major depression was made 
according to DSM3R or DSMIV criteria. Both scales were used as the study commenced 
when DSM3R was in use but continued after DSMIV was introduced. This stage of 
diagnosis was necessary as psychiatrists attached to the practices had also seen patients 
who did not agree to take part in further research studies at the time but were in any case 
treated according to usual clinical protocols. A number of these patients subsequently 
agreed to provide samples for genetic analysis, but were not prepared to attend for further 
interview. 
A small· proportion of patients described co-morbid psychiatric disorders including 
anorexia or bulimia nervosa but these patients were not excluded unless the co-morbid 
diagnosis appeared to have more relevance to the overall clinical state than the major 
depressive disorder itself. 
Patients included those with unipolar and bipolar depression but the diagnosis of a major 
depressive episode needed to be confirmed in both groups. History of a manic episode 
therefore did not exclude involvement per se as a number of patients with a history of 
bipolar disorder were found to respond to SSRI treatment clinically. 
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2.7.4 Informed consent 
Information sheets were provided at the screening interview or subsequently if the patient 
remained in ongoing treatment. Following the provision of information, both verbally and 
by an information sheet, a signed consent sheet was obtained. 
Patients who did not attend for interview but who had previously been involved in 
research studies in the unit were sent an information sheet with a buccal swab kit and 
those patients who had consented by telephone subsequently returned samples in the 
majority of cases. Those patients who were not prepared to attend the unit did not sign 
consent sheets and it was agreed by the Ethics Committee that furnishing the sample by 
post following the provision of information would be regarded as a consent procedure. 
2.7.5 Physical examination 
Those patients and subjects attending for neuro-endocrine research studies were examined 
to assess physical health prior to the research studies, however patients attending for 
routine clinical assessment without further involvement in studies other than the SSRI 
response study were not examined physically but rather, if there was any concern about 
the organic contributing fuctors in the case, a request was made to the general practitioner 
to follow up the physical condition ofthe patient. 
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2.8 DATA MANAGEMENT 
2.8.1 Information collected 
Patients who had previously been involved in research studies at the unit had rating scales 
completed at the time of the study including the Beck Inventory, the Ham-D depression 
scale and general clinical information. The Hertfordshire Neuroscience Oroup used the 
MADRS scores for the generation of COl's relating to response and patients completed 
questionnaires regarding their personal psychiatric history as well as other questionnaires 
detailing family history, relating to composition as well as to family psychiatric history. 
Further demographic information was recorded on questionnaires however a history of 
psychiatric illness in the family was not regarded as a specific exclusion criterion for 
invo Ivement in the studies. 
2.8.2 Clinical Global Impression Scale 
As the information relating to patient response to SSRIs derived from different forms of 
information, including rating scales that were not standardised across the entire group, all 
information regarding patients was processed to generate a clinical global impression 
(COl) as widely used in clinical trials (Newhouse and Richter, 1994). Clinical information 
at initial interview, follow-up information, rating scales and personal knowledge of the 
patients themselves allowed the COl to be completed. The COl included four levels (See 
Table 2.5), the most frequently used set of divisions in depression treatment trials. 
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Table 2.5: Clinical Olobal Impression Scale (COl) which combines information 
from different sources to generate a single score relating to clinical progress. 
Score Clinical response attained 
1 Marked resQonse 
2 Oood response 
3 Poor response 
14 No change or deterioration 
Level one was marked or excellent response, level two good response, level three poor or 
minor response and level four - no change or deterioration. The period considered for 
response was 4-6 weeks on an appropriate dosage regime. In all cases it can therefore be 
seen that the clinicians involved were responsible for generating the COl ratings. Where 
there were any concerns about whether a patient ful.fi1led criteria for inclusion in the study 
or regarding COl scores, meetings were held intermittent1y in the team to discuss these 
cases. A consensus decision could therefore be made on diagnosis and COl rating. 
2.8.3 Storage of patient and subject information 
Clinical details regarding the patients and personal information of subjects were stored 
according to protocols for the storage of confidential information This included the use 
of filing cabinets either in lockable research offices or in clinical areas which are subject 
to the provisions for confidentiality. Other patient information, which was part of the 
normal recording of clinical activity, was stored in the team bases of the psychiatric 
sectors involved, under usual arrangements for storage of confidential information 
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CHAPTER 3 
THE EFFECT OF PAROXETINE 
TREATMENT ON RESPONSES TO META-
CHLOROPHENYLPIPERAZINE 
3.1 BACKGROUND 
In an attempt to understand how the therapeutic effects of serotonin selective re-uptake 
inhibitors (SSRIs) are mediated, we undertook the present study to assess the effect of a 
short-term period of treatment with an SSRI, paroxetine, on hormonal, temperature and 
behaviouraI responses to m-CPP in healthy volunteers. In animal studies repeated 
administration of SSRIs produces a number of adaptive changes in both pre- and post-
synaptic serotonin receptors (Johnson, 1991). In human studies chronic SSRI treatment 
has shown a decrease in a number of functional responses to m-CPP, as discussed in 
Chapter 1 (Kennedy et al, 1993; Kennett et ai, 1994a; Maj et al, 1996). As 5-HT2C 
receptor antagonists have anxiolytic properties in animal models it was hypothesised that 
this latter action might underlie some of the anxiolytic effects ofSSRIs in patients. 
In those patients suffering from obsessive compulsive disorder the capacity of m-CPP 
(taken orally) to produce a worsening of symptoms was abolished by chronic treatment 
with fluoxetine (an SSRI), and clomipramine (a serotonergic tricyclic antidepressant) 
(Zohar et al, 1988; Hollander et ai, 1991). 
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This effect could, however, have been due to the clinical benefit derived from treatment. 
Although the symptomatic deterioration was abolished the hormonal responses to m-CPP 
were not, but this finding was further complicated by the fact that the m-CPP serum levels 
were elevated in the second challenge following clomipramine treatment, in the earlier 
study. lbis may have been due to the inhibition of m-CPP metabolism in the liver by the 
antidepressant . 
In this study it was therefore hypothesised that the period of treatment with paroxetine 
would attenuate both prolactin and hyperthermic responses to m-CPP. To avoid possible 
pharmacokinetic interactions between m-CPP and paroxetine the m-CPP was administered 
intravenously at a dose known to be well-tolerated. The study was powered to detect a 
reduction in behavioural effects as a replication ~f the OCD study quoted above where 6 
patients were treated with fluoxetine (Hollander et aI, 1991). 
3.2 METHODS 
3.2.1 Subjects 
The study was approved by the local Ethics Committee, the Oxford Psychiatric Research 
Ethics Committee, and healthy volunteers aged between 18 and 50 years were recruited by 
local advertisement or from the volunteer bank. At clinical interview before the start of the 
study it was determined that they had no personal history of mood disorder. 
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Subjects were excluded if they had a personal medical history of asthma or migraine as m-
cpp has been known to precipitate episodes of these conditions. The included subjects 
were found to be physically healthy by clinical examination and ECG trace. 
Blood tests were carried out to evaluate renal, liver, kidney and thyroid function. In 
addition, it was ascertained, on questioning, that the subjects had not used any 
psychotropic substances, either medical or illicit, in the three months prior to testing. 
Seven subjects were tested (5 males, 2 females), mean age 35.6 years (range 22 to 45 
years). They were fully informed regarding the protocol and gave signed informed 
consent to this study. The 2 female subjects were tested in the early follicular stage of the 
menstrual cycle (between days 3 and 8), details of which were determined at the initial 
clinical interview. 
3.2.2 Paroxetine treatment 
Subjects received paroxetine 20mg daily for one week, at which point the dose was 
increased to 30mg per day and they remained on the increased dosage for a further 2 
weeks. This period was chosen in view of literature showing superior paroxetine 
response compared to fluoxetine at week three (De Wilde et al, 1993; Geretsegger et aI, 
1994). One male was unable to continue at 30mg daily in view ofdiz~iness and nausea and 
the dose was therefore continued at 20mg per day. Other than this individual no 
significant side effects were described and the drug was tolerated well. 
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3.2.3 Neuro-endocrine challenge procedure 
The subjects attended the unit for blood sampling related to neuro-endocrine 
measurements on two series of occasions in total, and drug or placebo was administered 
on a random basis, in a balanced order design. The first series (two single days) took place 
prior to the subject commencing paroxetine in order to establish base line measures and 
achieve responses to m-CPP unaffected by anti-depressant medication The second series 
of visits (two days) occurred at three weeks after medication had been commenced and 
either placebo or drug was administered, depending on the order determined by the first 
test. (See Table 3.1). Neuro-endocrine testing was carried out following an over-night 
fast with the subjects having been requested not to eat or drink from midnight. They were 
transported to and from the research unit by taxi. 
Table 3.1: Paroxetine Study protocol. 
Occasion Procedure 
Visit 1 Assessment, screening, consent, phys. exam. 
Session 1 - neuroendocrine challenge test Placebo or drug administered. 
Session 2 neuroendocrine challenge test Alternative administered depending on 
previous session, by randomisation. 
Paroxetine commenced In females commencement was timed for 
subsequent tests to :full in follicular phase. 
Session 3 - neuroendocrine challenge test Three weeks post paroxetine started. Drug or 
placebo administered. 
Session 4 neuroendocrine challenge test Alternative administered depending on 
previous session, by balanced order. 
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3.2.3.1 m-CPP dose 
The subjects attended for 2 series of paired tests involving a neuro-endocrine challenge, 
each series consisting of m-CPP or placebo in a double-blind, random order (see table 
3.2), cross-over design. The time interval between the two sessions was 1-3 days. The 
drug or placebo was given at a point in the testing which fell between 9.30 and 10.00 a.m. 
(time '0'). m-CPP for intra-venous use (Mandeville Medicines Ltd.; Aylesbury; UK) was 
administered by a dosage schedule to avoid excessive side-effects (Kalus et al, 1992) 
according to mass (0.05mg per kg) and constituted into a 20ml volume using 0.9% NaCl. 
It was then administered intravenously over 20 seconds. On the other day 20 ml of 0.9'% 
saline was administered by intravenous injection, as placebo, also over a 20 second period. 
Table 3.2: Paroxetine treatment project - study design. Subjects who received m-
CPP on the first day of the first series of sessions a1so received the same order for 
the second series as randomisation dictated a specific order for the whole study in 
a balanced order design. (M=m-CPP; P=placebo) 
Test day 
Subject 1 2 3 4 
1 P M P M 
2 P M P M 
3 M P M P 
4 P M P M 
5 ffi P M P 6 P M P 
7 P M P M 
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3.2.3.2 Sampling protocol 
Subjects attended the laboratory at 08.30 hours and were cannulated with an indwelling 
venous catheter which was maintained patent with heparinised saline. Following a 30 
minute rest period blood samples were removed for base line endocrine measures and then 
at 15 minute intervals until one hour had lapsed, post administration of drug or placebo. 
m-CPP or placebo was administered 1 hour after cannulation. Following the 
administration of the intravenous injection via cannula, blood samples were therefore 
taken at 15 minute intervals, at fifteen minutes and then on 3 further occasions (+ 15, +30, 
+45 and +60 minutes post drug or placebo) and thereafter removed at 30 minute intervals 
(+90, + 120 and + 150 minutes post drug or placebo). 
3.2.4 Monitoring procedures 
Subjects were able to relax and read neutral material in between sampling procedures but 
were not permitted to eat, drink, smoke or watch television. Pulse, blood pressure and 
oral temperature were measured at base-line and at half-hourly intervals thereafter. Pulse 
and blood pressure measurements were taken automatically by machine and the oral 
temperature was recorded using a glass mercury thermometer which remained in place for 
10 minutes prior to the recording being made. 
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3.2.5 Subjective ratings and scales administered 
At baseline assessment the clinician involved completed a Hamilton-Depression scale 
(HAM-D) (Hamilton, 1960) and, at the start ofthe study, on the first neuro-endocrine test 
day. subjects completed the Beck Depression Inventory (BDI) (Beck et a~ 1961) in order 
to exclude intercurrent depression. None of the subjects was found to score in the 
depressed range, prior to paroxetine treatment, for either of these measures, which have 
been described in more detail in Chapter 2. BDI scores ranged from 0 to 7 pre-treatment 
(mean = 2.3). Ham-D scores ranged from 0 to 5 (Mean = 2). Subjective ratings were 
recorded on visual analogue scales (VAS) for the measures "nausea", "light-headedness'\ 
'happiness' and "anxious" on lOcm scales, as described in Chapter 2. These visual 
analogue ratings were commenced at time '0' and initially repeated five minutes post-
administration of drug or placebo. After this point they paralled the blood sampling 
frequency, at 15 minute intervals up to one hour post drug/placebo and thereafter at 30 
minute intervals until 150 minutes were completed post administration. Copies of the 
scales can be seen in appendix 3. 
3.2.6 Biochemical assays 
Initially 10mls of blood was removed prior to specimen sampling. This was to clear the 
heparinised saline remaining in the cannula. Following this 2 further blood samples were 
obtained and stored in ice. 
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Following the study these two samples were separated by centrifugation and the plasma 
was stored at -30°C. Prolactin concentrations were determined by a standard 
immunoradiometric assay, as described in Chapter 2 (reagents provided by Netria, 
London). The inter- and intra-assay co-efficients of variation over the range encompassed 
by this standard curve were 4.8% and 2.4% respectively. Plasma m-CPP was measured 
using HPLC as previously descnbed in Chapter 2 (Odontiadis, 1996). The limit of 
detection of the assay was 0.2 nanograms per mI, for Iml of plasma. 
3.2.7 Statistics 
Plasma m-CPP levels for each subject were calculated as the mean for the plateau phase 
(30-90 minutes) (Benjamin et at, 1996) and compared by paired t-tests. VAS scores were 
measured as peak change from base-line and analysed by repeated measures ANOV A in 
the same way as the prolactin and temperature data. 
Base-line PRL tests were also carried out using paired t-tests (2-tailed). Plasma PRL and 
temperature were plotted against time and calculated as area under the curve (AUC) using 
the trapezoid rule with subtraction of base-line extrapolated from time "0". The AUC's 
were then analysed by repeated measures analysis of variance (ANOV A) with two main 
factors, "treatment" (m-CPP vs placebo) and "occasion" (pre vs post - paroxetine). In 
addition, AUC responses to placebo were subtracted from those to m-CPP to provide 
placebo - corrected AUC responses to m-CPP. The values obtained pre and post -
paroxetine treatment were compared with paired t-tests. 
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3.3 RESULTS 
3.3.1 Prolactin levels 
The AUe PRL data showed a trend main effect ofm-CPP (F=3.09; df=1.6; P=O.l3) but 
no significant effect of placebo on ANOVA testing (F=1.07; df=L6; P=O.34). However, a 
significant interaction was seen between m-CPP and paroxetine (F=1O.1; df.=1.6; 
P=0.019). m-CPP day base-line (time '0') prolactin measures did not differ significantly 
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Figure 3.1: Plasma prolactin concentrations, (shown as change from base-line in 
mIU/ml) before and after paroxetine treatment, on m-CPP and placebo days. PRL 
response to m-CPP was significantly reduced after treatment, in mIUx hlml 
(ANOV A; P=0.007). Error bars omitted for clarity. 
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The mean ± SEM PRL response following p1acebo did not differ before and after 
paroxetine treatment (-20 ±15 vs 7 ± 42 mIU x Him!; P=O.65), but the PRL response to 
m-CPP was significantly decreased (103 ± 36 vs 12 ± 33mIV x Him!; P=0.007) (See 
figure 3.1; SEM points have been omitted for reasons of clarity). The p1acebo subtracted 
AVC data further confirmed that the PRL response to m-CPP was significantly less after 
the period of paroxetine treatment (See Table 3.3). 
Table 3.3: Summary of the effect of paroxetine on prolactin responses to m-CPP. 
The pre and post treatment difference was significant, P<0.025, for placebo 
corrected AVC measures. 
Prolactin AUe (mlUxhlml) 
Sub.ject pre-paroxetine Post paroxetine 
1 123 94 
2 52 -226 
3 180 65 
4 5 -31 
5 47 -44 
6 197 147 
7 75 -10 
Mean ± SEM 97±27 O.7±46 
3.3.2 Thermic responses 
The temperature data, calcu1ated as AVC, demonstrated a significant main effect of m-
CPP (F=7,4; df.=1.6; P=0.035) but no main effect ofparoxetine was seen (F=3,49; df.=1.6; 
P=0.11). However, a significant interaction between m-CPP and paroxetine was seen 
(F=6.54; df.=1.6; P=O.043). 
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It is therefore clear that the usually expected positive effect on temperature was seen 
following m~CPP administration but that the extent of the increase has been diminished by 
the period of treatment on paroxetine. This can be seen graphically in Figure 3.2 (SEM 
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Figure 3.2: Comparison of temperature change CO C) before and after paroxetine 
treatment on placebo and m-CPP days. Temperature elevation is significantly 
reduced following m-CPP administration after paroxetine treatment (ANOV A; 
P=O.031). 
Further testing, using the mean AVC data, showed that the mean ± SEM tempera~e 
response following placebo did not differ before and after paroxetine (2.3 ± 5 vs 2.8 ± 
7.5°C x min; P=O.96) but the temperature response to m-CPP was significantly reduced 
(38.5 ± 8 vs 8.1 ± 12°C x min; P=O.031). 
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The placebo-corrected AVC data also showed that the hyperthermic effect of m-CPP was 
significantly less after paroxetine treatment (See Table 3.4). 
Table 3.4. Summary of the effect ofparoxetine on thermic responses to 
m-CPP. The pre and post treatment m-CPP induced difference was significant for 
placebo-corrected AVC measures (P< 0.05). 
Temperature:- placebo corrected Aue 
(Oe x min) 
SubJect pre-paroxetine post paroxetine 
1 20 20 
2 90 17 
3 47 21 
4 27 -30 
5 32 -26 
6 90 17 
7 29 37.5 
Mean::l:SEM 36.6::1:9.8 5.4::1:9.7 
3.3.3 Visual analogue ratings 
The following graphs detail the results of the visual analogue scores as discussed 

















Figure 3.3: Nausea - visual analogue ratings (mm) before and after paroxetine 
treatment (P> 0.05, paired t-test). 
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The ANOV A of the V AS data for "nausea" and "anxious" showed no significant main or 
interactive effects of m-CPP and paroxetine (Figures 3.3 and 3.4). However, six out of 
seven subjects showed a reduction in mean VAS scores of anxiety on the placebo day 
after the three week period of paroxetine treatment. 
In a similar manner, six out of seven subjects (a different group) showed a non-significant 
reduction in mean anxiety scores on the m-CPP occasions after paroxetine treatment, 
supporting a general anxiolytic effect of the anti-depressant. Although it has been 
previously reported that elevation of anxiety levels occurs following the administration of 
m-CPP, it is evident from the self-report (VAS) anxiety measures recorded in Figure 3.4 
that although there is a suggestion of a small positive effect, there was no significant 











Figure 3.4: Anxiety - visual analogue ratings (mm) before and after paroxetine 
treatment (p> 0.05, paired t-test). 
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As might be expected, the "light-headed" data showed a significant main effect of m-CPP 
(F=7.66; df=1.6; P=0.032) but no main effect ofparoxetine (F=0.217; df=1.6; P=0.22) or 
paroxetine by m-CPP interaction (F=3.26; d:f-=1.6; P=0.12) (Figure 3.5). 
Peak ratings of light-headedness in response to m-CPP were lower after paroxetine 
treatment than before, but this was not statistically significant (Pre vs post paroxetine: 
24.3 ± 8.4 vs 10.0 ± 4.4; P=O.11, paired t-test). 
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Figure 3.5: Light headedness. Visual analogue ratings (mm) before and after 
paroxetine treatment (P=0.11, peak value post-hoc paired t-test). 
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3.3.4 Drug levels 
3.3.4.1 m-CPP levels 
Although an increase can be seen in the m-CPP levels following the period of paroxetine 
treatment, in Figure 3.6, the mean plateau levels of m-CPP after the intravenous injection 
did not differ significantly when compared statistically by paired t-tests (p=O.325). 
Table 3.5: Summary of the variation in plasma rn-CPP levels in ng/rnl, before and 
after paroxetine treatment (p>0.05; NS). 
Plasma m-CPP level (n~Jml) 
Subject Pre-paroxetine Post paroxetine 
1 58.7 41.2 
2 13.3 30.1 
3 41.9 42.3 
4 20.4 28.4 
5 23.6 43.5 
6 52.5 18.1 
7 Missing Missing 
Mean±SEM 33.9±7.5 35.1± 4.1 
As i.v administration avoids first pass metabolism, it is unlikely that this non-significant 
increase could have been caused by inhibition of the hepatic metabolism of m-CPP by 
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Figure 3.6: Plasma m-CPP drug levels in nglml (shown as mean ± SEM) measured before 
and after paroxetine treatment in seven healthy subjects. The values are calculated by 
measuring the mean levels from the plateau phase of the neuro-endocrine tests, from +30 
minutes to +90 minutes (Not significant by paired Student's t-test ; p=0.375). 
3.3.4.2 Paroxetine levels 
Blood samples taken at the final neuro-endocrine challenge session confirmed that the 
subjects had all been compliant with their paroxetine however there was wide variability in 
the levels and the doses were not modified according to BMI or previous level testing as it 
is not usual for these to be used in clinical practice (See Figure 3.7). 
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Figure 3.7: Plasma paroxetine drug concentrations in nglml at 3 weeks treatment 
in seven healthy volunteer subjects (plateau phase: +30mins to +90 mins) on final 
day of testing. 
3.4 DISCUSSION 
The major findings of this study are compatible with other work suggesting that SSRI 
treatment down-regulates the sensitivity of post-synaptic 5HT2C receptors. This was seen 
following treatment of healthy subjects with a lowering of the prolactin and hyperthermic 
response to m-CPP in the neuroendocrine test condition. It is unlikely that drug side 
effects of m-CPP could have contributed in a major way to these findings through other 
non-specific physiological effects. Although the visual analogue scale scores concerning 
light-headedness were reduced following the three week treatment period, this was not in 
a statistically significant mamer. 
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It is, however, necessary to consider alternative explanations for the above findings. As 
was discussed previously, m-CPP has activity at other serotonin receptor sites although its 
major agonistic effect is at the 5HT 2C receptor site. The 5HT IA receptor has also been 
implicated in prolactin release in humans (Anderson et al, 1990). This finding has been 
supported by the observed antagonism towards m-CPP of pindolol when monitoring 
pro1actin response, supporting the notion that 5HT IA receptors may playa role in m-CPP 
induced prolactin release (Meltzer and Maes, 1995). 
A further possibility involving the 5HT1A receptors in explanation of the above findings is 
that paroxetine treatment blunts the endocrine responses to 5HT1A receptor agonists 
including gepirone (Sargent et aI, 1997) and this could also account for the reduced 
prolactin response to m-CPP in this study. It is less likely that this could explain the 
reduced hyperthermic response as 5HT1A receptor activation usually leads to a decrease 
rather than an increase in body temperature (Anderson et al, 1990). 
There is also some evidence from animal studies involving in-vivo micro dialysis that m-
CPP can promote 5-HT release from presynaptic terminals (Baumann et al, 1993). This 
may suggest that the prolactin response to m-CPP could also involve indirect activation of 
post-synaptic 5-HT receptors. Other animal work has suggested that this effect can be 
blocked by SSRIs, possibly by the interference of SSRIs with the action of the releasing 
substance on the 5-HT transporter. In another study fluoxetine reduced the prolactin 
response to m-CPP in rats. Thus it is conceivable that paroxetine might prevent the 
endocrine and thermic effects of m-CPP by preventing m-CPP-induced 5-HT release. 
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Against this is the finding in animal studies that the release of prolactin after m-CPP 
administration is enhanced following destruction of serotonin neurones by 5-7 DHT. This 
suggests that m-CPP - induced prolactin release is indeed mediated by post-synaptic 5-HT 
receptors (Quattrone et a1, 1981). 
An alternative possibility for the effect of paroxetine to diminish the functional effects of 
m-CPP is that paroxetine may possess direct 5-HT2c receptor antagonist properties. 
However, this possibility is not supported by binding data as paroxetine has a lower 
affinity for 5HT2C receptors than fluoxetine (Wong et al, 1991). 
As regards the design of the study, it was not possible to control for order effects in the 
administration of m-CPP and placebo. It is therefore possible that the reduced responses 
represent a loss of reactivity in the second test. This has been found in other studies 
where intravenous injections of m-CPP induced tolerance to a number of its expected 
effects (Benjamin et at, 1996). This is less likely, however, in view of the time gap 
separating the two studies, which was three weeks. It has also been found previously, in a 
cross-over design study using intravenous m-CPP, that there was no evidence of an order 
effect on the hormonal and behavioural responses to m-CPP (Silverstone and Cowen, 
1994). Other studies mentioned previously, utilising clomipramine and fluoxetine in OCD, 
did not find reduced endocrine responses to m-CPP but, as discussed previously, this may 
have been due to the increased levels of plasma m-CPP (Hollander et al, 1991; Zohar et at, 
1988). Although powered as in the Hollander study, to detect behavioural effects, it may 
be that the sample size was too low to elicit psychological variations post treatment. 
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In spite of the absence of reduced endocrine responses to m-CPP in the above studies, it 
was noted that clomipramine treatment reduced m-CPP stimulated hyperthermia (Zohar et 
aI, 1988). In our study plasma levels of m-CPP were not significantly increased following 
paroxetine treatment. This is most likely due to the use of an intravenous mode of 
administration The dose of m-CPP used in our study was also chosen to be well 
tolerated, and endocrine responses were therefore sub-maximaL Should the above 
findings in our study be correct then the mechanisms involved in the reduction of 5-HT2C 
receptor sensitivity are not clear. Both 5-HT2C receptor changes or receptor transduction 
mechanisms could be involved 
3.5 CONCLUSIONS 
5-HT2C receptor down-regulation has been suggested to relate to the function of SSRIs in 
reducing anxiety in patients as well as in the treatment ofOCD. While drugs with 5-HT2C 
receptor antagonist properties may be effective in anxiety they do not appear to be 
effective in OCD . 
Indeed, 5-HT2C receptor antagonists such as ritanserin and metergoline can undermine the 
effect of SSRIs in OCD. Perhaps SSRIs increase 5-HT neurotransmission at 5-HT2c 
receptors and the down-regulation of post-synaptic 5-HT2C receptors occurs in response 
to this. 
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The role of 5-HT2C receptors in the treatment of depression is less clear. Some 
antidepressants such as mirtazapine and nefazodone are e:tThctive antidepressants but many 
antidepressants have no activity at the 5-HT2C receptor. It has also been noted that 
desipramine fails to reduce m-CPP stimulated behaviours in animals and it is not effective 
in the treatment ofOCD (Kennett et aI, 1994). This question can be better answered with 
the use of selective 5-HT 2C receptor antagonists and will increasingly continue to be 
investigated using molecular techniques in view of :findings suggesting that 
antidepressants not only act pharmacologically but physiologically. However molecular 
studies thus far have shown an increase in 5-HT2C m-RNA in the rat brain following 
imipramine treatment rather than a decrease, which might therefore imply an attempt to 
boost receptor numbers in the face of antagonism towards the receptors (Tohda and 
Watanabe, 1996). 
Further research possibilities include the studying of the time course during which SSRI 
treatment reduces the endocrine and thermic responses to m-CPP, as a delayed effect 
would suggest receptor desensitisation to a greater extent than a direct receptor effect or 
inhibition of pre-synaptic 5-HT release. 
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CHAPTER 4 
THE EFFECT OF ALLELIC VARIATION ON 
RESPONSE TO SEROTONIN SELECTIVE 
RE-UPTAKE INIDBITORS. 
4.1 BACKGROUND 
With the discovery of different polymorphic versions of the serotonin receptors and the 
serotonin transporter it has become a clinically relevant question as to whether 
polymorphic variation might lead to differential response rates in patients suffering from 
depression when treated with SSRIs. The details of these polymorphic variants were 
described in Chapter 1. 
The aim of the present study was therefore to establish whether the cys23ser polymorphic 
variation in the 5-HT2C receptor gene or the 5-HTTLPR variant might predict a greater 
response of patients to SSRIs and the serotonergic tricyclic antidepressant~ clomipramine. 
Initial work has focussed on two polymorphisms linked with the serotonin transporter (5-
HTT) gene - one in the promoter region (5-HTTLPR) and another in intron 2 (Stin2). 
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Several studies have detected allelic association between this gene and clinical response to 
SSRIs. In one study patients with the long polymorphic variant - 'VI' and heterozygotes 
with the short and long - 'sll' - versions of the promoter region polymorphism were more 
likely to show an improved response to fluvoxamine, an effect abolished in the group also 
treated with pindolol (Smeraldi et al, 1998). 
In two similar studies utilising paroxetine, an increased response rate was seen in subjects 
with at least one copy of the long variant of the 5-HTTLPR polymorphism in a study 
involving young adults (Zanardi et al, 2000) and in a further study involving an older 
group of patients. In the latter study a more rapid response was seen for those patients 
homozygous for 'VI' promoter alleles compared to those with an's' allele (heterozygotes 
or homozygotes) (pollock et al, 2000). However, an enhanced clinical response has also 
been reported in patients homozygous for the short version - 'sis' - of the 5-HTTLPR 
polymorphism, and in homozygotes with the Stin2.12 version of the intron 2 
polymorphism (Kim et al, 2000). In a related study in Obsessive Compulsive Disorder, no 
difference was seen between the two groups when both polymorphisms were examined, in 
considering their response to fluoxetine or clomipramine (Billett et al, 1997). Should it be 
ascertained that polymorphic variation is associated with differing relative response rates 
to different types of anti-depressant medication, this would provide the clinical option of 
genotyping, in advance of antidepressants being used, in order to facilitate an optimal 
pharmacogenetic choice of treatment. Although the sample size in this study is small for a 
genetic study it is powered to detect a minimum difference of 48% of responders with a 
serine allele if the non-responder serine rate were to remain constant at 33.3%. 
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Data suggest that pharmacogenetics can be used to predict response to clozapine 
treatment in schizophrenia since 19 polymorphisms have been shown to predict response 
to the atypical anti-psychotic, c1ozapine, with a 76,7 % rate of success i.e. a positive 
predictive value of 0.76 and a negative predictive value of 0.82, in a test of one model 
utilising algorithms (Arranz et al, 2000). 
In view of the potential of the above strategy and in order to extend the framework which 
arose from an initial paper showing a correlation of the serine substituted 5HT2C 
polymorphism with response to c10zapine (Sodhi et al., 1995), it was decided to 
investigate whether response to serotonergic antidepressant medication might also 
correlate with this 5-HT2C receptor polymorphic variation. 
Additionally, in view of the more recent interest in the promoter region variants of the 
serotonin transporter gene and the pivotal role of the transporter in the most widely 
accepted model of SSRI function, the 5-HTTLPR polymorphism was also investigated in 
the study. 
Related work on a healthy volunteer sample, from which subjects with specific serotonin 
transporter and 5-HT2C polymorphisms had been recruited for the studies described in 
Chapters 5 and 6, permitted the comparison of polymorphism rates in the depressive 
sample with rates in a control group who had described no current self-reported or 
previous psychiatric history. 
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4.2 METHODS 
4.2.1 Recruitment of groups studied 
4.2.1.1 Patient recruitment 
Patients were recruited from: a) the database of the Psychopharmacology Research Unit, 
where they had previously been involved in treatment studies of major depression. 
b) directly from a humber of general practices in the 
Oxfordshire area and, c) from a group of patients who had taken part in research 
studies on major depression according to the protocols of the Hertfordshire Neurosciences 
Research Group. 
Ethical approval for the study was obtained from the local Ethics Committee (OPREC). 
Patients were aged between 18 and 65 and specific exclusion criteria included:-
- presence of an organic disorder. 
- significant illicit substance misuse. 
- co-morbidity for severe personality disorder. 
The patients were contacted either by telephone or by letter to invite them to participate in 
the study or they were referred by local GP's for a psychiatric consultation and further 
management. At the initial interview it was established whether they had a DSM3-
RlDSMIV diagnosis of major depression (Axis 1 diagnosis). 
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For the patients who had previously been managed in the unit the diagnosis of DSM3-R 
major depression had already been made for previous studies. For those attending the unit, 
the diagnosis was confinned at clinical interview or, if unable to attend, a case note 
diagnosis was made according to DSM3-R/DSMIV criteria. Patients were invited to 
contribute a buccal swab or a blood sample, depending on their preference. Some patients 
preferred not to attend the unit but were willing to send a buccal swab by post. Should 
further information have been lacking regarding their clinical progress, this was obtained 
by letter, or by telephone. 
All patients who attended the unit gave written, informed consent, however the Ethics 
Committee had agreed that those patients sending a buccal swab by post would be giving 
implicit consent and that a separate form was therefore unnecessary. They had received an 
information sheet and patients sending swabs by post had also received a telephone call to 
discuss the study. 
The patients were or had been under the treatment of psychiatrists within the department 
and it was therefore possible to establish consensus diagnoses in situations where the 
diagnosis was not clear, at meetings convened for this purpose. 
4.2.1.2 Control group 
The control group consisted of subjects who had attended blood donor clinics in 
Oxfordshire, as described in Chapter 1. 
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They gave informed consent to provide a cheek swab for DNA analysis and also 
completed a questionnaire with demographic information as well as personal details 
regarding the presence or absence of mental health problems, past and present. 
4.2.2 Genotyping 
This was carried out according to the techniques described in Chapter 1. Samples taken at 
the Psychopharmacology Unit or received by mail were frozen at -70 degrees prior to 
genotyping. Those samples taken at Queen Elizabeth II Hospital, Hertfordshire, were 
frozen initially in a freezer box at -5 degrees and then transferred to the -70 degree freezer 
once local collection had been completed. 
4.2.2.1 5-HT 2C receptor polymorphisms 
The polymorphism used to determine relative response rates, according to the 5-HT2c 
gene was the serine/cysteine substitution at codon 23 (there is a G to C change at 
nucleotide 68). 
As discussed in chapter 1, the serine substituted version is found in approximately 13 % of 
the population (Sodhi et al, 1995) but, in view of X-linkage, females may be homo- or 
heterozygotic while all males are hemizygous (Lappalainen et a~ 1995). 
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4.2.2.2 5-HT Transporter polymorphism 
The polymorphism used to determine whether allelic variation in the transporter gene may 
be relevant to SSRI response is a variant derived from the promoter region of the human 
serotonin transporter gene (5-HTTLPR). This is a 44-base-pair insertion/deletion 
polymorphism which gives rise to a short (s) and long (1) form of the gene. The 
characteristics of this gene and its effects have been described in Chapter 1. 
4.2.3 Clinical response 
4.2.3.1 Clinical Global Impression Scale 
Sources of information regarding patient clinical response to serotonergic medication 
included the clinical case notes, which recorded details derived from consultations of the 
Psychopharmacology Unit medical staff with the patients, rating scales regarding entry to 
the studies and progress scores on those patients taking part in clinical research studies, 
and information received from general practitioners at either referral or by subsequent 
request, where information was lacking regarding response. As variability was evident in 
the quantity and type of data collected from the patients, relating to whether they had been 
involved in other studies or referred by G.P's, all ofthe available information was collated , 
and a single clinical global impression (CGI) score was derived (See Table 2.5). 
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In each case, wher~ possible, the treating clinician derived the score and completed a 
questionnaire regarding demographic details, age of onset, diagnosis, comorbidity, past 
history of treatment, details of response and past history of self harm. The clinicians were 
blind to the patients' 5-HT2c and 5-HTTLPR genotypes at the time of the decision 
regarding clinical response. For those patients recruited by the Hertfordshire Group, 
MADRS scores were available to the treating clinicians regarding response to paroxetine 
and CGI scores were derived according to common criteria with the Oxford patients. 
4.2.3.2 Consensus ratings 
For the derivation of CGI scores from those patients where the involved clinician had left 
the unit, information was initially collated from all of the clinical records. Where 
necessary, this included a confirmation of diagnosis according to DSM-3R1DSMIV 
criteria. For a number of these patients senior clinical academic staff had also been 
involved in decisions regarding the patient's treatment and in many cases, had met the 
patients themselves. 
For the above patients and in any other situations where either the diagnosis or clinical 
response to treatment was in question, the issues were considered at consensus meetings 
of the clinicians involved with the study. In this way consensus opinions were recorded 
regarding unclear diagnosis or response. The clinicians involved in these meetings were all 
blind to gene subtype. 
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4.2.4 Statistics 
Analyses regarding the serotonin transporter gene were different to those carried out 
concerning the 5-HT2C polymorphism, as the X-linkage of the latter gene necessitated 
separate analyses for males and females. 
Patients were grouped into 'responders' by grouping those with CGI=l and 2 (good and 
marked) and 'non-responders' which referred to CGI=3 and 4 (poor and deterioration). 
Chi squared analyses (Mantel Haenszel) were performed on the data dichotomised as 
above and by division of the gene groupings according to differing assumptions regarding 
the relevance of the effect of a specific allele. In addition to the chi-squared analyses, tests 
of linear association were carried out using the CGI score as one variable and incremental 
quantities of gene dose as the other. 
For the serine dominant model greater power was achieved by combining the 5-HT2C 
receptor gene cys/ser patients with the serine homozygote group in view of the limited 
numbers of serine homo zygotes. In the comparison of 5-HTTLPR polymorphisms both 
short (s) allele dominant and recessive models were used, as previous studies had 
demonstrated both an increased occurrence rate of this polymorphism in depressed 
samples (unipolar and bipolar) over healthy control populations (Collier et al, 1996a) and 
no association (Kunugi et al, 1997). In the comparisons of 5-HT2C and 5-HTTLPR 
polymorphism rates between the depressive group and the heahhy control group, X2 
analyses were used. 
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4.3 RESULTS 
4.3.1 General features of the samples 
4.3.1.1 Depression group 
Ofa total group of 416 patients who had been treated or had taken part in research studies 
at the Psychopharmacology Unit between 1995 and 2000, it was possible to obtain blood 
samples or a buccal swab on 188 patients who had been treated on SSRIs or clomipramine 
(110 females and 78 males), and who satisfied criteria for major depression (DSM3R14). 
A total of 17 patients were recruited from the Hertfordshire group. As unipolar 
depressives were over-represented in the target patient group only 6.3% of the final 
sample was diagnosed as suffering from bipolar disorder. 
The age of the patients was 45.2±1.3 years (mean±SEM) and the range was 21-70 years. 
Seven patients were excluded to ensure that age related effects relating to differential 
diagnosis were minimised. As a result 181 patients were aged 21 to 65 years. Of this 
sample, four individuals had a recorded non-Caucasian ethnicity and were therefore 
excluded from further analyses in view of the possibility that differences in the ratio's of 
polymorphisms between ethnic groups could confound the analyses. The final sample size 
for the main analyses was therefore 177 patients. Of these 71 were male and 106 female 
patients. In view of the small number of patients recruited from the Hertfordshire group 
and the small percentage of bipolar patients their results were not analysed separately. 
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4.3.1.2 Control group 
There were 328 subjects in total, 138 were male and 190 were female (mean age ± SEM is 
38±13 years; range: 19-71 years). All of the above subjects were Caucasian and their 
parents and grand-parents were born in the UK. 
4.3.2 Demography of response 
Of the total sample, 104 out of 177 patients were classed as responders (COI=1 or 2), 
which equates to 58.8 %, an average response rate to SSRI anti-depressant medication 
(Edwards and Anderson, 1999). This included 42 of 71 males (59.2 %) and 62 of 106 
females (58.5 %). Dividing the total sample into two groups around the median age (47 
years) reveals no age effect in response. 
Dividing the group by the possible four COl scores shows 19.2 % to have been marked or 
excellent responders, 39.5 % were good or moderately good responders, 27.7% were 
poor or minor responders and 13.6 % showed evidence of deterioration or no change. It 
is therefore possible to group all those who showed any measure of response (86.4%), in 
order to derive a total figure but this would not equate to measures used in clinical studies 
or in the meta-analyses of response mentioned above, where more stringent response 
criteria are applied. 
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4.3.3 5-HT1C receptor polymorphisms 
Of the sample of 177 patients, 120 had sufficient blood or buccal swab material available 
for extraction and identification of the 5-HT2C variants. This included 46 males and 74 
females. 
In the total sample, polymorphism rates were as seen in Table 4.1 (below). Of the males, 
12 (26.1 %) therefore had serine alleles and 34 (73.91>/0) cysteine alleles. In the female 
group 3 (4.0 %) patients were homozygotic for serine, 21 (28.4 %) were heterozygotes, 
and 50 (67.6 %) were cysteine homozygotes. 
Table 4.1: Total sample of 120 patients divided by gender and 5-HT2c 
genotype. The genotyping for the females is in Hardy-Weinberg equilibrium (chi 
sq=O.18, Idf, NS). The males cannot be tested for Hardy-Weinberg equilibrium 
because they are hemizygous. 
i Genotype Males(%) Females (%) Total (%) 
i 
i Ser 12 (26) 0 12 (10) 
SerlSer 0 3 (4) 3 (2:5) 
Cys/Ser 0 21 (28) 21 (17.6) 
Cys 34 (74) 50 (68) 84 (69.9) 




4.3.3.1 Gene frequencies in response 
The genotyped sample had a slightly lower proportion of responders than the whole 
patient sample with 65 patient responders out of a total of 120 (54,2 %). Of the 
responder group, 32.3% had at least one serine allele compared with 27.3% of the non-
responder group, a non-significant difference (Mantel Haensze~ X2 = 0.36; 1 d.t:; p=0.55). 
Findings relating to both patient and control groups for the 5-HT2c receptor are presented 
in Table 4.2. 
Findings for the serine homozygotes and heterozygotes versus cysteine homozygotes in a 
serine dominant model can be seen in Table 4.3, while the findings for the serine recessive 
model are seen in Table 4.4. Neither grouping is statistically significant. 
Table 4.2: Summary of frequencies of 5-HT2c genotypes and alleles in depressed 
patients and controls. 





Genotype M F Total M F Total M F Total M F Total I 




<:)rs/ser 0 12 12 0 9 9 0 21 21 0 51 51 
Serlser or 7 2 9 5 1 6 12 3 15 26 4 30 I 
ser ! 
TOTAL 25 40 65 21 34 55 46 74 120 138 191 329 
Cys allele 18 64 82 16 57 73 34 121 155 112 323 435 i 
Ser allele 7 16 23 5 11 16 12 27 39 26 59 85 i 
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Table 4.3: Comparison of response rates in patients according to the presence or 
absence of any serine alleles in a serine dominant model; (Mantel Haenszel; X 2 = 
0.36; d.f=l; p=0.55; NS) . 
. Genotype Non-responders (%) Responders (%) Total (%) 
CIS, S or SIS 15 (27.27) 21 (32.31) 36 (30) 
I 
C/CorC 40 (72.73) 44 (67.69) 84 (70) 
Total 55 (100) 65 (100) 120 (100) 
Table 4.4: Comparison of response rates in patients according to the presence or 
absence of any cysteine alleles in a serine recessive model; (Mantel Haenszel, X 2 = 
0.23; d.f=l; p=0.63; NS). 
1 Genotype I Non-responders (%) Responders (%) i Total (%) 
I I 
IS or SIS 6 (10.9) 9 (13.8) 15 (12.5) 
I 
C/C; CIS, or C 49 (89.1) 56 (86.2) 105 (87.5) 




I I Total 165 (100) 
~ 
4.3.3.2 Allele frequencies 
The patient group allele frequencies can be seen in Table 4.5 and the normal control group 
frequencies can be seen in Table 4.6. The frequencies are calculated by adding the number 
of allele subtypes in each group by gender to give a total group allele score. As males 
only possess one 'X' chromosome, they either possess a single serine or cysteine allele and 
are therefore counted once each whereas females, with two, are homo- or heterozygotic. 
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I Alleles 
Table 4.5: Allele rates in the patient sample. Division by polymorphism and 
gender. Difference is not statistically significant. X 2 (Mantel Haenszel) = 1.34; 
d.f.=I; p=0.25. 
Males (%) Females (%) Total (%) 
I Ser allele 12 (26.1) 27 (18.2) 39 (20.1) 
I Cys allele 34 (73.9) 121 (81.8) 155 (79.9) 
I 
Total 46 (100) 148 (100) 194 (100) 
The main difference in the allele frequencies seen in the patient sample compared to the 
normal subject sample is in the slight excess of male patients with serine alleles. This 
finding is also inflated in comparison with other reports of rates in large normal 
populations (Lappalainan et a~ 1995). The allele rates for the comparative normal control 
group are shown in Table 4.6. 
Table 4.6: Allele rates in the control sample. Division by polymorphism and 
gender.Difference is not statistically significant. X 2 (Mantel Haenszel) = 0.85; 
d.f.=I; p=0.36. 
I Alleles Males (%) I Females (%) Total (%) 
I Ser allele 26 (18.8) 59 (15.5) • 85 (16.4) 
hCy, allele . 112 (81.2) i 323 (84.5) 435 (83.6) 
--~ 











The male 5-HT2c serine excess contributes to the finding of a serine excess in the patient 
versus control group seen in Table 4.7, but the difference is not at a statistically significant 
level. 
Table 4.7: Comparison of frequencies of 5-HT2C alleles in normal controls and 
depressed patients. Difference is not significantly different. X 2 (Mantel Haenszel) 
= 1.39; d.f=1.; p=0.24. 
: Allele Normal subjects (%) Depressed patients (%) 
I 
i Ser allele frequency 
I 
85 (16.4) 39 (20.1) 
i Cys allele frequency 435 (83.6) 155 (79.9) 
I Total 520 (100) 194 (100) 
I 
4.3.4 Serotonin Transporter polymorphisms 
Of the sample of 177 patients, 129 had sufficient material for DNA extraction and 
genotyping. Rates of 5-HTTLPR polymorphisms were as follows: (See Table 4.8). 
Table 4.8: Serotonin transporter promotor polymorphism genotypes in patients. 
Both groups were in Hardy Weinberg equilibrium (males X 2 =0.18, d.f.=l, NS; 
females X2 .14, d.f.=I, NS). 
I Genotypes I Males (%) 
I 
Females (%) Total (%) I 
sIs 12 (23.5) 15 (19.2) 27 (20.9) 
sII , 27 (53.0) 33 (42.3) . 60 (46.5) 
i 
III 12 (23.5) 30 (38.5) 42 (32.6) 




Although differences are seen in the frequencies of genotypes between males and females, 
these differences are not statistically significant (X2 = 3.13; d.f.=2; NS). 
4.3.4.1 Gene frequencies in response 
The cor score was used to group patients into responders and non-responders as in the 
analyses performed in relationship to the 5-HT2c polymorphisms (responders are cor = 1 
and 2; non-responders are cor = 3 and 4 ). A summary of the results can be seen in Table 
4.9. 
Table 4.9: Summary of frequencies of 5-HTlLPR genotypes and alleles in 
depressed patients and controls. 
I Responders I Non responders All Patients I Controls 
I 
I Genotype M F Total M F Total M F Total Total 
I LIL 5 17 22 7 13 20 12 30 42 100 
I LIS 17 19 36 10 14 24 27 33 60 160 
SIS 6 7 13 6 8 14 12 15 27 65 
I,..IQTAL 28 43 71 23 35 58 51 78 129 325 
L allele 27 53 80 24 40 64 51 93 144 360 
S allele 29 33 62 22 30 52 51 63 114 290 
Response can be considered by division of the patient sample into two possible groups for 
analysis, by inclusion of the heterozygotes with either the '111' or 'sis' group of 
homozygotes (See Table 4.10). 
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When adopting a model where the short allele is dominant, no significant differences are 
seen in the rates of polymorphism between the responders and non-responders even 
though there are relatively more responders with at least one short allele (69.0% vs 
65.5%). 
Table 4.10: Comparison of rates of response to anti-depressants by presence or 
absence of a short variant (s) in a short allele dominant modeL X 2 (Mantel 
Haenszel) = 0.18; d.f-=l; p=O.67; NS. 
I Genes Non-responders(% ) ! Responders (%) Total (%) 
i 
i sll or sis 38 (65.5) 49 (69.0) 87 (67.4) 
I 
.1/1 20 (34.5) 22 (31.0) 42 (32.6) 
Total 58 (100) 71 (100) 129 (100) 
! 
Neither model is statistically significant, however the short allele recessive model exhibits 
a greater difference between responders and non-responders. 
Table 4.11: Comparison of rates of response to anti-depressants by presence or 
absence of a long variant (1) in a short allele recessive model. X 2 (Mantel 
Haenszel) = 0.65; d.f-=l; p=0.42; NS. 
I Genes Non-responders(% ) Responders (%) Total (%) 
i 
SIL orLL 44 (75.9) 58 (81.7) . 102 (79.1) 
SIS 14 (24.1) 13 (18.3) 27 (20.9) 
Total 58 (100) 71 (100) 129 (100) 
i 
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4.3.4.2 Allele frequencies 
As the serotonin transporter gene is not X-linked, two alleles are counted for each 
individual (See Table 4.12), both males and females. 
Table 4.12: Frequencies of Serotonin Transporter promoter region allele 
distrIbution in depressed patients by gender. Difference is not statistically 
significant. X 2 (Mantel Haenszel) = 2.3; d.t: = 1; p=O.13. 
Alleles Males (%) Females (%) Total (%) 
S allele 51 (50) 63 (40.4) 114 (44.2) 
I 
/1 allele 51 (50) 93 (59.6) 144 (55.8) 
Total 102 (100) 156 (100) 1258 (100) 
I 
As can be seen in Table 4.13, we did not replicate the occasionally seen excess of 5-
HTTLPR short allele variants in case control allelic association studies of depression 
(Collier et aL 1996a). 
In the latter Collier study three centres all demonstrated higher rates of the short variant 
compared to controls but the individual centre rates failed to reach significance. However, 
when pooling their results, a stratified analysis gave a significant overall odds ratio of 1.23 
(95% CI: 1.02-1.49; p=O.03) and the homozygous short allele group in the patient sample 
showed an even higher odds ratio, 1.53 (95% CI: 1.04-2.23; p=0.02). 
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Table 4.13: Comparison of frequencies of Serotonin Transporter promoter region 
alleles in normal controls and depressed patients. X2 = 1.97; d.f.= 1; p=0.16 . 
Allele . Normal subjects (%) Depressed patients (%) 
S allele frequency 290 (44.6) 114 (44.1) 
i 
i 
L allele frequency 360 (55.4) 144 (55.9) 
I 
Total 650 (100) 258 (100) 
4.4 DISCUSSION 
The previous literature is contradictory, as discussed in the introduction, with different 
outcomes in the studies due to likely under or over-activity of the transporter variants. 
Although it is theoretically predicted that the 111 polymorphism is more likely to correlate 
with improved response, as more of the studies have shown this correlation, in our sample 
no directional effect was seen. It is also important to note that the decisions regarding 
response were retrospective. Possible reasons for the lack of a significant effect need to be 
considered. Although the patients with known non-caucasian ethnicity were excluded from 
the study, the ethnic origin of a number of patients was not recorded by the clinician and 
so for 28 patients ethnicity was assumed as caucasian. Exclusion of these cases did not 
change the significance of the findings however, as in the 5-HT2c analysis (serine dominant 
model), 32.14% of responders had a serine allele. 
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In the non-responder group, 25.49% had a serine allele (Mantel-Haenszel X2=O.57, I d.t:; 
p=0.45). Similarly, in the 5-HTTLPR analysis, (short allele dominant model) 67.8% of 
responders had a short allele, compared with 67.92% of the non-responder group (Mantel 
Haenszel X2=o.00, 1 d.t:; p=0.989). Although the sample is a heterogenous group, all 
patients fulfilled DSM3R14 criteria for major depression 
4.5 CONCLUSIONS 
In the present study we were unable to confirm the previous findings of a contribution of 
the 5-HTTLPR polymorphism to patient response when on serotonergic anti-depressant 
medication Possible reasons for the fuilure to replicate are discussed above. It is of note 
that the previous findings were also not consistent between studies. Although a positive 
contribution of the '1' allele has been more consistently seen and better predicted by the 
prior animal studies, the Korean study (Kim et aI, 2000) showed a positive effect of the 
short allele. This may reflect ethnic diversity as this is the on1y study to show the's' 
version being correlated with response. 
This is the first study to consider the role of the 5-HT 2C receptor polymorphism in the 
response of depressed patients to serotonergic medication Although a meta-analysis 
appears to show a positive effect of the serine variant in relation to clozapine response in 
schizophrenia (Sodhi et a1, personal communication), this has not been borne out with 
regard to SSRls and clomipramine in our study. 
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A further issue which could not be explored relates to the :filct that approximately 30% of 
patients responding to SSRIs and clomipramine in treatment trials in depression would 
also respond to placebo. It is therefore unclear in our sample which individuals would be 
considered as placebo responders. One further way to analyse the data, in an attempt to 
overcome this difficulty, is to calculate rates of response and non-response in only those 
individuals who appear to be treatment resistant in spite of numerous complete trials of 
anti-depressant treatment. This step would require additional clinical information and is 
therefore not possible at present but such data would provide a clearer picture as to 
whether analysis of polymorphisms has any predictive value in detecting likely non-
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As described in Chapter 1, one 5-HT2C receptor polymorphism results in a serine 
substitution in place of cysteine following from a C-G variation at codon 23 (nucleotide 
68) (Lappalainen et aI, 1995). It is of clinical relevance to know if there is evidence that 
the two receptors are functionally different. Although initial in vitro work on receptors 
expressed on xenopus oocytes showed equal concentration/response curves to 5-HT 
application, later work has shown a difference in binding affinity (Goldman, 1995). 
A number of early mammalian studies established a possible role for the 5-HT2C receptor 
in relation to appetite, prolactin secretion and locomotor activity (Kahn and Wetzler, 
1991). In a study of 'knockout mice', those without 5-HT2c receptors became obese and 
had a lower threshold for seizures induced by audiogenic stimulus (Tecott et aL 1995 ). 
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As further detailed in the introduction, in human studies it has been found that the 
relatively specific 5-HT2C agonist - meta-Chlorophenylpiperazine (m-CPP) causes 
increases in anxiety, temperature and prolactin levels, together with reduced appetite 
(Cowen et a~ 1995) and decreased slow wave sleep in healthy subjects (Katsuda et a~ 
1993). In studies involving psychiatric patients m-CPP has been found to exacerbate 
obsessional symptoms (Hollander et aI, 1993), precipitate panic attacks (Charney et a~ 
1987) and increase formal thought disorder in patients with schizophrenia (Iqbal et a~ 
1991). 
The aim of the present study was to establish whether functional differences exist between 
two groups of healthy volunteers exhibiting polymorphic variation at the 5-HT2C receptor 
using previously established neurobehavioural measures of likely 5-HT2c function, 
including anxiogenic, thermic, hormonal and hypophagic responses to m-CPP effects. 
5.2 METHODS 
5.2.1 Subjects 
Subjects were recruited from the volunteer register maintained in the Psychopharmacology 
Research Unit (now Neurosciences), Oxford University Department of Psychiatry, as well 
as from blood donors who were approached when presenting to donate blood, as 
coordinated by the Oxfordshire Blood Transfusion Service (See Chapter 2). 
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The included subjects gave signed, informed consent to a buccal swab being taken for 
genotyping and they also completed a questionnaire requesting demographic details and 
information regarding past psychiatric history, and history of migraine. No one was taking 
psychotropic medication. Ethical approval for the study was granted by the local Ethics 
Committee (OPREC). Subjects were divided into groups by gender and by 5-HT2C 
polymorphism, either cysteine or serine substituted. Following this initial phase and in 
view of the clozapine response data in schizophrenia suggesting a serine dominant model 
correlates more highly with response (Sodhi, 1995), 13 women with a serine substituted 
allele ( 2 homozygotic - Ser/Ser, 11 heterozygotic - Cys/Ser), mean age 38.8 years (range 
22-60 years), and for comparison, 15 women with homozygosity for the cysteine allele 
(Cys/Cys), mean age 30.9 years (range 18-56 years), were included in the study (See 
Table 5.1). 
Table 5.1: Female subjects included in the 5-HT2c function study, by subtypes of 
allelic variation, tabled according to a serine dominant model. 
I Genotype HomoZY2otic HeterOZY2otic Total 
Serine 2 11 13 
I Cysteine 15 0 15 
The subjects had no history of psychiatric illness or of significant physical illness which 
would preclude neuroendocrine testing or complicate interpretation of the results. It had 
originally been planned to include male subjects in the study however relatively fewer 
males volunteered to donate blood. 
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In addition, an insufficient number were found to be serine substituted. In view of this, it 
was decided to limit the analysis to females in the first instance. 
5.2.2 Genotyping 
DNA was extracted from the buccal swabs and blood samples using standard methods, as 
described in Chapter 2 and amplification was achieved using PCR, with primers directed at 
nucleotides 40-60 and 324-345 of the human 5-HT2C receptor gene. PCR products were 
analysed by dot blotting using allele-specific - 5'G32P - labelled oligonucleotides. The 
subjects genotype was confirmed by independent restriction analysis of a 104bp fragment 
using the Hsp9211 isoschizomer of NIall 1, as described (Burnet et aI, 1997). 
5.2.3 Neuro-endocrine challenge procedure 
5.2.3.1 m-CPP dose 
The subjects received m-CPP on one occasion and placebo on the other, packaged in 
matching opaque capsules at a dose of 0.4mg per kg body weight. It was decided to use 
oral m-CPP, as an extended effect of the drug is reported by comparison with intra-venous 
administration, as described in the paroxetine study (Chapter 3). This was important in 
order to ensure that any possible hypophagic effect would not have decreased by the time 
the test mea1s were presented to the subjects. 
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Previous work has established the appropriateness of the model and the dosage schedule 
needed to reliably reduce appetite under test conditions (Walsh et aI, 1994). 
5.2.3.2 Sampling protocol 
Subjects were tested after an overnight fast at 09.00 hours on two occasions (mean ± 
SEM intervals 5.0 ± 1.1 days) in a double-blind, placebo-controlled balanced order, cross-
over design. All of the women were tested in the follicular stage of their menstrual cycle, 
which was established at the first clinical interview. Following an initial 30 minute rest 
period for base-line blood sampling the m-CPP or placebo was administered. The venous 
blood samples were taken and oral temperature measured over the next 3 hours at half 
hourly intervals. 
5.2.4 Test meal procedure 
Following the neuroendocrine challenge test subjects were given a test meal of pre-
selected sandwiches made following a standardized preparation schedule leading to a 
known approximate calorie content (See Appendices 4 and 5). Preference had previously 
been established, as described in Chapter 2, and all of the subjects had consumed a test 
meal in advance of the study to establish whether amounts consumed on the test day were 
similar to the previous quantity consumed. 
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The sandwiches were presented to excess with an instruction to consume the quantity 
desired rather than to eat the maximum number possible. The meal was provided in an 
isolated setting, with water available to drink, and there was no time limit for the subjects. 
5.2.5 Subjective ratings 
At each time point following withdrawal of the base-line sample, visual analogue scales 
were completed for "drowsy", "anxious", "nausea", and "light-headed", as previously 
described. These were completed by the choosing of points on 10cm scales with divisions 
marked at 10mm intervals, as described in Chapter 2. It was thought important to obtain 
these VAS measures in order to assess whether the quantity of sandwiches eaten was 
influenced by factors other than the m-CPP administered. 
5.2.6 Statistics 
Plasma samples were analysed for prolactin, cortisol and m-CPP and calculated, from 
base-line as area under the curve (AUC), as previously described (Quested et aI, 1997; 
Sargent et ai, 1998). For each measure of interest, both physiological or behavioural, 
values derived on the placebo day were subtracted from those derived on the m-CPP day, 
in order to yield a net response to the m-CPP challenge. Data were analysed by factorial 
ANCOV A with genotype as the between-subjects factor and m-CPP levels as the 
covariate. 
171 
Differences on V AS measures between groups were compared as peak change from base-
line by Student's t-tests. 
5.3 RESULTS 
5.3.1 m-CPP drug levels 
Plasma m-CPP levels were a potential significant covariate of all the functional responses 
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Figure 5.1: Comparison of m-CPP drug levels in nglml (mean±SEM) in two 
groups differing by allelic variation ·at the 5-HT2C receptor. The levels did not 




The techniques used in the analysis of the serum levels have been discussed in detail in 
Chapter 2. Mean drug levels for the two groups can be seen in Figure 5.1. 
5.3.2 Effect on food intake 
None of the responses varied significantly with genotype when analyses were carried out 
after covariation with m-CPP levels, however the hypophagic effects of m-CPP were 
significantly attenuated in subjects with a 5HT 2C Ser receptor allele prior to covariation 
with m-CPP levels (p<0.05) to the extent that no reduction is seen and the quantities of 
sandwiches consumed on the m-CPP and placebo day are similar (See Table 5.2). 
Table 5.2: Difference in quantity of sandwiches consumed between the two test 
days, on m-CPP or placebo, testing for the m-CPP induced hypophagic effect. 
Each sandwich is a quarter of a round ( one round is 2 slices of medium thickness 
bread). Result is significant (Student's t-test; p =0.017) prior to covariation for m-
CPP levels. 
Genotype Mean sandwich intake (SEM) Difference (SEM) 
. m-CPPday Placebo day m-CPP - Placebo 
! 
Cysteine 4.53 (0.64) 6.07 (0.53) -1.54 (0.54) 
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Figure 5.2: Correlation of body mass in kilogrammes with difference in sandwich 
intake between m-CPP and placebo days (p>o.05 - R2 = 0.0039). 
There was also no significant effect seen when calories were used as the measure of 
possible difference in appetite. Although the sandwich preparation was standardized in 
order to ensure that each sandwich of a particular type had a similar calorific content to 
other sandwiches of the same type, there were absolute differences in calorie content 
between the types (See Table 5.3). 
Table 5.3: Difference in calorie intake between m-CPP and placebo days, after 
covarying for m-CPP levels. Adjusted means are shown (Student's t-test; p=O.14). 
Genotype Change in mean calorie intake 
(±SEM) 
Cysteine -87 ± 37 
Serine -2±41 
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The differences between the m-CPP and placebo days were correlated with body weight to 
assess whether this could have caused a systematic effect on the direction of the results. 
As the mean body mass of the subjects differed between the two groups defined by 
possession of the 5-HT2c allele, it had to be established whether this general difference 
between the two groups could be biasing the measures of outcome related to diet and food 
intake. This was not found to be the case as the coefficient of correlation was not 
significant (See Figure 5.2; p>O.05). 
5.3.3 Prolactin and cortisol levels 
Prolactin levels were measured using the techniques described in detail in Chapter 2. 
The data show that this particular 5-HT2c polymorphism does not seem to influence 
endocrine parameters following m-CPP. 
Data regarding the difference between the two groups by polymorphism, according to a 
serine dominant modeL is presented in Table 5.4 and the variation in prolactin levels 




















Figure 5.4: Prolactin levels in nglml (mean±SEM) in serine subjects. Comparison 
of AVC measures (nglml x minutes) between m-CPP and Placebo days (change 
from baseline) is significant (p<O.05, Student's t-test). 
Although there is a stimulatory effect on prolactin by m-CPP, as was discussed in 
Chapters 1 and 3, there is no significant effect of the polymorphism. This is also the case 
with cortisol where increases are seen on the m-CPP days (Figure 5.5) but not between 
the groups according to the polymorphic variation (Table 5.5). 
Table 5.5: Mean difference in cortisol levels between m-CPP and placebo days 
according to change from baseline AVC measures by gene prior to covariation 
with m-CPP levels. (Comparison of means by Student's t-test: p=O.565). 
Genotype Mean cortisollevel (±SEM) 
(Jlg/100ml x minutes) 
Cysteine 946 ± 336.18 
Serine 662 ± 283.6 
177 
-+-Cys (m-CPP) I 
-0-Cys (placebo) • 
30 
--t'r- Ser (m-CPP) 








·s 10 ......., 
-0 
rJ'l 
'f 5 0 
U 
0 
0 30 60 90 120 150 180 
Time (minutes) 
Figure 5.5: Cortisol levels (microgrammesll OOml) in all subjects. Comparison 
between m-CPP and placebo days in serine and cysteine substituted groups. Error 
bars are omitted for clarity. No significant group difference on factorial ANCOV A 
with m-CPP as a covariate using adjusted means (p=O.99). 
5.3.4 Thennic responses 
The data shows that the polymorphism does not seem to influence thermic parameters 
following m-CPP significantly although it is apparent from inspection of the AVC 
measures (See Figure 5.6) that the cysteine group exhibits almost no effect on temperature 
until the fmal two time points whereas the serine group appears to show a more marked 
positive effect over time. This result is therefore in contrast to the hypophagic effect 
although following covariation for m-CPP levels the result similarly remains non-
significant. 
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Table 5.6: Comparison of difference in temperature levels between m-CPP and 
placebo days by gene following covariation for m-CPP levels. Adjusted AUC 





Mean temperature ditf. (±SEM) 
(OC x minutes) 
5.5±5.2 
O.11±5.6 
When the group was considered as a whole, the expected positive thermic effect of m-
CPP was seen, confirming that there was no other explanation for the failure to establish a 
difference between the two groups with different 5-HT2c alleles. As can be seen in Figure 
5.6, the m-CPP day temperatures are higher than placebo day temperatures when shown 









Figure 5.6: Comparison of temperature measurements (OC) between the two 
groups differing according to possession of a Cys or Ser polymorphism, depicted 
as change from baseline (N.S - see table 5.6). Error bars are not shown for clarity. 
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5.3.5 Visual analogue scores 
While the differences between m-CPP challenge days and placebo days were predictable 
due to direct effects of the drug, as seen in other m-CPP studies, it was not known 
whether the two groups would exhibit differences as an effect of the polymorphic 
variation As discussed in Chapter 1 and shown in Chapter 3, m-CPP has been 
demonstrated to enhance anxiety in normals and in those predisposed to anxiety as a 
disorder (Charney et aL 1987). Measures differing between the groups at a statistically 
significant level prior to covarying for m-CPP levels include 'anxiety' and 'light-
headedness'. For all figures shown, occasion 1 is the 'm-CPP' day and occasion 2 is 
'placebo' although in practice the order was randomized. 
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Figure 5.7: Comparison of VAS drowsiness scores in mm (Mean±SEM), 
according to groups differing by polymorphism (cysteine and serine) on m-CPP 
and placebo days (Student'S t-test; p=O.318). Occasion 1 is m-CPP. 
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For 'drowsiness' (cysteine group only) and 'nausea' (both cysteine and serine groups) 
measures on the VAS scales, an increase was seen on the m-CPP days compared to the 
placebo days (See Figures 5.7 and 5.10) however Student's t-test of the difference 
between m-CPP and placebo days according to the two groups by 5-HT2cpolymorphism 
is non significant (p=O.318 and 0.715 respectively). 
Anxiety was found to be highest in the cysteine group on the m-CPP day (See Figure 5.8). 
This was not significant in comparison with the serine group after subtraction of the 
placebo day from the m-CPP day and comparison of the difference between group means 
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Figure 5.8: Comparison of VAS anxiety scores in mm (Mean±SEM) according to 
group differing by polymorphism (cysteine and serine) on m-CPP and placebo days 
(Student's t-test; NS; p=0.197). Occasion 1 is m-CPP and occasion 2 is placebo. 
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Light-headedness measures were not found to be significantly different between the two 
groups, with probablility at the p=O.332 leveL by Student's t-test (See Figure 5.9). 
Understandably, the m-CPP day was seen to be worse for both groups on this measure but 
to a much greater degree on the m-CPP day for the cysteine group. 
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Figure 5.9: Light headedness VAS measures in mm (Mean±SEM) compared 
between groups differing by the two polymorphisms. The difference is not 
significant between the two groups (p=O.332; Student's t-test). Occasion 1 is 
m-CPP and occasion 2 is placebo. 
The difference between the groups is again not significant for the VAS score concerning 
light-headedness. For the nausea measure, although there is a clearly visible difference 
between the m-CPP and placebo days, there is no statistical difference between the two 











Figure 5.10: Nausea VAS scores in rnm (Mean±SEM) compared between groups 
differing according to the two polymorphisms. Difference between m-CPP and 
placebo days and between groups is non-significant (p==O.715 by Student's t-test). 
Occasion 1 is m-CPP and occasion 2 is placebo. 
5.4 DISCUSSION 
The predicted difference of the hypophagic effect of m-CPP was seen with an enhanced 
effect in the cysteine group, compared to the serine group but, although the expected 
reduction of calorie intake was seen in the whole sample (p=O.045) only a non-significant 
trend was seen between the two genotyped groups (See Table 5.3). 
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There was also no variation between the groups in the effect of m-CPP on prolactin and 
cortisollevels. An increased temperature was seen on the m-CPP day in both groups but 
no significant difference was seen between the two groups. 
In view of the binding and the clozapine response data it was predicted that functional 
differences would be found between the genetically differing groups. As the results show a 
trend in the predicted direction for appetite (ie: a greater hypophagic effect in cysteine 
patients) it may be that a larger sample is required, or more sensitive measures. Previous 
work has demonstrated a negative effect of m-CPP on appetite using a full buffet meal, 
possibly a more sensitive measure of appetite than that used in the present study ( Walsh 
etal, 1994). 
It is unlikely that the dose of m-CPP was too small as a reduction of calorie intake was 
seen across the whole sample on the m-CPP occasion and blood levels of m-CPP were as 
expected. In view of X-chromosomal inactivation in females (Migeon, 1994), it is possible 
that the responses of the heterozygote females may have been equivalent to the cysteine 
substituted rather than the serine substituted homozygotes, which would have confounded 
the outcome. 
5.5 CONCLUSIONS 
As discussed above the present data set does not support a significant functional effect of 
this 5-HT2c polymorphism on endocrine, behavioural or thermic parameters. 
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The most interesting finding is that of a trend towards significance in the reduction of food 
intake following m-CPP in those individuals with a cysteine allele. This fmding was 
significant prior to covarying for m-CPP levels, a necessary step in establishing a direct 
link between the 5-HTzc agonist and a measureable functional effect. 
Subjects with serme substituted receptors, 5-HT2c Ser, consumed approximately 80 
calories more on the day of m-CPP administration than those with cysteine genotype, 5-
HT 2C Cys. While the difference in hypophagic effect is not currently significant once m-
CPP levels have been covaried for, it is evident that a sample size of twice the current 
number would be needed for 80% power to exclude the effect of the genotype, ~ssuming a 
functional response of 25% to be of likely clinical significance. In order to establish 
whether there is a recessive effect of the allele it would also be necessary to include a 
sufficiently large group of 5-HT 2C Ser receptor homo zygotes. In view of reported gender 
differences in measures of response to m-CPP it would also be important to carry out 
similar investigations in male subjects (Bagdyand Arato, 1998). 
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CHAPTER 6 
THE EFFECT OF ALLELIC VARIATION IN 
THE SEROTONIN TRANSPORTER 
PROMOTER ON FUNCTIONAL RESPONSES 
TO CLOMIPRAMINE 
6.1 BACKGROUND 
The serotonin transporter (SERT) has been increasingly studied in view of its role in the 
sodium dependent pre-synaptic re-uptake of serotonin during neurotransmission in the 
serotonergic system (Rudnick and Clark, 1993). It is the target of numerous 
antidepressant drugs, as both the tricyclic antidepressants and the SSRIs occupy sites 
overlapping the 5-HTT binding site (Schloss and Betz, 1995). As discussed in Chapter 1, 
the 5-HTT derives from a number of different polymorphic variants. 
In this study intravenous clomipramine was administered to normal subjects in order to 
establish whether there may be a functional difference relating to allelic variation in the 
serotonin transporter promoter-polymorphism (5-HTTLPR), which occurs in long (1) and 
short (s) forms (As discussed in Chapter 1). 
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The'!' fonn has been associated with greater expression of 5-HTT sites (Lesch et a~ 
1996; Little et aI, 1998) and it is therefore important to evaluate whether human brain 
function might be influenced according to the possession of a specific promoter 
polymorphism. 
As previously described, it is possible to assess human 5-HT function in the brain using a 
neuro-endocrine paradigm, by measuring fluctuations in honnones secreted by the anterior 
pituitary gland as a proxy marker for central neurotransmitter activity (Cowen, 1993). In 
this study prolactin levels were monitored as a marker of the increase in 5-HT neuro-
transmission which occurs with acute 5-HT reuptake blockade. 
6.2 METHODS 
6.2.1 Subjects 
Subjects were either recruited from the volunteer database in the Psychopharmacology 
Research Unit or at local blood donor clinics. Following the screening of volunteers at the 
blood donor clinics in Oxford, two samples of seven female homozygote subjects each 
were identified from those without a history of psychological problems, possessing 'U' or 
'ss' genotypes. The subjects were interviewed using the structured interview for DSM IV 
(SCID). It was thereby determined that no subjects had a current or previous history of 
an axis-one psychiatric diagnosis in DSMIV. 
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The mean age of the women with the '11' genotype was 40 years (range 23·60 years) while 
that of the 'ss' subjects was 38 years (range 22·54 years). One woman in each group was 
post·menopausal. All tests were carried out in the follicular stage of the menstrual cycle, 
where appropriate, as previously discussed in Chapter 1. The mean body weight of the '11' 
subjects was 72.5 kg (range 60.8·94.8 kg) and that of the 'ss' subjects was 67.7 kg (range 
55-87.6 kg). Subjects gave signed consent to the study which had been approved by the 
local Ethics Committee, OPREC. 
6.2.2 Genotyping 
DNA was extracted from cheek swabs provided by the blood donor volunteers or from 
blood taken by venous samples from other volunteers to the Psychopharmacology 
Research Unit, following their informed and signed consent. Genotyping of the 
polymorphism was carried out as previously described (Lesch et a~ 1996). 
The oligonucleotides were directed against bases -1416 to -1397 and -910 to -888 of the 
human SERT gene, giving rise to 484 ('s' allele) or 528 ('1' allele) basepair fragments. 
PCR was carried out in a final volume of 20 microlitres, with 12% DMSO, using cycling 
conditions as described in Chapter 2 (Klauck et al, 1997). Products were then resolved on 
a 3% agarose gel by electrophoresis with ethidium bromide and DNA molecular weight 
markers. 
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6.2.3 Neuroendocrine protocol 
Subjects were tested at 09.00 hours after an over-night fast in a single-blind, balanced-
order, placebo-controlled design. Following insertion of an in-dwelling venous cannula, a 
30 minute rest period elapsed after which clomipramine or placebo (saline) was infused 
intravenously over 15 minutes. 
The dose of clomipramine was calculated as 0.1 mg per kg on the basis of previous studies 
showing that this dose of clomipramine produced a reasonably well tolerated increase in 
plasma prolactin and the sample size was also selected in view of a measureable effect 
being achieved with clomipramine at significant levels in previous studies (McCance et a4 
1989). Venous samples for prolactin and clomipramine were taken from the cannula, 
following the initial removal of 10mI of blood for discarding on each occasion, at 15 
minute intervals for the next 120 minutes. The mean interval between the tests was 25 
days (range 2-134 days) for the '11' group and 14 days (range 5-56 days) for the 'ss' 
group. 
6.2.4 Subjective measures 
Subjects rated themselves for 'happiness', 'anxiety', 'drowsiness', 'dizziness' and 
'nausea', every 30 minutes using a 10cm visual analogue scale, as previously described in 
Chapter 2. 
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6.2.5 Biochemical assays 
Plasma prolactin concentration was measured by standard immunoradiometric assay and 
clomipramine levels were determined by high performance liquid chromatography with 
ultra violet detection (Anderson et a4 1992), as described in Chapter 2. 
6.2.6 Statistics 
A two-way repeated measures analysis of variance (ANOVA) was used for the analysis of 
prolactin and cortisol levels with 'treatment' (clomipramine vs saline) and 'time' as within-
subject factors while 'genotype' (ll vs ss) was the between-subjects factor. The Huynh-
Feldt correction was applied as is always done where the assumption of sphericity is 
violated. In addition to the use of the above method, prolactin levels were also calculated 
as an AVC measure by the trapezoid method following the subtraction of baseline values 
at time '0'. To derive a 'change in AVe' measure (MVC), placebo day values of 
prolactin were then subtracted from the responses following clomipramine administration. 
Clomipramine levels were also calculated according to the above AVC method. VAS 
ratings were calculated as peak increase over base-line and the placebo day value was 




6.3.1 Endocrine Measures 
Administration of the intravenous clomipramine produced a significant increase in plasma 
prolactin relative to placebo saline infusion as shown by a significant treatment by time 
interaction on a repeated measures analysis of variance (ANOVA) (F=4.48, P<O.OOl). 
See Figure 6.1, below. 
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Figure 6.1: Plasma prolactin levels (mean ±SEM) in two groups of female 
volunteers before and after clomipramine (open symbols) and saline (closed 
symbols). Subjects with an '11' genotype had a significantly greater response to 
clomipramine than saline. 
(*p<O.05; **p<O.OI; Fisher's test of least significant difference) 
]9] 
There was no main effect of genotype (F=0.024, P=O.88), but a significant occasion by 
time by genotype interaction (F=3.32, P=0.005). In comparison with saline, clomipramine 
significantly increased plasma prolactin in subjects with the 'II' genotype but not in those 
with the 'ss' genotype (See Figure 6.1). However, there were no baseline (mean +/- SEM) 
differences between prolactin levels in the 'II' and 'ss' groups (256 +/- 43 vs 224 +/- 34 
mlUIl respectively, P=O.56, unpaired t-test). 
6.3.2 Subjective Measures 
The increase in subjective nausea (change from baseline) produced by clomipramine did 
not differ between the genotypes (27.0 +/- 11.5 vs 27.4 +/- 9.0 rom, P=O.98, unpaired t-














I~" polymorphism ! 
C ss polymorphism I 
.... or 
I I I 
Occasion 2 
Figure 6.2: Nausea scores measured on Visual Analogue Scales (mm). 
Occasion 1 is clomipramine day and occasion 2 is placebo day. No significant 
difference is seen on the measure (placebo subtracted or A nausea) between 
genotypes 'II' and 'ss' (P=O.98, paired Student's t-test). 
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Figure 6.3: V AS scores for anxiety compared between the two variant groups. 
Occasion 1 is clomipramine and occasion 2 is placebo. Difference is not 
statistically significant on the measure (placebo subtracted or A anxiety) between 
the 'll' and 'ss' groups. (p=O.186 by paired Student's t-test). 
While the chart concerning the VAS anxiety (Figure 6.3) scores suggests that females with 
the 'sis' genotype experience higher anxiety levels on the clomipramine day, the statistical 
significance is at the trend level rather than at p<O.OS. 
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Figure 6.4: VAS scores for drowsiness compared between the two variant groups. 
Occasion 1 is clomipramine and occasion 2 is placebo. Difference is not 
statistically significant on the measure (placebo subtracted or A drowsiness) 
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Figure 6.5: V AS scores for dizziness compared between the two variant groups. 
Occasion 1 is clomipramine and occasion 2 is placebo. Difference is not 
statistically significant on the measure (placebo subtracted or A dizziness) between 
the '11' and 'ss' groups. (p=O.830 by paired Student's t-test). 
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Figure 6.6: VAS scores for happiness compared between the two variant groups. 
Occasion 1 is clomipramine and occasion 2 is placebo. Difference is not 
statistically significant on the measure (placebo subtracted or /). happiness) 
between the '11' and 'ss' groups. (p=O.719 by paired Student's t-Test). 
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6.3.3 Clomipramine levels 
The mean area under the curve (AVC) of plasma clomipramine following infusion was 
found to be higher in '11' subjects in comparison to the 'ss' group, (See Figure 6.7) but not 
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Figure 6.7: Comparison of serum clomipramine levels as measured by High 
Performance Liquid Chromatography. Actual levels in mIVlml are displayed 
however the statistical analysis was carried out using AVC measures (Student's t-
test; p>O.05) 
To control for the possible pharmacokinetic effects of different plasma clomipramine 
levels, the AVC clomipramine levels were co-varied with the prolactin response to 
clomipramine (change in prolactin AVC) in a factorial ANCOV A. 
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This showed no significant effect of clomipramine level on prolactin response (F=2.89, 
P=0.12) but the prolactin AVe was significantly higher in the '11' subjects (mean +/- SEM 
~ Ave prolactin response to clomipramine in '11' subjects, 126 +/- 48 vs -7.2 +/- 40 mIVx 
hll, F=7.78, P=0.018). 
There were no significant correlations between change in prolactin AVe and the following 
variables: clomipramine Ave level (R- 0.14, P=O.64), change in nausea (R- 0.18, 
P=0.54), body weight (R=0.10, P=O.73), or interval between clomipramine and placebo 
tests (R= -028, P=0.33). 
6.4 DISCUSSION 
The results as discussed above suggest that subjects with the '11' genotype have an 
enhanced prolactin response to clomipramine. In the case of the subjects with the 'ss' 
genotype little response was seen. This would suggest that the '11' genotype is associated 
with increased 5-HT response to 5-HT re-uptake blockade, presumably at 5-HT uptake 
sites in nerve terminals in the hypothalamus, although it is acknowledged that the sample 
size in this study is somewhat small. Other studies which may have relevance to this 
finding include a report suggesting that depressed patients with the 'ss' genotype may 
respond less well to the SSRI fluvoxamine than heterozygotes with at least one'!, allele 
(Smeraldi et ai, 1998). In the latter study administration of pin dolo I (a 5-HT1A receptor 
antagonist) improved the response rate so that the 'ss' homozygotes' responses looked 
more similar to the 'Is' and '11' groups. 
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As 5-HT1A receptor antagonists promote an increase in 5-HT neurotransmission it is 
possible that the 'ss' genotype in this study failed to show a corresponding increase similar 
to the '11' group in view of excessive activation of cell body 5-HT1A auto-receptors which 
are inhibitory to 5-HT cell firing (Adell and Artigas, 1991; Bel and Artigas, 1992). 
It would therefore seem in the pindolol study that receptor blockade was preventing extra-
cellular serotonin from causing negative feedback on 5-HT cell-firing, thereby enhancing 
terminal 5-HT neurotransmission. An alternative explanation for the present finding is that 
animal studies have shown an increased uptake of serotonin into both lymphoblasts and 
platelets in association with the '11' genotype, which suggests an increased expression of 
transporter sites (Lesch et a~ 1996; Collier et a~ 1996a; Greenberg et aI, 1999). This 
could lead to an enhanced response to clomipramine with increased prolactin release, 
should a greater number of transporter sites allow a 5-HT reuptake-blocker to 
correspondingly enhance 5-HT neurotransmission. Although the above findings could 
suggest a reduced effect of 'ss' genotypes, this would not correspond well to the animal 
and experimental studies. 
6.5 CONCLUSIONS 
Although this is a striking finding with possible relevance for antidepressant treatment 
response, the effect needs to be replicated and extended to male subjects. It would also be 
appropriate to test those individuals who are heterozygous for the '1' and's' alleles. 
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It would be of interest for similar studies to be carried out looking at the response to 
clomipramine challenge in depressed patients. Here many other factors, such as cortisol 
hypersecretion, which may have a role in the aetiology of the depressive condition, may 
further complicate response to the challenge and would therefore need to be evaluated 
accordingly. Some studies have suggested that the cortisol responses to clomipramine 
might be regulated differently. For example, in one study which investigated the effect of 
short term treatment with lithium on prolactin and cortisol responses to clomipramine, 
only the prolactin response was elevated (McCance et al, 1989). One possibility for these 
kinds of differences is that 5-HT has the ability to increase cortisol secretion directly from 
the adrenal gland where different 5-HT release mechanisms may be involved. 
A possible effect of stress can also not be excluded but the clomipramine was tolerated 
relatively well and a low dose was chosen for this reason. Clomipramine is highly 
serotonergic (Attar-levy, 1999), but not particularly selective for the 5-HTT and it would 
also be preferable to repeat the study with a more highly selective serotonin reuptake 
inhibitor such as citalopram, as a more direct test of the hypothesis. 
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CHAPTER 7 
DISCUSSION AND CONCLUSIONS 
7.1 GENERAL DISCUSSION 
In this thesis a number of specific hypotheses have been tested, within a more general 
framework linking dysfunction of the serotonin neurotransmitter system to major 
psychiatric illnesses and, for the purposes of this thesis, specifically to depression. 
The studies in this thesis have therefore followed two main lines of investigation :-
1) the effect of SSRI treatment on the function of the 5-HT 2C receptor and the possible 
influence of one 5-HT2C polymorphism - cys23ser - on previously estabHshed 
functional indices of 5-HT2C receptor function and, in a similar manner, the influence 
of variation in the promoter polymorphism of the serotonin transporter on hormonal 
fluctuation as a proxy measure of functionality. 
2) the possible relevance of polymorphic variation in the 5-HT2C receptor (cys23ser) 
and in the promoter polymorphism of the serotonin transporter, to treatment response, 
with the use of SSRIs in depression. 
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In the first experimental chapter (Chapter 3). it was established that a three week period 
of treatment on the SSRl paroxetine was followed by significant attenuation of both the 
prolactin and hyperthermic responses to intra-venous m-CPP challenge, a relatively 
selective 5-HT2C agonist, in healthy subjects, as predicted by the theoretical model 
derived from previous studies concerning patients suffering from OCD and animal 
studies. 
The study differed from previous work in the field as m-CPP was administered intra-
venously, in order to avoid the difficulties relating to variation in plasma drug levels by 
the effect of anti-depressant drugs on hepatic metabolism. Possible causes of a finding at 
odds with the original hypothesis were thought to be unlikely. These included :-
a) the non-selectivity of m-CPP, with a possibility that 5-HT1A desensitisation 
could contribute to the reduction in PRL release (Sargent et aI, 1997) however this 
explanation is countered by the fact that body temperature would be expected to fall 
rather than rise if 5-HT lA receptors were involved (Anderson et aI, 1990). 
b) a possible argument linking m-CPP - induced PRL release to pre-synaptic 5-
HT 
release stimulating post-synaptic 5-HT 2C receptors by an indirect effect. In this scenario 
SSRls could block the ability of m-CPP to release 5-HT in a similar manner to how they 
block the 5-HT releasing effect of d-fenfluramine. This is supported by animal work 
where SSRls attenuate m-CPP stimulated PRL release (Baumann et aI, 1993). However, 
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this possibility is countered by the fact that 5-HT neuro-toxic lesions in rats produce an 
increase in the prolactin response to m-CPP. 
This in turn suggests that the prolactin response is through post-synaptic receptors, which 
in this case are showing an up-regulation (Quattrone et aI, 1981). 
c) a possible direct antagonist effect of paroxetine was also considered but the 
affinity of paroxetine for 5-HT2C receptors is known to be considerably less than 
fluoxetine (Wong et aI, 1991) and this explanation is therefore unlikely. 
The corollaries derived from the above predictive framework have been supported by 
more recent work which has upheld the perspective argued in the points listed above, 
namely that 5-HT2C desensitisation is the most tenable explanation for the data in the 
paroxetine study (Chapter 3). A 5-HT2C antagonist - SB-242084 - was able to reverse the 
5-HT 2C mediated anxiogenic effects of fluoxetine, sertraline and m-CPP while the 5-
HTIA antagonist, WAY-I00635, was not, in a study concerning Sprague Dawley rats 
(Bagdy et aI, 2001). The rate of desensitisation may have relevance to speed of onset of 
action. 
In the second experimental chapter (Chapter 4). we failed to replicate either the three 
previous studies showing an association between possession of the long allele of the 
promoter region polymorphism of the serotonin transporter and response to anti-
depressants or the one study linking the shortest polymorphism (Kim et aI, 2000) with 
response. In a similar manner, we did not find any any correlation between possession of 
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a polymorphic variant of the 5·HT2C receptor (serine substitution at codon 23) and the 
response of patients to SSRIs or clomipramine. 
It had been predicted that the polymorphism might be relevant to SSRI response as 
binding differences between the two forms had been reported and a study had also linked 
the serine substituted receptor to therapeutic response in schizophrenic patients treated 
with c10zapine (a 5-HT2C receptor blocker), as discussed in Chapter Four (Sodhi et aI, 
1995). 
It is also known that m-CPP aggravates formal thought disorder in schizophrenia and that 
clozapine has been shown to be particularly effective in patients with the disorganisation 
syndrome, one of the major features of which is formal thought disorder. A number of 
lines of reasoning had therefore suggested that the 5-HT 2C receptor and its 
polymorphisms might have some relevance to the treatment of different psychiatric 
conditions but, in view of the varying nature of the effects on the receptors (agonism vs 
antagonism), by differing means. Although subsequent work has supported a positive 
correlation of clozapine response and this serine substitution in schizophrenia, leading to 
its incorporation in an algorithm with other polymorphisms (Arranz et aI, 2000), some 
studies have not replicated the finding (Masellis et aI, 1995; Segman et aI, 1997). 
In spite of the non-replication of the above finding in some groups, the link between 5-
HT2C blockade occurring due to the atypical anti-psychotic drugs and weight gain is well 
supported by both the knockout mice studies (Tecott et aI, 1995), where obesity ensued 
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and in the clinical studies which have monitored weight gain in patients commencing 
atypical anti-psychotic drugs (Fenton, 2000). 
Although the drugs differ by the degree to which weight is increased, with clozapine and 
olanzapine contributing to the greatest average gain, there is an overall positive effect on 
appetite and weight in both the typical and atypical groups, as reported in meta-analyses 
(Allison et aI, 1999). 
Alongside the reports of significant weight gain, there are now large scale studies noting 
a positive association of the atypical drugs with Type 2 diabetes mellitus (Desai et aI, 
2002), even in the absence of significant weight gain, and an increase in serum leptin 
levels (Herran et aI, 2001). 
In an attempt to establish which 5-HT2c polymorphism/s are most highly correlated with 
obesity, studies have initially examined a possible link between the cys23ser 
polymorphism and disorders of body mass but association and linkage studies were 
negative in one study which involved children, adolescents and adults who were obese, 
normal weight or underweight (Lentes et aI, 1997). This finding is analogous to the 
absence of correlation with either 5-HT2c polymorphism (Cys or Ser) and absolute body 
mass reported in Chapter Five, which also only reported a trend towards a decreased m-
cpp induced hypophagic effect in females with serine substituted 5-HT 2C receptors. 
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In view of the absence of a clear correlation between the cys23ser receptor polymorphism 
and weight, a further study investigated the possible link between 5-HT2c polymorphisms 
deriving from the promoter region, obesity and diabetes (Yuan et ai, 2000). 
Of the three single nucleotide substitution loci (G to A at -995; C to T at - 759 and G to 
C at 697) and one dinucleotide repeat locus at -1,027, haplotype '9' «Z+2; -9950; -
759C and -697G) was associated with obesity and haplotype 2 (Z-6; -9950; -759C and -
697C) was more common in non-obese subjects. Haplotype 3 ( Z-6; -995A; -759T and -
697C) was associated with 'leanness' and the absence of diabetes. In view of this finding, 
it was hypothesised by the researchers that the C to T -759 promoter polymorphism 
might be relevant to the potential side-effect of weight gain for patients on anti-
psychotics. 
A subsequent study therefore investigated whether weight gain in first episode psychotic 
patients is associated with this polymorphism (Reynolds et ai, 2002). As predicted, 
significantly less weight gain was recorded in patients with the -759T variant allele than 
in those without the allele. It would therefore seem that the this polymorphism has more 
evidence for its association with anti-psychotic induced weight gain than the cys23ser 
polymorphism investigated in our study on possible functional differences between the 
two alleles (Chapter Five). 
A further polymorphism relating to the 5-HT2C gene has been identified in the 3'-
untranslated region of the 5-HT2C gene (2831T>0) which is approximately 100 kb from 
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the Cys23Ser variant site (Song et aI, 1999). As we did not, in our 5-HT2C cys23ser 
function study, show any significant differences on m-CPP induced measures, or 
correlation of either the cysteine or serine substituted receptors with SSRI response in 
Chapter 4, it is hoped that the newly reported polymorphism might relate not only to 
weight gain but also to the clinical response of depressed patients to SSRIs. 
However, as 5-HT2c receptor heterogeneity derives from a minimum of three possible 
sources, including allelic variation (as discussed above), two further lines of investigation 
are also now underway, namely RNA alternative splicing and RNA editing and these 
have been investigated in some initial studies. Messenger RNA editing of the 5-HT2C 
receptor was previously noted to occur, with the conversion of one to four adenosines to 
inosines in rat studies, leading to a change in up to three out of the five codons in the 
second intra-cellular loop. 
It has now been established that the same process occurs in humans, where an editing site 
exists in the middle codon, resulting in 6 additional isoforms. Whereas the receptor 
binding affinity was conserved in the rat studies, in human isoforms binding affinity is 
reduced, with full agonists being the most affected and antagonists showing no effect 
(Fitzgerald et aI, 1999). 
In studies involving psychiatric patients, one study has shown reduced RNA editing in 
the frontal cortex of the brains of schizophrenic patients in relation to control healthy 
subjects as well as variations in the expression of isoforms (Sodhi et aI, 2001), while in 
another investigation no changes were seen in either schizophrenic patients or those with 
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major depression (DSM~4), in comparison with healthy controls (Niswender et aI, 2001). 
However, in the latter study, individuals from both patient groups who had committed 
suicide exhibited a significant increase in editing at one specific site (The 'A ' site). 
Although the positive correlation of treatment response in schizophrenic patients to 
clozapine and possession of the 5~HT2Cser substitution was a significant aspect of the 
background to the m~CPP study in the 5~HT2C variant groups, there is now evidence that 
the efficacy of clozapine may relate to factors other than serotonin receptor subtypes. 
Recent findings have again implicated dopamine receptors specifically in models of 
response to clozapine, rather than models invoking ratio's of different neurotransmitters 
which are blocked by clozapine. One current line of investigation relates to the speed at 
which clozapine detaches from the dopamine receptor, in the so~called 'fast off' model 
(Seeman et aI, 1999), where atypical anti~psychotic drugs are seen to dissociate more 
rapidly than typical anti~psychotics from D2 receptors. 
While there are new directions referred to above in the attempt to unravel the relevance 
of 5~HT2C blockade to the treatment of schizophrenia, it is less clear how the receptor 
relates to the efficacy of anti~depressants. In Chapter 3 of this thesis evidence was 
presented for a reduced response of the receptors to m-CPP after a three week treatment 
period on paroxetine. While this could be explained as the attempt by the neuro~ 
transmitter system to maintain homeostasis, it may be linked to the onset of anti-
depressant efficacy, some one to two weeks after treatment is commenced. Although 
work on the 5-HTIA auto~receptor also showed a gradual desensitisation following SSRI 
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treatment (Sargent et aI, 1997), subsequent studies aiming to induce an earlier reduction 
in function pharmacologically by the use of 5-HTIA antagonists, as investigated 
pharmacologically, (Blier and Bergeron, 1998), have not been consistently successful 
clinically. The delayed onset of effect with anti-depressants therefore continues to be 
investigated further. 
Although the role of 5-HT2C receptor modulation in antidepressant efficacy continues to 
be unclear, it should be noted that a number of antidepressant drugs, notably mirtazapine 
have potent antagonist properties at 5-HT 2C receptors. Animal studies suggest that this 
property might be associated with increased dopamine release in mesocortical regions. It 
is also possible, however, that differing effects of antidepressants on 5-HT2C receptors 
may contribute more to side effect profile (for example sleep disturbance and aspects of 
sexual dysfunction) than therapeutic efficacy. Clinical antidepressant trials with selective 
5-HT2C receptor agonists and antagonists might enable this question to be resolved. 
In Chapter 4 of this thesis, no correlation was found between SSRI response and either 
the serotonin transporter promoter polymorphism or the 5-HT2C cys23ser polymorphism. 
Although a number of studies have considered the cys23ser polymorphism in anti-
psychotic response in schizophrenia, no previous studies have reported on the 
polymorphism in relation to response to anti-depressants. It is therefore not clear whether 
our finding is a valid negative or a chance finding until replication studies have been 
conducted. We were also unable to replicate the previously reported excess of's' 
serotonin transporter promoter alleles in patients with major depression (DSM-IV), in 
comparison with samples from individuals who do not suffer from major depression. 
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The clomipramine finding is of significant relevance to the whole area of possible 
genetic contributions to anti-depressant response and could be usefully advanced with a 
larger sample and the link of weight gain and therapeutic response could also be 
extended with anti-depressants such as mirtazepine which has a 5-HT2C antagonist effect. 
7.2 FUTURE RESEARCH 
As a different 5-HT2C polymorphism to the one studied in this thesis has now been more 
closely associated with anti-psychotic induced weight gain it will be important to re-
analyse the findings in Chapter Five according to the sample split dictated by possession 
or absence of the -759T variant, when the remaining samples can be genotyped. A 
positive link with m-CPP - induced hypophagia would lend added weight to the above 
explanatory framework and suggest that the -759T variant is protective against induced 
weight gain. A finding such as this would have both clinical and research implications as 
genotyping prior to treatment would enable clinicians to avoid placing genetically 
vulnerable patients, at risk of Type 2 Diabetes Mellitus or raised cholesterol and 
triglycerides, on antipsychotic drugs such as olanzapine. In view of gender differences 
seen in other studies using m-CPP, it would be important to repeat the tests of 5-HT2c 
functionality in males. This is also important in view of the X-linkage of the cys23ser 
gene. Furthermore, as the cys/ser and ser/ser groups were pooled in the initial analysis 
according to a serine dominant model, it would be important to investigate serine 
homozygote women as a separate group. Although the analysis was carried out 
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considering this group alone, there were too few individuals represented in the cell for 
reliable statistics to be derived. 
In view of the above mentioned information on schizophrenia and increasing evidence 
on the need for anti-depressant medication to be taken by many patients on a long term 
basis, further clarification of the determinants of response remains an important aim in 
psychopharmacological research. 
APPENDICES 
APPENDIX 1: BECK DEPRESSION INVENTORY (Beck et aI., 1961) 
On this questionnaire are groups of statements. Please read each group of statements 
carefully, then pick out the one which best describes the way you have been feeling in the 
past week including today. Circle the number beside the statement you have picked. If 
several statements apply equally well, circle each one. Be sure to read all the statements 
in each group before making your choice. 
o I do not feel sad 
1 I feel sad 
2 I am sad all the time and cannot snap out of it 
3 I am so sad or unhappy that I can't stand it 
• 2 0 I am not particularly discouraged about the future 
1 I feel discouraged about the future 
2 I feel I have nothing to look forward to 
3 I feel that the future is hopeless and that things cannot improve 
[ 3 0 I do not feel like a failure 
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1 I feel I have failed more than the average person 
2 As I look back on my life, all I can see is a lot of failures 
3 I feel that I am a complete failure as a person 
4 0 I get as much satisfaction out of things as I used to 
I don't enjoy things the way I used to 
2 I don't get real satisfaction out of anything any more 
3 I am dissatisfied or bored with everything 
5 0 I don't feel partiCUlarly guilty 
I feel guilty a good part of the time 
2 I feel quite guilty most of the time 
3 I feel guilty all of the time 
6 0 I don't feel I am being punished 
I feel I may be punished 
2 I expect to be punished 
3 I feel I am being punished 
7 0 I don't feel disappointed in myself 
I am disappointed in myself 
2 I am disgusted in myself 
3 I hate myself 
8 0 I don't feel I am worse than anyone else 
1 I am critical of myself for my weakness and mistakes 
2 I blame myself all the time for my faults 
3 I blame myself for everything bad that happens 
9 0 I don't have thoughts of killing myself 
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I have thoughts of killing myself but I would not carry them out 
2 I would like to kill myself 
3 I would kill myself if I had the chance 
10 0 I don't cry any more than usual 
1 I cry more than I used to 
2 I cry all the time now 
3 I used to be able to cry but now I can't cry even though I want to 
11 0 I am no more irritated now that I ever am 
1 I get annoyed or irritated more easily than I used to 
2 I feel irritated all the time now 
3 I get irritated now by things that didn't used to irritate me 
12 0 I have not lost interest in other people 
I am less interested in other people than I used to be 
2 I have lost most of my interest in other people 
3 I have lost all interest in other people 
13 0 I make decisions as well as I ever could 
1 I put off making decisions more than I used to 
2 I have greater difficulty in making decisions than before 
3 I can't make decisions at all anymore 
14 0 I don't feel I look any worse than I used to 
1 I am worried that I am looking old or unattractive 
2 I feel there are permanent changes in my appearance that make me look old or 
unattractive 
3 I believe that I look ugly 
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15 0 I can work as well as before 
1 It takes an extra effort to get started at doing something 
2 I have to push myself hard to do anything 
3 I can't do any work at all 
16 0 I can sleep as well as usual 
I don't sleep as well as I used to 
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep 
3 I wake up several hours earlier than usual and cannot get back to sleep 
17 0 I don't get more tired than usual 
1 I get tired more easily than I used to 
2 I get tired from doing almost anything 
3 I am too tired to do anything 
18 0 My appetite is no worse than usual 
1 My appetite is not as good as it used to be 
2 My appetite is much worse now 
3 I have no appetite at all any more 
19 0 I haven't lost much weight lately 
I have lost more than 5 pounds 
2 I have lost more than 10 pounds 
3 I have lost more than 15 pounds 
20 0 I am no more worried about my health than usual 
1 I am worried about aches and pains, upset stomach and constipation 
2 I am very worried about physical problems and it is hard to think of much else 
3 I am so worried about my physical problems that I can't think of anything else 
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21 0 I have not noticed any recent change in my interest in sex 
I am less interested in sex than I used to be 
2 I am less interested in sex now 
3 I have lost interest in sex completely 
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APPENDIX 2: HAMILTON DEPRESSION RATING SCALE 
(Hamilton, 1960) 
NAME ____________________________ _ DATE ____ _ 
SCORING GUIDE: 0-4: 0 = ABSENT, 1 = MILD-TRIVIAL; 2,3 = MODERATE 
4 SEVERE/INCAPACITATING 
0-2: 0 = ABSENT, 1 = SLIGHTIDOUBTFUL, 2 = CLEARLY PRESENT 
1. Depressed mood 1 Indicated on questioning 
2 Spontaneously reported 
3 Obvious at interview 
4 Only feeling reported 
2. Guilt 1 Self reproach 
:2 Ideas/rumination of guilt 
3 Delusions of guilt 
4 Persecutory 
hallucinations 
3. Suicide 1 Feels life not worth 
living 
2 Wishes were dead 
3 Suicidal ideas/gestures 
4 Attempts at suicide 
4. Initial insomnia more than 1 Occasional 
Ih an hour 2 Persistent 
5. Middle insomnia 1 Restless and disturbed 
during night 
2 Waking / getting out of 
bed 
6. Late insomnia 1 Wakes but returns to 
sleeplUnable to fall 
asleep again 




10. Psychic anxiety 
! 11. Somatic anxiety 
! 
incapacity 
2 Loss of interest 
3 Decrease in 
time/productivity 
4 Stopped working 
because of illness 
Slight 
2 Obvious 
3 Interview difficult 




Playing with hands/hair 
Moving about/can't sit 
still 





Worrying over minor 
matters 
3 Apprehensive in body 
language 








12. Gastrointestinal 1 Loss of appetite 




13. Somatic symptoms 1 Heaviness I aches I 
fatigue 
2 Clear cut symptoms 
14. Genital symptoms 1 Mild 
2 Severe 
15. Hypochondriasis 1 Bodily self absorption 
2 Preoccupation with 
health 
3 Frequent complaintsl 
requests for help 
4 Delusions 
16. Loss of weight 1 Probable 
2 Definite 
17. Insight 1 Partial 
2 Clear Loss 
TOTAL SCORE 
18. Diurnal variation a.m. or p.m. 
mild or severe 




20. Paranoid symptoms Suspicious 
ideas of reference 
delusions 
21. Obsessional symptoms Mild 
severe 
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APPENDIX 3: VISUAL ANALOGUE SCALES 
PLEASE EITHER PLACE A MARK ON THE LINE OR 
CIRCLE THE NUMBER WHICH BEST INDICIATES HOW 




o 10 20 30 40 50 60 70 70 
Not at all happy 
80 90 100 
Very happy 
o 10 20 30 40 50 60 70 70 80 90 100 
1-------------------------------------------------------------------------------------------------1 
Not at all drowsy Very drowsy 
o 10 20 30 40 50 60 70 70 80 90 100 
1-------------------------------------------------------------------------------------------------1 
Not at all anxious Very anxious 
o 10 20 30 40 50 60 70 70 80 90 100 
1-------------------------------------------------------------------------------------------------1 
Not at all light-headed Very light-headed 
o 10 20 30 40 50 60 70 70 80 90 100 
1------------------------------------------------------------------------------------------------1 
Not at all nauseous Very nauseous 
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APPENDIX 4: 5-HT2c POLYMORPHISM m-CPP CHALLENGE 
STUDY. RECORD OF FOOD PREFERRED. 
FOOD PREFERENCE 
NAME: DATE: 




Section ]: Bread 
White ----
3 4 5 6 
Neutral 
____ Soft grain (mighty white) 
Wholemeal ----
Section 2: Sandwich fillings 
Tuna ----
Cheddar Cheese ----
---- Chicken (wafer thin American style) 
---- Ham (wafer thin American style) 








APPENDIX 5: 5-HT2c POLYMORPHISM m-CPP CHALLENGE 
STUDY. RECORD OF FOOD CONSUMED. 
Results Sheet 
Name: 






Number quarters consumed: 
Kcal/Quarter: 
Total Kcal consumed: 






Number quarters consumed: 
KcallQuarter: 










Number quarters consumed: 
Kcal/Quarter: 
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